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Summary 
 
In the first part of this PhD thesis entitled Photo-Activatable Organic and Organometallic 
Compounds for Enzyme Inhibition and Targeted Drug Delivery, the main research topic of 
the dissertation is discussed. As an introduction, a review on organometallic enzyme 
inhibitors highlights the opportunities that the use of organometallic compounds gives in 
medicinal chemistry (chapter 1). Several concepts are discussed and explained on basis of 
literature examples. The topics include: 1) Organometallic compounds as inert scaffolds; 
2) Organometallic compounds targeting specific protein residues; 3) Bioisosteric substitution; 
4) Novel mechanisms of enzyme inhibition with organometallic compounds; 
5) Organometallic compounds as cargo delivers of enzyme inhibitors; 6) Organometallic 
enzyme inhibitors for theranostic purposes. The following chapters 2 and 3 shift the focus 
towards light-activatable bioactive compounds. In chapter 2, the acquisition of uncaging 
quantum yields in the UV-A range is discussed. Surprisingly, the frequently used reference 
molecule 1-(2-nitrophenyl)ethyl-phosphate (“caged phosphate”) leads to vastly wrong 
uncaging quantum yields (up to an order of magnitude). The correct values could be 
determined using measurements with classical actinometers based on photo-induced 
ferrioxalate decomposition and azobenzene photo-isomerization. To elucidate the reason for 
this inaccuracy, further measurements with 1-(2-nitrophenyl)ethyl-ATP (“caged ATP”), the 
second important reference molecule for uncaging quantum yields, which is based on the 
same photo-cage, were undertaken. The data suggest that the broad-band light source 
originally used to acquire the uncaging quantum yield of caged phosphate is the most likely 
cause. Thus, a new, convenient, and precise alternative protocol for the determination of 
uncaging quantum yields at wavelengths around 350 nm was designed based on 
inexpensive azobenzene. In chapter 3, a more recent variant of light-controlled activation, 
two-photon uncaging, is applied to spatially and temporally control the activity of an enzyme, 
namely Cyclooxygenase-2 (COX-2). The advantage of the two-photon mechanism lies in the 
light that is needed to initiate the uncaging process. Traditional photo-cages rely on 
activation by UV-light, which can be harmful for biological structures. Two-photon processes 
on the other hand are initiated by the simultaneous absorption of two photon, each 
contributing half of the energy. Therefore, firstly the required light is in the near-IR range, 
which is favorable because it is (almost) not absorbed by biomolecules. Secondly, as the 
excitation probability depends on the square of the light intensity, three-dimensional 
selectivity can be accomplished with focused laser beams. Enzyme inhibitors have been de-
activated by attaching them to two-photon-cages. The cages have been designed to be 
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modifiable with targeting vectors via click-chemistry. The attachment of a targeting peptide 
has been demonstrated. The enzyme inhibitors could be released not only by irradiation with 
UV-light, but also by two-photon uncaging upon irradiation with pulsed light in the near-IR 
range. The successful de- and re-activation of an enzyme inhibitor has been confirmed by a 
fluorescence-based enzyme inhibition assay. The project described in chapter 4 combines 
the two concepts of photo-uncaging and the special properties of organometallic 
compounds. The cytotoxic compound aminoferrocene (Fc-NH2) has previously been shown 
to be unstable under physiological conditions, leading to ferrocenium and free iron ions. Both 
products catalyze the production of reactive oxygen species (ROS) in cells. Cancer cells are 
especially vulnerable to ROS since they have inherently elevated ground levels. To deliver 
Fc-NH2 to target tissues without prior decomposition, it was protected with two different 
photo-cages. Both cages have been equipped with a targeting peptide, which was supposed 
to direct the complex to mitochondria, an organelle particularly prone to alternations of the 
redox potential. The caging of Fc-NH2 was realized via formation of a carbamate bond. The 
electronic properties of the bond lead to a stabilization of the organometallic moiety. The 
uncaging of both Fc-NH2 derivatives led to the formation of free iron ions. However, the 
effectivity of this process is very differently between the two caged versions. Cytotoxicity 
tests against healthy and cancer cell lines in the dark and upon UV-irradiation showed a 
positive selectivity for both factors. The previously observed differences between the cages 
also manifested in the biological tests. At the end of the first part of the thesis, chapter 5 
presents an outlook for possible future research endeavors. 
 
The second part of the thesis focuses on the use of peptide nucleic acid (PNA) in 
(bio-)nanotechnology. PNAs are artificial analogues of deoxyribonucleic acid (DNA). The 
backbone of PNA is made up of a peptide (hence the name), while the backbone of DNA 
consist of ribose and phosphodiesters. Consequently, PNA is not charged and structurally 
less flexible than DNA. Both factors contribute to the superior binding strength of PNA to 
DNA, which surpasses the natural duplex formation. In chapter 6, examples from the 
literature are highlighted which used PNA for bio-nanotechnology. So far, only relatively few 
reports in this field have been published. Among the nanoscopic materials which have been 
functionalized with PNA are silicon nanowires, carbon nanotubes, and nano graphene oxide. 
The described materials and devices demonstrate the possibilities and advantages of PNA, 
including the aforementioned superior binding affinity, but also going beyond that, for 
example by exploiting the uncharged nature in electronic devices. Chapter 7 then deals with 
a case, in which exactly this property of PNA causes problems. DNA-functionalized gold 
nanoparticles are already being used for many different applications, ranging from gene 
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regulation to nanofabrication. In almost all cases, the properties of PNA would be of interest. 
However, the direct functionalization of gold nanoparticles with PNA has not been realized. 
The combination of both led to destabilization and precipitation of the nanoparticles since the 
needed repulsion, usually realized through charged species on the particle surface, between 
the particles was abolished by the uncharged PNAs. A novel step-wise approach which first 
stabilizes the particles electrostatically and sterically before addition of PNA led to stable 
particles. To this end, also new thiol linkers, which can be easily employed in solid-phase 
synthesis, have been designed for the attachment of the PNA to the gold surface. The 
utilizability of the new PNA-functionalized gold nanoparticles has been demonstrated by 
sequence specific self-assembly onto PNA-functionalized gold surfaces. The assemblies 
showed greater coverage densities, i.e. more nanoparticles per surface area unit, than 
corresponding DNA-functionalize gold nanoparticles. The final chapter 8 outlines possibilities 
for further research in the field of PNA-based nanotechnology. 
 
  
 
Zusammenfassung
XVII 
 
Zusammenfassung 
 
Im ersten Teil dieser Doktorarbeit mit dem Titel Photo-Aktivierbare Organische und 
Organometallische Verbindungen zur Enzyminhibierung und zum Zielgerichteten Wirkstoff-
transport wird das Hauptforschungsthema der Dissertation besprochen. Einleitend wird ein 
Überblick über organometallische Enzyminhibitoren gegeben, welcher die Möglichkeiten, die 
die Verwendung organometallischer Verbindungen der medizinischen Chemie bietet, 
aufzeigt (Kapitel 1). Mehrere Konzepte werden erörtert und basierend auf Beispielen aus der 
Literatur erklärt. Die Themen umfassen: 1) Organometallische Verbindungen als inerte 
Gerüste; 2) Organometallische Verbindungen die auf bestimmte Proteinseitenketten 
abzielen; 3) Bioisosterische Substitution; 4) Neue Mechanismen der Enzyminhibition mit 
organometallischen Verbindungen; 5) Organometallische Verbindungen als 
Beförderungsmittel für Enzyminhibitoren; 6) Organometallische Enzyminhibitoren für 
theragnostische Zwecke. In den folgenden Kapiteln 2 und 3 wird der Fokus auf licht-
aktivierbare bioaktive Verbindungen gelenkt. In Kapitel 2 wird die Erfassung von 
Freisetzungsquantenausbeuten im UV-A Bereich diskutiert. Überraschenderweise liefert das 
häufig verwendete Referenzmolekül 1-(2-Nitrophenyl)ethyl-phosphat („photoaktivierbares 
Phosphat“, im englischen „caged phosphate“) erheblich falsche Freisetzungsquanten-
ausbeuten (bis zu einer Zehnerpotenz). Die richtigen Werte konnten über Messungen mit 
klassischen Aktinometern basierend auf der photo-induzierten Zersetzung von 
Tris(oxalato)ferrat(III) und der Photoisomerisierung von Azobenzol erhalten werden. Um 
dieser Diskrepanz auf den Grund zu gehen wurde weitere Messungen mit 1-2(-
Nitrophenyl)ethyl-ATP („photoaktivierbares ATP“), dem zweiten wichtigen Referenzmolekül 
für uncaging Quantenausbeuten, welches auf der gleichen photolabilen Gruppe basiert, 
durchgeführt. Das Datenmaterial legt nahe, dass die ursprünglich zur Erlangung der 
Freisetzungsquantenausbeuten von photoaktivierbarem Phosphat verwendete breitbandige 
Lichtquelle die wahrscheinlichste Ursache ist. Daher wurde ein neues, komfortables und 
genaues alternatives Protokoll für die Bestimmung von Freisetzungsquantenausbeuten für 
Wellenlängen um 350 nm basierend auf dem preiswerten Azobenzol entworfen. In Kapitel 3 
wird eine neuere Variante der Licht-kontrollierten Aktivierung, die Zwei-Photonen-
Aktivierung, angewendet um die Aktivität eines Enzymes, der Cyclooxygenase-2 (COX-2), 
zeitlich und räumlich kontrolliert zu aktivieren. Der Vorteil des Zwei-Photonen 
Mechanismuses ist hierbei das Licht das zur Einleitung des uncaging Prozesses benötigt 
wird. Übliche photolabile Gruppen sind auf die Aktivierung mit UV-Licht angewiesen, 
welches schädlich für biologische Strukturen sein kann. Zwei-Photonen-Prozesse dagegen 
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werden durch die beinahe gleichzeitige Absorption zweier Photonen angeregt, wobei beide 
die Hälfte der Energie beisteuern. Daher liegt, erstens, das benötigte Licht im nahen IR 
Bereich, welches von Vorteil ist, da es (fast) nicht von Biomolekülen absorbiert wird. 
Zweitens, da die Anregungswahrscheinlichkeit vom Quadrat der Lichtintensität abhängt kann 
mit einem fokussierten Laserstrahl eine dreidimensionale Selektivität erreicht werden. 
Enzyminhibitoren wurden durch Anbindung an Zwei-Photonen-Schutzgruppen deaktiviert. 
Die Schutzgruppen wurden so entworfen, dass sie mittels Click-Chemie mit Zielvektoren 
modifiziert werden konnten. Die Anknüpfung eines Zielprotein wurde vorgeführt. Die 
Enzyminhibitoren konnten nicht nur durch Bestrahlung mit UV-Licht, sondern auch mit 
gepulstem Licht im nahen IR Bereich freigesetzt werden. Die erfolgreiche In- und 
Reaktivierung eines Enzyminhibitors wurde durch ein Fluoreszenz-gestütztes 
Enzyminhibierungs-Assay bestätigt. Das in Kapitel 4 beschriebene Projekt vereint die beiden 
Konzepte der Photoaktivierung und die besonderen Eigenschafen von organometallischen 
Verbindungen. Es hat sich gezeigt, dass die zytotoxische Verbindung Aminoferrocen 
(FcNH2) unter physiologischen Bedingungen instabil ist und in Ferrocenium und freie 
Eisenionen zerfällt. Beide Produkte katalysieren die Produktion reaktiver Sauerstoff Spezies 
(ROS, vom englischen reactive oxygen species) in Zellen. Krebszellen sind besonders 
anfällig gegenüber ROS da sie ein von Natur aus höheres Grundlevel besitzen. Um FcNH2 
ohne vorherige Zersetzung zum Zielgewebe zu bringen wurde es mit zwei verschiedenen 
photolabilen Gruppen geschützt. Beide Schutzgruppen wurden mit Zielpeptiden 
ausgestattet, die den Komplex zu den Mitochondrien führen sollte, einer Organelle die 
besonders anfällig für Veränderungen des Redoxpotentials ist. Das schützen von FcNH2 mit 
den photolabilen Gruppen wird durch die Bildung einer Carbamat-Bindung realisiert. Die 
elektronischen Eigenschaften der Bindung führen zu einer Stabilisierung des 
organometallischen Teils. Die lichtinduzierte Zersetzung beider FcNH2-Derivate führte zur 
Bildung freier Eisenionen. Allerdings ist die Effektivität dieses Prozesses für die beiden 
lichtlabil geschützten Varianten sehr unterschiedlich. Zytotoxizitätstests mit gesunden und 
Krebszelllinien im Dunkeln und mit UV-Bestrahlung zeigten positive Selektionen hinsichtlich 
beider Parameter. Die zuvor beobachteten Unterschiede zwischen den beiden 
Schutzgruppen zeigte sich auch in den biologischen Tests. Am Ende des ersten Teils der 
Thesis präsentiert Kapitel 5 Perspektiven für mögliche künftige Forschungsbestrebungen. 
 
Der zweite Teil der Doktorarbeit beschäftigt sich mit der Verwendung von Peptid-
Nukleinsäure (PNA) in der (Bio-)Nanotechnologie. PNAs sind künstliche Nachbildungen der 
Desoxyribonukleinsäure (DNA). Das Rückgrat der PNA besteht aus einem Peptide (daher 
der Name), wohingegen das Rückgrat der DNA aus Ribose und Phosphodiestern besteht. 
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Folglich ist PNA ungeladen und strukturell weniger flexibel als DNA. Beide Faktoren tragen 
zur überlegenen Bindungsstärke der PNA zu DNA bei, welche über der natürlichen 
Duplexbildung liegt. In Kapitel 6 werden Beispiele aus der Literatur hervorgehoben die PNA 
für Bio-Nanotechnologie verwendeten. Bisher gibt es nur relativ wenige Berichte auf diesem 
Gebiet. Zu den nanoskopischen Materialen, die mit PNA funktionalisiert wurden, zählen 
Silikonnanodrähte, Kohlenstoffnanoröhren und Nanographenoxid. Die beschriebenen 
Materialien und Objekte zeigen die Möglichkeiten und Vorteile von PNA auf, einschließlich 
der zuvor erwähnten zuvor erwähnten höheren Bindungsaffinität, aber auch darüber hinaus, 
zum Beispiel durch Nutzung der Ladungsfreiheit in elektronischen Bauteilen. Kapitel 7 
behandelt dann einen Fall, in dem genau diese Eigenschaft der PNA Probleme bereitet. 
DNA-funktionalisierte Goldnanopartikel werden bereits für viele verschiedene Anwendungen, 
die von Genregulation bis zur Nanofabrikation reichen, verwendet. In beinahe allen Fällen 
wären die Eigenschaften von PNA reizvoll. Allerdings wurde die direkte Funktionalisierung 
von Goldnanopartikeln mit PNA noch nicht verwirklicht. Die Vereinigung beider führte zur 
Destabilisierung und Präzipitation der Nanopartikel, da die benötigte Abstoßung zwischen 
den Partikeln, üblicherweise aufgrund geladener Spezies auf der Partikeloberfläche, durch 
die ungeladenen PNAs aufgehoben wurde. Ein neuer schrittweiser Ansatz, der zunächst die 
Partikel elektrostatisch und sterisch stabilisiert bevor die PNA zugegeben wird, führte 
stabilen Partikeln. Zu diesen Zweck wurden ferner neue Thiol-Bindeglieder für die 
Anbindung der PNA an die Goldoberfläche entwickelt, die bequem in der 
Festphasensynthese eingesetzt werden können. Die Einsatzfähigkeit der neuen PNA-
funktionalisierten Goldnanopartikel wurde anhand von sequenzspezifischer 
Selbstorganisation auf PNA-funktionalisierten Goldoberflächen bewiesen. Diese 
Anordnungen zeigten größere Bedeckungsdichten, also mehr Nanopartikel pro 
Oberflächeneinheit, als entsprechende DNA-funktionalisierten Goldnanopartikel. Das 
Schlusskapitel 8 umreißt Möglichkeiten für weiterführende Forschung auf dem Gebiet der 
PNA-basierten Nanotechnologie. 
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1 Introduction: Organometallic Complexes as Enzyme 
Inhibitors: A Conceptual Overview 
Philipp Anstaetta and Gilles Gassera* 
 
a Department of Chemistry, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, 
Switzerland. 
* Corresponding author: e-mail: gilles.gasser@chem.uzh.ch; Fax: +41 44 635 46 03; 
Tel: +41 44 635 46 30; homepage: http://www.gassergroup.com. 
 
This chapter has been accepted for publication as chapter in the book Bioorganometallic 
Chemistry (Eds.: G. Jaouen, M. Salmain), John Wiley & Sons Ltd. Copyright © Wiley-VCH 
Verlag GmbH & Co. KGaA. Reproduced with permission. 
 
1.1 Contributions to the publication 
P.A: wrote the first drafts of the subchapters on organometallic compounds as inert structural 
scaffolds, bioisosteric substitution, and novel mechanisms of enzyme inhibition with 
organometallic compounds. Furthermore, feedback and suggestions to all subchapters were 
given. 
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1.2 Abstract 
Enzyme inhibitors represent an important class of drugs currently on the market. 
Organometallic compounds with their unique properties, compared to purely organic 
compounds, offer great opportunities to the field of enzyme inhibition. Their additional 
geometries and electrostatic profiles allow the use of otherwise unavailable binding and 
interaction modes between the inhibitor and the enzyme. Beyond that, the metal ions can be 
easily tracked and therefore used for theranostic purposes. For these reasons, great 
advances have been made in the field of organometallic enzyme inhibitors - the activity of 
these inorganic inhibitors sometimes even surpasses those of their heavily optimized organic 
counterparts. 
In this chapter, we focus on reviewing and explaining the different concepts that have been 
applied found valuable for the design and mode of activity of organometallic enzyme 
inhibitors. More specifically, this chapter discusses the following topics: 
1) Organometallic compounds as inert structural scaffolds. 
2) Organometallic compounds targeting specific protein residues. 
3) Bioisosteric substitution. 
4) Novel mechanisms of enzyme inhibition with organometallic compounds. 
5) Organometallic compounds as cargo delivers of enzyme inhibitors. 
6) Organometallic enzyme inhibitors for theranostic purposes. 
 
Keywords: Bioinorganic chemistry • Organometallic chemical biology • Medicinal 
organometallic chemistry • Enzyme inhibition. 
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1.3 Introduction 
Enzyme inhibitors are currently playing a crucial role in medicine. A high proportion of the 
drugs currently reaching the market are exerting their activity by inhibiting an enzyme. For 
example, the best-selling drug in pharmaceutical history, the lowering blood cholesterol drug 
Atorvastatin, sold under the trade name Lipitor, is inhibiting an enzyme present in liver 
tissue.[1] The anticancer drug Imatinib marketed under the trade names Gleevec and Glivec 
specifically targets a tyrosine kinase. From a medicinal inorganic chemistry perspective, the 
mechanism of action of several metal-based drugs having reached the market can be linked 
to enzyme inhibition. Examples of such compounds include the anti-arthritic gold complexes, 
the antimony-based drugs against leishmaniasis or the arsenic-based drugs against syphilis, 
trypanososiamis and cancer although the exact mechanism(s) of action of these compounds 
have not been (yet) fully uncovered. Due to these successful examples, several research 
groups around the world are currently exploring the possibility of using organometallic 
compounds to inhibit enzymes involved in diseases. This field of research has been 
reviewed in detail over the last years.[2–6] In this book chapter, we aim to take an alternative 
approach by presenting the different concepts employed to achieve enzyme inhibition using 
organometallic complexes rather than to list all organometallic compounds reported to date 
which can act as enzyme inhibitors. We will use a few concrete examples to exemplify each 
concept. 
 
1.4 Organometallic Compounds as Inert Structural Scaffolds for Enzyme 
Inhibition 
Nature evolved proteins, including enzymes, with active sites of very unique and specific 
shapes and electrostatic surfaces, providing unmatched specificity and catalytic activity for 
the intended substrates. Obtaining a great selectivity is a challenge in the design of enzyme 
inhibitors. These small molecules have to match the interaction pattern dictated by the active 
pocket in order to effectively bind to and block the activity of an enzyme. For this task, the 
greater the chemical space used in the search of an inhibitor is, the greater are the chances 
to find a “perfect” inhibitor. Thus, the use of metal complexes greatly increases the structural 
possibilities to form enzyme inhibitors. Additional metal-specific geometries, such as square-
planar or octahedral, can be indeed exploited. Moreover, unique bond lengths and bond 
polarities, which are unavailable to purely organic compounds, further increase the potential 
associated with the use of metal compounds as enzyme inhibitors. There are several 
examples in the literature describing organometallic enzyme inhibitors which have been built 
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around an inert metal center and this topic has been previously reviewed.[7,8] The most 
extensively studied organometallic complexes are undoubtedly the kinase inhibitors 
developed by the group of Meggers. Below, we highlight the range of opportunities that has 
been opened up with the use of metal centers as inert scaffolds, on basis of this work. 
 
Protein kinases are enzymes which catalyze the attachment of phosphate groups to 
proteins, thereby regulating their function. Hundreds of different subtypes are known, usually 
phosphorylating only a few specific substrates. Consequently, protein kinases are involved in 
many cellular pathways, including, but not exclusively, ones up-regulated in cancer tissues 
leading to their uncontrolled growth. Therefore, selective protein kinase inhibitors represent 
attractive targets for drug discovery, e.g. as anticancer agents (see introduction). 
The common phosphate source of all protein kinases is ATP (Figure 1 a)), whose terminal 
phosphate group is transferred to the respective substrates. The ATP binding pocket is the 
main target for protein kinase inhibitors.[9] As there are more than 500 human kinase 
genes,[10] which have a structurally highly conserved ATP binding pocket, it is essential, and 
particularly difficult, to design inhibitors with high specificity for a particular kinase subtype. 
 
Figure 1. Structure of a) ATP; b) Staurosporine; c) Staurosporine-inspired octahedral metal complex 
with variable ligands L1-L4. The colors indicate the parts of the respective molecules that occupy the same spatial position in the binding pocket of the protein kinases; the red parts show the parts 
involved in hydrogen bonding to corresponding amino acids, the green parts occupy an area allowing 
for secondary interactions potentially leading to subtype specificity. 
Staurosporine (Figure 1 b)) is a natural alkaloid which inhibits protein kinases with low 
nanomolar IC50 values, but which possesses only low subtype specificity.[11] It binds to the 
ATP binding site of kinases, which is very similar among the different subtypes. Within the 
ATP binding site, the lactam (the red part in Figure 1 b)) forms two hydrogen bonds to the 
protein, as adenine does in the case of ATP.[12] The glycosyl unit in staurosporine (green part 
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in Figure 1 b)) replaces the ribose part of ATP. This part of the inhibitor was found to be less 
important for the binding affinity of staurosporine to the active site of kinases.[13] On the basis 
of those observations, Meggers and co-workers designed their organometallic kinase 
inhibitors. They envisaged keeping the general structure of staurosporine. However, they 
modified it in a way that it could serve as a ligand for metal complexation (Figure 1c)). 
Hence, the initial affinity towards protein kinases would be conserved. The remaining open 
coordination sites of the metal ion then give the opportunity to introduce additional ligands, 
inter alia replacing the glycosyl moiety present in staurosporine. These ligands were later 
shown to influence the specificity, but also to some extend the affinity of the metal-containing 
inhibitors to certain kinase subtypes (see below). 
Accordingly, ruthenium complexes such as 1 were synthesized and their binding affinity 
towards protein kinases was investigated (Figure 2).[14] 1 has been found to be over 100 
times more potent against the kinase GSK-3 than staurosporine and more than 50 times 
more potent than the pyridocarbazole ligand by itself. 
 
Figure 2. Isostructural ruthenium and osmium complexes with pyridocarbazole ligand. 
A cocrystal structure of the protein kinase Pim-1 and 1 showed that the complex 1 binds to 
the ATP binding site in a homologous manner to staurosporine (Figure 3).[15] Previously, a 
Lineweaver-Burke analysis, which is a kinetic method allowing the distinction of competitive 
and non-competitive binding modes, was performed for the ruthenium complex 2, revealing 
an ATP-competitive binding mode.[16] Both findings together clearly show that Meggers’ 
organometallic staurosporine-derivatives, like staurosporine itself, bind to the ATP binding 
pocket of kinases. The cyclopentadienyl moiety and particularly the carbonyl ligand of 1 
occupy positions within the ATP binding pocket which are not accessible to purely organic 
molecules due to the specific geometric properties of the metal complex. For example, as 
can be seen in the cocrystal structure of 1 with Pim-1, the CO ligand of 1 is involved in 
dipolar interactions with the glycine-rich loop of Pim-1.[15] This interaction seems to be of 
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Figure 3. Ruthenium complex 1 (purple; PDB code 2BZI) and staurosporine (green; PDB code 1YHS) 
inside the ATP binding pocket of Pim-1.[15,17] Both inhibitors occupy a similar spatial position and 
exhibit homologous interactions to the enzyme. 
 
 
Figure 4. Superimposed cocrystal structures of Pim-1 (green) with 1 (red; PDB code 2BZI)[15] and with 
3 (blue; PDB code 3BWF).[18] The amino acid residues involved in the most important interactions with 
the inhibitors are shown as stick models.[17] 
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great significance for the subtype specificity towards Pim-1 and GSK3, which possess 
similar glycine-rich loops. Similar observations were made for other related organometallic 
kinase inhibitors,[15,18–22] and, to date, all specific organometallic inhibitors found for those 
enzymes carry this CO ligand. Worthy of note, a CO ligand, unlike an organic carbonyl group 
in a molecule, is not polar.[22] Hence, the electronic properties responsible for the favorable 
interactions of the CO ligand of Meggers’ enzyme inhibitors with the protein cannot be 
imitated by organic carbonyl groups. Due to their unique geometric and electronic 
characteristics, only other organometallic inhibitors are, to the best of our knowledge, known 
to establish comparable interactions with the glycine-rich loop of protein kinases, introducing 
hence this great selectivity.[19] 
The metal center of 1 appears to be unable to directly interact with the protein as the metal is 
“protected” by its ligands. In order to further confirm that the role of the metal is solely of 
structural nature, an complex isosteric to 1, namely the osmium complex 3 was prepared.[18] 
In contrast to their geometry, the redox potentials of the two metal complexes are different. 
Hence, if the metal has a purely structural role the bioactivity should remain unaffected, 
while any additional influences should alter the activity profile. Cocrystal structures of Pim-1 
with 1 and 3 show nearly identical binding geometries and interactions for both complexes 
(Figure 4). In vitro studies, such as the anticancer activity in 1205 Lu melanoma cells and the 
activation of Wnt signaling as result of inhibition of GSK-3β in human embryonic kidney cells 
(HEK293OT), also verified the almost identical biological activity of both compounds 1 and 3, 
thus clearly demonstrating the purely structural role of the metal center. 
Nevertheless, the change of the metal center in this type of inhibitors can lead to an overall 
different affinity and selectivity pattern among protein kinases. Apart from 
ruthenium(II)[8,14,15,20–32] and osmium(II),[18] iridium(III),[19,33–36] platinum(II),[37] and 
rhodium(III)[36,38,39] have also served as metal centers for kinase inhibitors. Such swaps can 
lead to several consequences depending on the metal ion chosen. Firstly, due to the 
different electronic properties of the metal ions, different synthetic pathways might be 
employed to prepare the complexes and thus ease the screening of large compound 
libraries (vide infra). Secondly, a swap of the metal center can, in contrast to the isosteric 
replacement of ruthenium with osmium discussed above, lead to a different overall complex 
geometry, which can alter the affinity and selectivity for certain kinases. In accordance with 
these points, the change from one metal center to another is an option worth considering, as 
it opens up new avenues for molecular diversity.  
Although tetrahedral half-sandwich complexes have geometries which can hardly be 
mimicked by organic compounds (vide supra), octahedrally substituted complexes are even 
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more intriguing as they offer additional geometric complexity.[19,20,25,32,33,35,38–40] The 
consequences of this become striking if the number of possible stereoisomers is taken into 
consideration: a tetrahedral center can form up to two enantiomers, octahedral centers can 
form up to 30 stereoisomers. Meggers coined the term “octasporines” for this group of 
compounds, as they feature an octahedral coordination sphere and are derived from 
staurosporine. Notably, the group of octasporines is not limited to organometallic 
compounds, but also includes classical inorganic complexes, such as 4 (see Figure 5). 
Compounds 4–7 (Figure 5) nicely demonstrate the tremendous impact of the geometric 
complexity on biological systems. Despite their similar general arrangement, all of these 
complexes are highly selective inhibitors of different protein kinase subtypes (Figure 5 and 
6).[19,33] It has to be noted that already most of the tetrahedral metal complexes also show 
high subtype selectivities which surpass many organic inhibitors. 
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Figure 5. Octasporines with distinct selectivity profiles. 
 
Figure 6. Selectivity of 5 in a screening against 102 kinases. Adapted with permission from ref. [19]. 
Copyright 2011 American Chemical Society. 
The great structural variability gained by the multiple ligands around the metal center can be 
exploited for Structure Activity Relationship (SAR) studies. The synthesis of complexes with 
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labile ligands allows for rapid screening of different ligands around the metal center as it is 
the case for the ruthenium complex 8 (Figure 7).[25,37,38] For example, 6 is a selective Pim-1 
inhibitor (IC50 = 0.075 nM), while 4 is selective for DAPK1 (IC50 = 2.0 nM). Replacement of 
the CO ligand, which is a common motif for Pim-1 selective inhibitors, with a NCS ligand 
changes the selectivity towards DAPK1. The switch in selectivity is due to the interaction of 
the respective ligands with the glycine-rich loop of the respective enzymes. In the case of 
DAPK1, compared to other kinases such as Pim-1, the glycine-rich loop provides more 
space and can therefore accommodate the larger thiocyanato ligand. 
 
Figure 7. Precursor complex 8 can be used to create libraries of complexes carrying different ligands 
L1-L4 by substituting labile ligands at elevated temperatures.[25] 
 
Figure 8. Major revisions of the pyridocarbazole framework (excluding "simple" substitutions of the 
pyridocarbazole) leading to the new frameworks 9,[41] 10,[39] and 11.[35,40] 
Apart from exchanging ligands around the metal center, the ligands themselves can also be 
modified as part of the screening process to obtain the best enzyme inhibition possible. This 
is in line with conventional medicinal chemistry approaches. For example, the 
pyridocarbazole ligand has been substituted with a variety of functional groups.[28,42] A library 
of 68 amides has been screened, which was synthesized from a ruthenium(II) complex 
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carrying a NHS active ester modified cyclopentadienyl ligand.[26] More recently, even the 
pyridocarbazole unit, which has been the essential part of almost all enzyme inhibitors 
previously developed by Meggers and co-workers, has been substantially modified (9–11 in 
Figure 8).[35,39,40] In all cases, it was shown that the ligand modification leads to substantially 
different affinity and/or selectivity profiles. In this regard, the complexes behave like 
“traditional” fully organic enzyme inhibitors. 
The impressive scope of the above described system can be seen by the number of different 
kinases that can be targeted by these various complexes. It includes GSK3α,[16,42] 
GSK3β,[27,43] Pim1,[25,38] Pim2,[21] PAK1,[20,40] MST1,[23] BRAF,[30] PI3Kγ,[31] FLT4,[33,34] TrkA,[29] 
DAPK1,[19] MYLK,[41] PKCδ,[39] among others (Figure 9). This is a result of the extensive 
variation possibilities gained by using inert metal centers as scaffolds for ligands, which can 
be altered or exchanged – in addition to the metal itself. However, the complete biological 
consequences of the changes in the ligand or metal center have to be considered. Changes 
in the electronic properties of the metal ion lead to different excited state energies, possibly 
introducing previously unavailable (side-)reactivity.[34,44] Such drastic changes in complex 
stability can completely change the modes of action of the metal complexes. For example, 
ruthenium(II) complex 12 possesses, additionally to the protein kinase inhibition, light-
activatable properties which can lead to apoptosis.[34] It was indeed recently found that light 
irradiation of 12 leads to a ligand exchange generating complex 13 (see Scheme 1). The 
exact cellular pathway leading to apoptosis is not known, but kinase dependence has been 
ruled out. Nevertheless, metal centers can serve as inert structural elements giving access 
to geometries that are not available for purely organic compounds. It is expected that the 
concept of metal complexes as inert scaffolds for enzyme inhibition purposes will become 
increasingly important in the future, leading to more agents with unprecedented affinity and 
selectivity. 
 
Scheme 1. Photo-induced exchange of the SeCN ligand of 12 with a chloride leads to metal complex 
13 which can induce apoptosis via a kinase independent pathway. 
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Figure 9. Binding selectivities of selected Meggers-type kinase inhibitors within the human kinase 
dendrogram which displays the evolutionary relationship between kinases. Adapted with permission 
from ref. [41]. Copyright 2011 American Chemical Society. 
 
1.5 Organometallic Compounds targeting Specific Protein Residues 
One of the most used and effective methods to inhibit enzymes using organometallic 
complexes, and more generally metal complexes, is by covalent coordination of a metal 
center to a residue of a specific amino acid involved in the catalytic activity of the enzyme (at 
active or allosteric sites). This metal coordination renders the enzyme inactive, usually in an 
irreversible manner (see Scheme 2 for an example with a tyrosine phosphatase and a gold 
organometallic complex inhibitor[45]). More specifically, the catalytic mechanism of tyrosine 
phosphatases relies on the transfer of a phosphate group from the substrate to a cysteine 
residue in the catalytic site (Scheme 2, path (a)). The covalent coordination of the gold 
center to the cysteine residue allows for the irreversible inhibition of the tyrosine 
phosphatase (Scheme 2, path (b)). 
To achieve such an inhibition, the organometallic compound should ideally have several 
features:  
1) The complex has to be designed in a way that a ligand exchange is possible as for the 
gold complex in Scheme 2 where a chloride ligand is exchanged by the sulfur of the cysteine 
residue. 
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Scheme 2. Simplified depiction of the catalytic mechanism (path (a)) and covalent inhibition (path (b)) 
of a tyrosine phosphatase. 
2) The complex must be specific for an amino acid residue. This means that the metal ion 
has to be carefully selected. For example, if a cysteine residue is targeted, a (relatively) soft 
metal ion such as Au(I) or Pt(II) has to be chosen (see also point 3). 
3) The complex has to be stable enough to reach its anticipated target. In other words, the 
ligand must stabilize the complex but has to be labile enough! This “ideal” reactivity can be 
achieved by fine-tuning of the metal-ligand interaction. As an example of this improved 
kinetic stability, Berners-Price and co-workers demonstrated that Au(I) N-heterocyclic 
carbene (NHC) complexes such as 14 shown in Figure 10 could display a high kinetic 
stability in presence of thiols.[46] Interestingly, the authors showed that their complexes were 
much more reactive (rate constants 20 to 80-fold higher) towards selenocysteine (Sec) than 
to cysteine (Cys).[46] This difference was explained by the difference in pKa values of the two 
amino acids (Cys = 8.5;[47] Sec = 5.2[48]). At pH = 7.2, the selenol is fully ionized while the 
thiol is not, facilitating the attack of the selenium to the gold cation.[46] Importantly, these 
lipophilic, cationic Au(I) complexes selectively induced apoptosis in cancer cells but not in 
normal cells.[46] 
4) The complex should be selective for a specific enzyme. To date, as mentioned by Dyson 
in a recent review, this endeavor has never been achieved.[6] The metal complexes are 
targeting several enzymes instead of a single enzyme. In the case of Au(I) complexes, in 
addition to the targeted enzymes thioredoxin reductases (TrxRs), cysteine proteases, 
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kinases and glutathione S-transferases (GST P1-1), these compounds were also shown to 
inhibit other cysteine-containing proteins such as serum albumin.[6] However, the quest of 
highly selective enzyme inhibitor is a topic of intensive investigations and researchers from 
all around the globe are becoming closer and closer to achieve this important aim. For 
example, Ott et al. have recently demonstrated that both the enzymatic inhibition and 
enzyme selectivity of NHC-Au-L complexes could be tuned by subtle ligand modifications (L 
= Cl (15), PPh3 (16) or NHC (17); see Figure 10 for the structures).[49] More specifically, the 
authors showed that the more stable the Au-L bond was (15 < 16 < 17), the less reactive the 
complex was towards enzyme inhibition. However, a higher selectivity could be achieved 
when the Au-L bond is extremely stable.[49] For example, the most stable complex 17 was 
much more selective to TrxR than for glutathione reductase (GR) and glutathione peroxidase 
(GPx).[49] These findings on gold compounds, although obtained on isolated enzymes, are 
extremely promising and it can be anticipated that even more selective organometallic-based 
inhibitors will be discovered in the near future. 
 
Figure 10. Structure of Au(I) N-heterocyclic carbene complexes. 
Below, we will not review all organometallic complexes which inhibit enzymes by covalent 
coordination of a metal center to an amino acid residue, we send the reader to specific 
reviews and book chapters.[3,4,6,50,51] We will rather highlight an extension of the concept 
presented in this section. As mentioned above (point 4)), ideally, an organometallic complex 
should be selective for an enzyme and hence not inhibit several enzymes. As a first step 
towards solving this problem, Metzler-Nolte et al. recently reported the preparation of 
organometallic Au(I)-peptide bioconjugates which act as TrxR inhibitors.[52] More specifically, 
the authors envisaged to selectively bring different organometallic Au(I) complexes to a 
specific cellular organelle, namely mitochondria, which are known to host the targeted 
enzyme. For this purpose, they coupled, using a [3 + 2] cycloaddition reaction, tetrapeptides 
which have been previously shown by Szeto[53] and Kelley[54] to cross cell membranes and 
accumulate in mitochondria.[52] Examples of Au(I) peptide conjugates prepared in their work 
are presented in Figure 11. As desired, the metal conjugates 18–20 displayed prolonged 
stability in the presence of one equivalent of cysteine.[52] Worthy of note, the authors could 
demonstrate an interesting selectivity of their metal-containing bioconjugates for the 
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selenocysteine-containing TrxR over the cysteine-containing GR with EC50 values for TrxR 
lower by at least one order of magnitude compared to the EC50 values for GR. The inhibition 
of TrxR is of high relevance since this enzyme plays an important role in the cellular and 
mitochondrial redox system.[52] It has been described that TrxR was responsible for the 
antiproliferative activity of gold compounds.[55] 
 
Figure 11. Structures of organometallic Au(I)-peptide bioconjugates prepared by Metzler-Nolte et 
al.[52] 
 
1.6 The Bioisosteric Substitution 
Although still not fully obvious for part of the drug design community, many organometallic 
complexes can be handled in presence of oxygen and water just like “normal” organic 
compounds. Therefore, additionally to screening the substitution on a drug candidate with 
organic groups (e.g. methyl, ethyl, isopropyl or phenyl), organometallic moieties like 
ferrocenyl or ruthenocenyl could (should?) be employed during this screening as well. This 
would allow for the exploration of additional structures which can possibly occupy the binding 
pocket of an enzyme in a more efficient manner than purely organic inhibitors. The idea of 
adding organometallic moieties to enhance the activity of enzyme inhibitors is not new. 
Already in the 1970’s, Edwards et al. prepared ferrocenyl substituted penicillin and 
cephalosporin derivatives, which showed high antibacterial activity.[56] In this section, we will 
explain, on the basis of examples from recent literature, how to design organometallic 
enzyme inhibitors starting from known bioactive organic molecules. 
 
Starting from pre-existing organic enzyme inhibitors, a straight-forward manner to introduce 
organometallic moieties is to make use of so-called bioisosteric substitutions. Bioisosteric 
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groups exhibit similar biological effects as a result of their structural resemblance. Most 
prominently in terms of organometallic chemistry, ferrocenyl moieties are, despite their three-
dimensional rather than flat structure, classified as bioisosteric to phenyl. Ferrocene has 
therefore been extensively used in medicinal chemistry.[57] Ferrocene derivatives have been 
tested for their toxicity against various cancer cell lines as well as for their antimicrobial 
activity. However, in most cases, the exact mechanism of action has not been identified. In 
this section, we will focus on examples in which the mechanism clearly involves inhibition of 
an enzyme. 
 
Histones are proteins which are responsible for packing and ordering DNA in the nucleus. 
They are inherently basic and therefore positively charged at physiological pH. The charge 
state of histones controls their binding strength to DNA and can be altered by changing their 
degree of acetylation. Histone deacetylases (HDACs) catalyze the removal of negatively 
charged acetyl groups from the ε-lysine tails of histone proteins utilizing a catalytic zinc 
ion.[58] Negatively charged DNA then tightly wraps around the positively charged histone core 
leading to transcriptional silencing of genes. Different subtypes of HDACs control the 
acetylation of different histones leading to different changes in the transcription. Class I 
HDACs, comprising HDAC1, 2, 3 and 8, are often overexpressed in cancer tissues and are 
linked to circumvention of apoptosis and progression of cancer.[59] Subtype specific HDAC 
inhibitors are therefore subject of ongoing research as anticancer agents.[60]A number of 
HDAC inhibitors have been found to feature an aryl “cap” combined with a zinc binding motif, 
such as hydroxamic acid. Vorinostat 21 (Suberoylanilide hydroxamic acid, SAHA) is a 
representative of this class and is marketed as Zolinza for the treatment of cutaneous T-cell 
lymphoma (Scheme 3).[61] 
Making use of the bioisosteric substitution paradigm, Spencer et al. designed N1-hydroxy-N8-
ferrocenyloctanediamide 22 (Jay Amin hydroxamic acid, abbreviated JAHA) along with other 
similar derivatives (Scheme 3).[62,63] Docking studies with 22, starting from a cocrystal 
structure of Vorinostat 21 with HDAC8[64] supported the expectation of homologous binding 
interactions.[62] The hydroxylamines of both 21 and 22 interact with the catalytic zinc of the 
enzyme and the amides of 21 and 22 form an hydrogen bond with an aspartic acid of 
HDAC8. The ferrocene unit of 22 occupies a part of the binding pocket of HDAC8 which is 
known to be malleable. Indeed, 22 inhibits class I HDACs with nanomolar affinity (in vitro 
assays). The docking results are in agreement with the experimentally obtained IC50 values 
for 21 and 22 with HDACs (including HDAC8). The series of different ferrocene-containing 
derivatives all showed selectivity for class I and IIb over class IIa HDACs. The IC50 obtained 
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Scheme 3. Structures of the clinical HDAC inhibitor Vorinostat and of ferrocene derivatives which 
have been designed by bioisosteric substitution of the aromatic moiety. 
values surpass the affinity of Vorinostat for certain HDAC subtypes with inhibition levels in 
the subnanomolar range for the class IIb HDAC6. Cytotoxicity investigations further showed 
that 22 is inhibiting growth of MCF7 breast cancer cells. Triazole derivatives such as 23 were 
also shown to inhibit HDACs with low nanomolar IC50 values. However, the biological 
potential of these compounds, as evaluated in vivo in Xenopus laevis, falls short of this 
finding.[63] This was attributed to their inferior cellular uptake due to their poor membrane 
permeability caused by the ferrocene and triazole moieties present in 23. 
22 and 24 were also tested for their ability to inhibit cell growth of triple-negative breast 
cancer cell line MDA-MB231 in vitro.[65] These cells lack receptors for estrogen, 
progesterone, and epidermal growth factor. They are very aggressive and have a high 
malignant potential.[66] Despite the similar activity profiles against the pure HDACs, out of 22 
and 24, only 22 shows significant activity against MDA-MB231. The mechanisms involved in 
the cytotoxicity of 22 towards MDA-MB231 cells were further investigated. Unfortunately, 
Vorinostat 21 was not tested in the same study, hence complicating direct comparison to 22. 
Nevertheless, the cytotoxic effects found for 22 are similar to those observed for 21 in other 
studies, although partially on different cancer tissues cells.[67] 
It has to be noted, that the replacement of phenyl derivatives in known drugs with ferrocene 
can also have non-desired effects going up to the abolition of the activity of the parent 
compound. For example, the fungicide fluconazole has been modified to incorporate a 
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ferrocene unit instead of the difluorophenyl moiety (Scheme 4).[68] 25 does not inhibit fungal 
growth, neither on fluconazole resistant, nor on non-resistent yeast stems – it even 
stimulates growth under certain conditions. 
 
Scheme 4. Fungicide Fluconazole and its ferrocene derivative 25. 
In contrast to the examples highlighted above, in the following examples, organometallic 
moieties were introduced into enzyme inhibitors without replacing a specific bioisosteric 
group, such as a phenyl moiety. Carbonic anhydrase (CA) is an enzyme which catalyzes 
decomposition of carbonic acid to water and carbon dioxide: H2CO3  H2O + CO2.[69,70] 
There are several CA isozymes involved in different cellular processes. Inhibitors of CAs are 
in clinical use as diuretics, for gastric and duodenal ulcers, neurological disorders, 
osteoporosis, and others.[71] In order to control the biological effect of these inhibitors, 
subtype specificity is essential. In this regard, subtype hCA IX is of interest as it is 
overexpressed in cancer tissues and only very little expressed in normal tissues.[72] 
Benzenesulfonamides, or more generally arylsulfonamides, are a class of carbonic 
anhydrase inhibitors which consist of a sulfonamide attached to an aromatic moiety, 
classically a benzyl ring.[69–71] The deprotonated sulfonamide coordinates the catalytically 
active Zn2+ in the substrate binding pocket of the enzyme (see Figure 12). Many different 
additional substituents are tolerated on the aromatic system as can be seen by the broad 
range of structures of carbonic anhydrase inhibitors in clinical use including 
dichlorophenamide, brinzolamide, and acetazolamide (Figure 13). 
Poulsen and co-workers have studied the effect of ferrocene and ruthenocene as 
substituents on benzenesulfonamides (Figure 13).[74] Metallocene derivatives 26–29 all 
showed good binding affinity towards CAs. Ruthenocene derivative 27 was the most active 
compound against the relevant carbonic anhydrase hCA IX, surpassing the clinically 
available sulfonamides. Four cocrystal structures of 26–29 with hCA II showed the expected 
coordination of the sulfonamide group to the catalytic Zn2+ center of the enzyme (see Figure 
12 with 27 as an example).[73] The metallocenes are oriented towards the exterior of the 
binding pocket and form hydrophobic interactions with the surrounding amino acid residues. 
Notably, the metal centers are not directly interacting with the enzyme. An observed  
  
Part I – Photo-Activatable Compounds
1 Introduction
20 
 
 
Figure 12. Cocrystal structure of sulfonamide ruthenocene derivative 27 bound to carbonic anhydrase 
hCAII (PDB: 3P44).[73] Only amino acid residues close enough for interactions with the ligand and Zn2+ 
are shown. Hydrogen bonds are depicted as pink dotted lines, carbon in white, oxygen in red, 
nitrogen in blue, metals in grey. Protons are omitted for clarity. 
 
 
Figure 13. Therapeutic (top) and organometallic (bottom) arylsulfonamide carbonic anhydrase 
inhibitors. 
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difference in binding strength between ruthenocene and ferrocene derivatives is therefore 
thought to be due to the different size of the metals which makes the Cp-Cp distances 
slightly longer for the ruthenocenes. 
Interestingly, organometallic fragments have also been directly attached to the aromatic 
pharmacophore (30 in Figure 13).[75] Presumably for steric reasons, these compounds were 
less active than their benzenesulfonamide ligands. 
 
1.7 Novel Mechanisms of Enzyme Inhibition with Organometallic 
Compounds 
The structural modification of a known organic drug with an organometallic fragment can 
dramatically alter its mode of action. A prominent example to demonstrate this fact is 
ferrocifen. Ferrocifen is a ferrocenyl derivative of the anticancer drug tamoxifen.[76] It was 
found to have an additional mode of action compared to its parent organic compound, which 
is based on the oxidation of the iron present in ferrocifen. Below, we will focus our attention 
to the case of hexacarbonyl[2-propyn-1-ylacetylsalicylate]dicobalt (Co-AAS, 31; see Figure 
14). 
 
Figure 14. Antiproliferative compound hexacarbonyl[2-propyn-1-ylacetylsalicylate]dicobalt (Co-ASS, 
31) and its parent drug, aspirin (ASS). 
More than 15 years ago, Jung and co-workers reported the synthesis of the 
dicobalthexacarbonyl derivative 31 (Co-ASS) of the well-known analgesic aspirin 
(acetylsalicylic acid, abbreviated ASS).[77] Non-steroidal anti-inflammatory drugs (NSAIDs) 
such as ASS are known to bind to cyclooxygenases (COXs). This family of enzymes is 
responsible for the formation of prostaglandin H2 from arachidonic acid. Three subtypes of 
COX are known, namely COX-1, COX-2, and COX-3 which is a splice variant of COX-1. 
COX-1 is constitutionally expressed, while COX-2 is overexpressed in many cancer cell 
lines. ASS is a selective inhibitor of the COX-1 subtype and its analgetic and anti-
aggregating effects stem from this interaction. 
Co-ASS 31 has been shown to be toxic towards several cancer cell lines, including 3677 
human melanoma and H2981 lung adenocarcinoma cancer cell lines,[77] LAMA-84 and 
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K-562 leukemia cells,[78] as well as MCF-7 and MDA-BM 231 human breast cancer cells.[79] 
For classical NSAIDs including aspirin, there are still debates whether they are effective 
against cancer, and if so, by which mechanism(s).[80,81] However, ASS has been clearly 
proven to be ineffective in all screenings against the cancer cell lines in which 31 has shown 
to be active. There has been great interest in understanding the molecular mechanism(s) 
responsible for the cytotoxicity of 31. Below, we discuss the reasons for the spectacular 
changes in cytotoxic activity between Co-ASS 31 and ASS. 
 
By analogy to the known effects of ASS, the inhibition efficiency of both COX subtypes has 
been evaluated for a series of dicobalthexacarbonyl complexes. The inhibition constants of 
31 for COX-1 and COX-2 are lower than those for ASS.[79] Interestingly, 31 binds equally 
strongly to COX-2 and COX-1, while ASS is known to bind only strongly to COX-1. As the 
binding pocket of COX-2 is bigger than the one of COX-1, the bulkiness of the Co2(CO)6 
group could explain this shift in selectivity. Importantly, comparison of the COX inhibition 
among dicobalt hexacarbonyl complexes 31- 34 (Figure 15) with their order of cytotoxic 
strength revealed that a higher inhibition strength towards COX correlates with a higher 
cytotoxicity. COX inhibition is therefore thought to be (part of) the mode of action of this class 
of compounds. 
ASS is known to deactivate COX by irreversibly acetylating serine 530 in the active site of 
COX-1,[82] and correspondingly serine 516 in COX-2.[83] Hence, Ott and co-workers were 
interested in the potential of Co-ASS 31 to acetylate COX.[83] The exact acetylation sites of 
COX-2 after incubation with Co-ASS were examined by LC-ESI tandem mass spectrometry. 
In contrast to ASS, incubation with Co-ASS did not lead to acetylation of serine 516, but to 
acetylation of several lysine residues, namely lysine 166, lysine 346, lysine 432 and lysine 
598 (see Figure 16). Lysine 346 is part of the entrance channel of the active site and thus 
acetylation could hinder the access of the substrate. Lysine 166 and lysine 432 are close to 
the heme prosthetic group, and therefore acetylation of these residues could abolish the 
function of the protein. In analogy to ASS, these modifications can be assumed to be 
irreversible. In summary, Co-ASS 31 leads to acetylation of COX, however, at different sites 
than ASS. Nevertheless, these acetylations are certainly involved in the inactivation of the 
COX enzymes. 
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Figure 15. Co-ASS 31 and derivatives Co-Prop 34, [84] Co-Diph 38[84], and the salicylates 32, 33, 35, 
36[79] and 44.[85] 
 
Figure 16. Acetylation sites of COX-2 due to incubation with Co-ASS 31. Figure reproduced with 
permission from ref. [83]. Copyright © 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. 
Interestingly, 32, which lacks the acetyl moiety present in Co-ASS 31 and ASS and, thus, 
cannot acetylate COX, is still inhibiting COX.[86] However, the presence of the organometallic 
moiety in Co-ASS enables to postulate several alternative modes of COX inhibition. It has 
been shown that both the alkyne ligand and the Co cluster by themselves are not effective 
antiproliferative agents.[86] However, if the salicylate ligand acts as a carrier to bring the 
organometallic cluster to the COX binding pocket, the Co2(CO)6 moiety could exert an 
enzyme inhibition activity as previously demonstrated by Jaouen and co-workers with the 
interaction of the Co2(CO)6 motif with an amino acid residue inside a protein binding 
pocket.[87] In this work, the authors designed the organometallic hexacarbonyl[ethinyl-
estradiol]dicobalt 37, a derivative of 17α-ethinylestradiol, to bind to estrogen hormone 
receptors to deactivate them (Scheme 5).[87] Indeed, the Co2(CO)6 moiety of 37 could react 
with a close-by nucleophilic cysteine moiety inside the binding pocket of the estrogen 
receptor in a Nicholas-type reaction via formation of a reactive carbocation binding 
covalently to the receptor.[88] In analogy, a similar reactivity pattern has to be considered as 
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mode of action of Co-ASS 31. However, the overall structure of 31 is significantly less 
favorable for the formation of a carbocation than the structure of 37.[87,89,90] Furthermore, the 
structurally related cobalt complex 38 (Figure 15), which is cytotoxic, does not contain any 
methylene groups enabling the formation of a carbocation species.[78] Another indicator 
against the reactive carbocation hypothesis is the absence of Nicholas-like reactions when 
incubating 31 with nucleophilic thiols.[91] In summary, a COX inhibition mechanism based on 
the formation of a reactive carbocation species seems extremely unlikely for 31. 
 
Scheme 5. Hexacarbonyl[ethinylestradiol]dicobalt 37, its potential formation of a carbocationic 
species and subsequent reaction with a thiolate.[87,90] 
Depending on the substituents on the alkynyl ligand, Co2(CO)6 moieties can release carbon 
monoxide.[92] The COX enzymes contain a heme prosthetic group which is essential for 
electron transfer between the protein and the physiological substrate arachidonic acid. Since 
the heme group is known to bind CO, a CO dependent mechanism seems appealing. The 
influence of the alkyne substituents on the CO release of dicobalt hexacarbonyl alkyne 
complexes is significant, leading either to compounds which are stable or to compounds with 
rapid CO release rates (t1/2 = 1.1 min).[92] Indeed, decomposition of the Co2(CO)6 moiety of 
31 has been observed after treatment with thiols.[91] On the other hand, UV/vis and HPLC 
analysis of 31 incubated in EMEM cell culture medium containing fetal calf serum did not 
clearly show any decomposition of 31 within 24 h.[91] Notably, other metal-based ASS-
derivatives without CO ligands, namely copper and silver derivatives, were also shown to 
have antiproliferative properties.[93] Based on these findings, CO release could potentially 
play a role in the activity of Co-ASS 31 although there is no clear evidence to date. 
 
As presented above, an interaction between 31 and COX enzymes seems likely to be 
involved in the cytotoxic activity observed. The higher inhibition efficiency of COX and the 
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altered subtype specificity of 31 compared to its parent drug ASS could explain the 
differences in activity on cancer cell lines. Furthermore, the aforementioned molecular 
mechanisms could be amplified by a greater cellular uptake and accumulation of the 
compound in cells. The lipophilicity of the Co2(CO)6 moiety is typically higher than the 
lipophilicity of the alkyne ligand by itself.[79,94] This might play an important role in the 
bioactivity of 31 since a greater lipophilicity often leads to a better cellular uptake through the 
hydrophobic cellular membrane. Indeed, for the Co2(CO)6-modified 5-alkynyl-2’-
deoxyuridines 39 and 40 (Figure 17) a correlation between cellular uptake, which was 
determined by measuring the intracellular cobalt content via atomic absorption spectroscopy, 
and their cytotoxicity in MCF-7 and MDA-MB 231 breast cancer cells has been 
demonstrated.[94] 
 
Figure 17. Dicobalt hexacarbonyl derivatives of 5-alkynyl-2‘-deoxyuridine.[94] 
A similar trend has been observed for the only moderately cytotoxic fructopyranose 
derivatives 41–43 (Figure 18).[95] For these compounds, it was found that the cytotoxicity 
depends on the degree of acetalization of the hydroxyl groups of the sugar which is directly 
responsible for the lipophilicity of the compounds. The cellular uptake was found to correlate 
with both cytotoxicity and lipophilicity. 
 
 
Figure 18. Dicobalt hexacarbonyl derivatives of fructopyranose 41, 42, and 43. The degree of 
acetylation determines the lipophilicity and correlates with their cytotoxicity in MCF-7 breast cancer 
cells. [95] 
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Gust and co-workers showed by analysis of HPLC retention times that the coordination of 
the Co2(CO)6 cluster fragment to ASS derivatives indeed increases their lipophilicity.[79] 
Additionally, it was found that the accumulation grade of 31, i.e. the resulting concentration 
of 31 inside cells, is six times higher for 31 than for cisplatin. However, comparison of Co-
ASS 31 with the potential metabolite Co-Prop 34 and the pseudo-dimer 38 (Figure 15) 
revealed a lack of correlation between lipophilicity, cellular uptake, and cytotoxicity in 
leukemia cells.[78] A more extensive study with other salicylate cobalt derivatives confirmed 
this finding.[79] Thus, the lipophilicity and cellular uptake of cobalthexacarbonyl derivatives of 
ASS seem unrelated to their cytotoxicity. 
Some doubt about a pathway based purely on COX inhibition came from a recent report on 
other metal cluster ASS derivatives. Compounds with structures corresponding to 31 with 
Co4(CO)10 or Ru3(CO)9 clusters showed lower COX-inhibition efficiencies than 31, but similar 
inhibition of cell growth.[96] Simple COX inhibition seems not to be exclusively the reason for 
the activity of 31. Further investigations for alternative mechanisms of action for the 
cytotoxicity of 31 are therefore discussed below. 
Since the great success of the inorganic anti-cancer drug cisplatin, metal-based drug 
candidates are suspected to interfere with DNA, e.g. by direct coordination. Incubation of 
salmon testes DNA with 31–36 showed efficient DNA association for all compounds.[79] 
Indeed, the attachment was more efficient than for cisplatin. Even more effective was the 
precursor Co2(CO)8. This suggests that the interaction with DNA results from the cobalt-
alkyne moiety. However, a correlation between the efficiency of DNA association and 
cytotoxicity could not be found. Moreover, after incubation with cobalt salicylates, the nuclei 
of both MCF-7 and MDA-BM 231 cells did not contain significant amounts of cobalt, as 
determined by atomic absorption spectroscopy.[79] Cell cycle analysis of MDA-MB 231 cells 
after incubation with 44 (Figure 15) revealed an increased amount of cells in the S phase, 
and less in the G2/M phase.[85] This means that the cells underwent DNA duplication but did 
not divide afterwards. Since DNA synthesis appears to function normally, an interaction of 44 
with the DNA is very unlikely. Overall, the in vitro studies exclude DNA binding to be part of 
the mechanism of action of dicobalt hexacarbonyl salicylates, including 31.  
Of note, due to the high cytotoxicity against the human breast cancer cell lines MCF-7 and 
MDA-MB-231 with IC50 values of less than 2 µM, the possibility of an interaction of 31 with 
the estrogen receptor was also investigated.[79] The binding efficiency was very low and the 
hypothesis was dismissed. 
Furthermore, the redox system of the cell could be influenced by the cobalt cluster. 31 has 
been shown to form disulfides when treated with thiols such as glutathione or cysteine.[91] 
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The activity of glutathione reductase is a very sensitive indicator for the redox state within 
cells. It has been shown that glutathione reductase activity was not influenced by 34, 31, 
ASS, or the alkyne ligand of 31.[79] A mechanism of action based on changing the redox 
state of the cell can therefore be excluded. 
 
All in all, the combination of the results presented above suggests that several mechanisms 
are responsible for the cytotoxicity observed for 31. The inhibition of the COX enzymes is 
most likely one of them, but both the NSAID as well as the organometallic moiety could have 
additional activities. The cytotoxicity of celecoxib, a COX-2 specific NSAID, in cancer cell 
lines which lack COX,[81] as well as the cytotoxicity of Co2(CO)6 modified peptides, which 
clearly do not interact with COX,[97] underline that additional mechanisms of action are likely. 
The case as a whole illustrates that the search for the exact mechanism of action of a 
complex can be very tedious and the use of organometallic complexes brings even more 
possibilities for modes of action. This is not a disadvantage though! As shown in the case of 
the ferrocifens or the antimalarial drug candidate ferroquine the additional activities gained 
with organometallic compounds can be used to circumvent resistances of purely organic 
enzyme inhibitors, or even establish an inhibitory activity. 
 
1.8 Organometallic Compounds as Cargo Delivers of Enzyme Inhibitors 
A very recent and innovative concept using organometallic-based assemblies for enzyme 
inhibition purposes has been described by Therrien et al. In their work, the authors employed 
water-soluble organometallic cages to deliver biologically active compounds to cancer 
cells.[98] An example of one of their constructs is shown in Figure 19. These cages presents 
two main interests in the field of medicinal chemistry: 1) Despite containing several aromatic 
moieties, these cages are water soluble as they are usually highly charged, which offers the 
opportunity to bring very lipophilic compounds into cells; 2) They allow a selective increase 
of the cellular uptake of the biologically active compounds into cancer cells thank to the 
enhanced permeability and retention effect (EPR effect). This effect discovered by 
Matsumura and Maeda in 1986 describes the ability of large molecules to accumulate much 
more in solid tumors than in healthy tissues.[99] Diverse types of compounds were 
encapsulated into the organometallic cages including photosensitizers,[100] antiproliferative 
agents,[101] fluorescent agents,[102] dendrimers[103] and recently enzyme inhibitors.[104,105] For 
the latter, two different kinds of enzyme inhibitors were encapsulated into the organometallic  
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Figure 19. Structure of a water-soluble organometallic cage which can be used to deliver lipophilic 
guests. 
drug used against colorectal cancer Floxuridine which is an irreversible inhibitor of 
thymidylate synthase; 2) antiproliferative ruthenium arene complexes from the so-called 
RAPTA family (see Figure 20 for the chemical structures of these compounds). More 
specifically about this class of compounds, the organometallic RAPTA complexes from the 
Dyson group are very promising anticancer drug candidates. RAPTA stands for Ruthenium 
Arene PTA whereby PTA is the abbreviation for the ligand 1,3,4-triaza-7-phosphatricyclo-
[3.3.1.1]decane present in all complexes of this family. RAPTA-C (Figure 20) is one of the 
most famous examples of this family. The exact mechanism of action of RAPTA-C, and in 
general from all this class of compounds, is not understood in a definitive manner. However, 
it is clear that these compounds have a fully different behavior compared to cisplatin which 
targets DNA. At this stage of the research, enzyme binding is the most probable explanation 
for the activity of the RAPTA complexes.[51] It was indeed demonstrated that such 
compounds form adducts with proteins[106] and that the reactivity of RAPTA-C and cisplatin in 
the presence of proteins was much different.[107] 
To allow a stable encapsulation of these two types of enzyme inhibitors into their 
organometallic cages, Therrien and co-workers connected them to pyrene derivatives 
(Figure 21). The encapsulation of the pyrenyl group into the cage is driven by hydrophobicity  
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Figure 20. Structures of the anticancer drug candidate RAPTA-C and of the FDA approved anticancer 
drug Floxuridine. 
and π-π interactions. Of note, the successful encapsulation of the compounds was 
confirmed by diverse NMR, X-ray crystallography and ESI-MS techniques. In the case of the 
Ru arene complexes, an increase in cytotoxicity on four different human cancer cell lines 
was observed for 45–47 (Figure 21) when these compounds were encapsulated. These 
observations reinforce the postulate that the encapsulation increases the cellular uptake.[105] 
This effect was clearly demonstrated by monitoring the fluorescence of the pyrenyl moiety. 
An increase of uptake by a factor of two was determined for complex 45. Of note, the cage 
itself employed in this work was found to be highly cytotoxic and even in some cases more 
toxic than the encapsulated pyrenyl-arene ruthenium complex system itself. This intrinsic 
toxicity of the cage can be potentially beneficial, provided the cage is selectively delivered to 
cancer cells. In the case of the caged Floxuridine derivatives, an important difference in 
cytotoxicity between the cage and the encapsulated pyrenyl-enzyme inhibitor was observed. 
Hence, all encapsulated pyrenyl-Floxuridine system studied were found to be more toxic 
than the empty cages alone.[104] Importantly, as anticipated by the authors, the host-guest 
complexes were found to be highly water-soluble contrary to the Floxuridine compounds 
used in the clinic.[104] 
In a similar line of thought to what has been presented above, namely the delivery of known 
enzyme inhibitors into cancer cells using organometallic cages, the Dyson group coupled, for 
example, the glutathione S-transferase (GST) inhibitor ethacrynic acid (EA) to two RAPTA 
derivatives (48 and 49, Figure 22).[108,109] In this work, in addition to the enzyme inhibition by 
the known inhibitor, the authors also anticipated to engender an inhibition by the 
organometallic delivery compound used to bring the enzyme inhibitor to the cancer cells 
(dual cytotoxic mode of action). More specifically, knowing that EA, which has been 
investigated as a potential anticancer drug,[110] binds competitively to the hydrophobic 
cosubstrate (H-site) of GST and that the RAPTA compounds react with soft nucleophilic 
centers (e.g. thiol groups), the authors postulated that 48 and 49 could bind to the enzyme at 
the H-site and could also interact with the two reactive cysteine residues present in 
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Figure 21. Structures of the encapsulated pyrenyl-arene ruthenium complexes and of pyrenyl-
Floxuridine of Therrien et al. 
 
 
Figure 22. Structures of Ru organometallic complexes containing an EA moiety (48 and 49) or 
phenoxazine- (50) and anthracene-based (51) ligands. 
GST P1-1.[108,111] As anticipated, 48 and 49 were found to bind the catalytic H-site but also to 
have inhibition constants on GST P1-1 three or four times lower than EA. This observation 
clearly demonstrates that the ruthenium centers of 48 and 49 are involved in the inhibition of 
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GST P1-1. This was confirmed by X-ray crystallography and ESI-MS measurements. Hence, 
49 was found to decompose, over a period of time, into EA and a ruthenium derivative. This 
cleavage is assumed to occur by virtue of a possible allosteric effect or simply due to binding 
of the EA moiety present in 49 to the H-site of GST.[108] 
The same research group coupled phenoxazine-[112] (50) and anthracene-based (51) 
multidrug resistance (MDR) modulator ligands to Ru organometallic complexes (Figure 
22).[113] More specifically, the inhibition of P-glycoprotein (Pgp), which is a plasma membrane 
protein responsible for drug efflux from cells and which is implicated in MDR was 
studied.[111,114] The combination of the selectivity of ruthenium complexes towards cancer 
cells and the ability of the phenoxazine and anthracene derivatives for Pgp inhibition was 
found to lead to a synergistic effect. The coordination of the anthracene-based ligand to the 
Ru complex (51) resulted indeed in an enhancement of the cytotoxicity as well as of the 
inhibition of Pgp, compared to the anthracene-based ligand itself.[113] The other newly formed 
complexes in this study such as 50 were found to be also generally more cytotoxic than their 
MDR modulator ligands. However, they inhibited in a lesser extend Pgp than the original Pgp 
inhibitor derivatives used as ligands.[113] Interestingly, it could be demonstrated with 
fluorescence measurement that 51 was accumulating in cell nuclei thank to the presence of 
the fluorescent anthracene group in 51. This observation correlates well with the results 
obtained by 3H-thymidine incorporation assay which suggests inhibition of DNA synthesis as 
possible mechanism of cytotoxic action. All in all, these latest results indicate that, although 
Pgp inhibition was confirmed in vitro, the main mechanism of action of 51 could be 
independent from inhibition of efflux proteins.[113] Of note, Hartinger, Arion and Keppler used 
a similar strategy to couple ruthenium or osmium organometallic complexes to flavonoids 
derivatives which are known to inhibit human topoisomerases,[115,116] paullone derivatives 
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Figure 23. Structures of two Ru and Os organometallic complexes containing flavonoid (52)[116] and 
paullone (53)[117] derivatives. 
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which are known to inhibit cyclin-dependent kinase (CDK) glycogen synthase kinase-3 
inhibitors and mitochondrial malate dehydrogenase,[117,118] 3-(1H-benzimidazol-2-yl)-1H-
quinoxalin-2-one bearing pharmacophoric groups of known protein kinase inhibitors[119] or [3-
(1H-benzimidazol-2-yl)-1H-pyrazolo[3,4-b]pyridines (and indolo[3,2-d]benzazepines 
derivatives which are known CDK inhibitors (see Figure 23 for two examples of such 
compounds).[120] It must be however stated that for none of these compounds it was proven 
that the enzyme inhibitors were actually released in cells, although it is reasonable to 
anticipate that release will ultimately happen. 
 
1.9 Organometallic Enzyme Inhibitors for Theranostic Purposes 
The idea of having a drug (or two very similar drugs) which can be used for both diagnostic 
and therapeutic purposes is extremely appealing, not to say the holy grail of researchers in 
drug discovery! This strategy is called theranostics. This term is a portmanteau of the words 
therapy and diagnostics. For this purpose, a potential approach is the use of a bioconjugate 
that contains a ligand that can be coordinated to an element which is known to have two 
different radioisotopes. One of them should have the right radionuclear properties to be used 
for diagnosis and the other one for therapy. Hence, by designing a single bioconjugate 
incorporating a ligand suitable for one element, diagnosis and therapy could be 
undertaken.[121] Among the different elements of the periodic table, potential dual candidates 
are 64Cu-67Cu, 123I-131I and 86Y-90Y. Note that due to their comparable chemical behaviors, 
111In and the more “exotic” 177Lu have been proposed as alternatives to 90Y due to the high-
radiation energy of the latter. However, an important drawback of these duos is the 
production of the radioisotopes. A synchrotron is indeed required. A more favorable option is 
the use of the 99mTc-188Re matched pair. The 99mTc radioisotope has ideal radio-nuclear 
properties for diagnostic purposes and is available from a commercial 99Mo/99mTc generator. 
It is the reason why this radionuclide is used in over 90% of nuclear medicine scans.[122] 
Furthermore, its third row congener, Re, has relatively similar chemistry to that of Tc 
(although the kinetic behaviour and stability in the higher oxidation states is somewhat 
different[123,124]) and has two particle-emitting radioisotopes (188Re and 186Re). One of those is 
of particular interest for therapy due to its specific activity, namely 188Re (t1/2 = 16.98 h, β = 
2.12 MeV, γ = 155 keV).[125] Importantly, in the view of easy clinical applications, 188Re can 
be produced conveniently using a 188W/188Re generator. In addition, the non-radioactive 
isotopes of Re (185Re and 187Re) provide a model for the chemistry of both the radioactive 
analogues. With this concept in mind, several groups have embarked into this field of 
research using the so-called bifunctional chelator (BFC) approach (see Figure 24 for an 
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example). In the BFC approach, a metal chelator is linked via a spacer to a targeting vector 
whose role is to bring the radionuclide to a specific location (e.g. an over-expressed 
receptor). 
 
Figure 24. Schematic representation of the BFC approach using the peptide neurotensin as an 
example of biomolecule (PDB code: 2LNE). 
To date, no such dual 99mTc/188Re theranostic bioconjugates have entered into the market. 
Furthermore, with regard to the topic of this book chapter, in most of the radioactive 
conjugates currently approved for diagnostic or therapeutic purposes, and more generally in 
the clinical pipeline, the target of the radiolabeled bioconjugate is not an enzyme but a 
specific receptor (e.g. somatostatin receptor, epidermal growth factor receptor (EGFR), etc.). 
In this context, Alberto et al. recently developed a fully novel theranostic concept related to 
enzyme inhibition. They envisaged preparing, for therapeutic purposes, an enzyme inhibitor 
containing a cold Re atom. The diagnostic counterpart to this Re complex was anticipated to 
be a 99mTc analogue that could be easily synthesised via the [99mTc(CO)3(H2O)3]+ precursor 
which is generated using the Isolink® kit “Carbonyl Labeling Agent”.[123] The enzymes 
targeted in their study were carbonic anhydrases (CAs). This family of enzymes, which holds 
16 different isozymes, catalyses the formation of carbonic acid from water and CO2 (see also 
section 3 of this chapter). Importantly, from a drug discovery point of view, the two human 
CAs, namely hCA IX and hCA XII, are known to be over-expressed in a large number of 
hypoxic tumors, mostly in the perinecrotic areas.[126] These two isozymes are therefore 
interesting targets for both cancer diagnosis and therapy. With this in mind, Alberto and co-
workers synthesised a small series of arylsulfonamide, -sulfamide and -sulfamate based 
compounds with the [(Cp-R)Re(CO)3] motif (54–57, Figure 25)[127] knowing that unsubsituted 
sulfonamides and their bioisosters (sulfamates and sulfamites) bind to the Zn(II) ion of the 
active site of CA by substitution of the non-proteinogenic zinc ligand to generate a 
tetrahedral adduct[4,69,128] and, importantly, that metal complexes and notably organometallic 
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compounds have been previously shown to be excellent candidates as CA inhibitors (see 
also section 4 of this chapter).[4,5,129]  
 
Figure 25. Structures of Re-containing CA inhibitors prepared by Alberto et al.[127] and of the drug 
Acetazolamide (AZA). 
Of the four compounds prepared in their laboratories, 54 was found to be of particular 
interest. 54 inhibits CA II, CA XII and CA XIV in the low nanomolar range similarly to the 
known CA inhibitor acetazolamide (AZA) which is an approved drug against a range of 
conditions including glaucoma, abnormal retention of fluids, epileptic seizures, etc.[130] 
However, as can be seen in Figure 26, 54 has a much more pronounced selectivity pattern 
over the range of the twelve CA isozymes studied in this work compared to AZA. The 
enhanced selectivity of 54 was proposed to be due to a better space occupancy as 
previously described by Meggers et al. with kinase inhibitors or by Paulsen and co-workers 
with CA inhibitors (see sections 2 and 4 of this chapter). [25,73] Of great importance from a 
pharmaceutical point of view, 54 inhibits much more hCA IX, which is overexpressed in 
certain tumors, than the physiologically dominant hCA II.[127] 
 
Figure 26. Comparison of the inhibition constants of 54 and AZA over a range of isozymes of hCAs. 
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The authors of the study could also demonstrate by X-ray crystallography that one of their 
organometallic CA inhibitors, namely 57, was indeed able to bind to hCA II. As shown in 
Figure 27, 57 binds its target in a similar manner than other CA inhibitors by coordinating the 
Zn atom of the active site of hCA II through the deprotonated nitrogen of arylsulfonamide. As 
in the case of Meggers’ kinase inhibitors and of Paulsen’s CA inhibitors, the metal ion is not 
playing a direct role in the binding of the inhibitor to the enzyme. The organometallic part 
CpRe(CO)3 is neither interacting with the protein nor with water molecules. However, a 
hydrophobic interaction between the CpRe(CO)3 moiety and three amino acids 
(phenylalanine 131, leucine 198 and proline 202) was observed (Figure 27). 
 
Figure 27. Crystal structure of complex 57  hCA II (PDB code: 3RJ7). The Rhenium CA inhibitor 57 
coordinates the Zn atom (in magenta) of the active site of hCA II through the deprotonated nitrogen of 
arylsulfonamide. The Zn atom is bound to three histidines. 
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Scheme 6. Synthetic procedure for the 99mTc analogue of 56, namely 58; i) Isolink kit “Carbonyl 
Labeling Agent”, [99mTcO4]-. 
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In order to confirm the theranostic concept of their project, Alberto et al. had still to 
demonstrate that a 99mTc analogue of their Re-containing CA inhibitors could be easily 
prepared in water since the 99mTcO4- is eluted from the 99Mo/99mTc generator as a saline 
solution from the generator. Towards this aim, as presented in Scheme 6 with the 99mTc 
analogue of 56 (58) as an example, they prepared the 99mTc complex by reacting [99mTcO4]- 
with the dicyclopentadienyl dimer 59 that they had initially synthesized. The authenticity of 
58 was then confirmed by comparison of the HPLC retention times of 58 (γ trace) and 56 
(UV trace). As mentioned by the authors, this concept can be extended to any enzyme 
inhibitor and holds therefore great promises. 
 
1.10 Conclusion 
The increasing demand in specific enzyme inhibitors by the pharmaceutical industry for the 
development of new drugs is a fantastic opportunity for bioorganometallic chemists to 
display the full potential of their compounds in medicinal chemistry. As explained in this 
chapter, one important advantage of organometallic compounds compared to purely organic 
ones lies in the additional geometric and electrostatic profiles that can be created. This can 
be exploited by “simple” bioisosteric derivatization of a known enzyme inhibitor, or by 
designing new inert organometallic scaffolds. As nicely demonstrated with the work of 
Meggers on kinase inhibitors, by using the unique physico-chemical properties of such 
complexes, higher enzyme specificity can be obtained compared to when purely organic 
compounds are employed. Importantly, this specificity can be found to be useful not only for 
drug development reasons but also in the field of chemical biology where such inhibitors are 
highly valued to understand cellular processes. For instance, two of Meggers’ Ru(II) 
organometallic complexes are currently commercially available as GSK3 and Pim-1 
inhibitors. Moreover, the reactivity of metal centers of organometallic compounds as well as 
their electrochemical properties can also be exploited for enzyme inhibition purposes. For 
example, metal centers can covalently bind to certain protein residues or release bio-active 
compounds, allowing for modes of enzyme inhibition for which no resistances are known to 
date. Moving beyond therapeutic uses, the metal ions present in organometallic complexes 
can be tracked by various analytical methods, making them valuable diagnostic tools. We 
are optimistic that the various advantages that organometallic compounds yield will soon 
lead to news exciting advances in the field of medicinal chemistry and chemical biology. 
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1.12 Abbreviations 
ASS Acetylsalicylic acid, aspirin 
ATP Adenosine triphosphate 
AZA Acetazolamide 
BFC Bifunctional chelator 
CA Carbonic anhydrase 
CDK cyclin-dependent kinase 
COX Cyclooxygenase 
Cp Cyclopentadienyl 
Cys Cysteine 
DNA Deoxyribonucleic acid 
EA Ethacrynic acid 
EGFR Epidermal growth factor receptor 
EPR effect Enhanced permeability and retention effect 
ESI-MS Electron Spray Ionization – Mass Spectrometry 
FDA Food and Drug Administration 
GPx Glutathione peroxidase 
GR Glutathione reductase 
GST Glutathione S-transferase 
HDAC Histone deacetylase 
HPLC High performance liquid chromatography 
IC50 Inhibitory concentration 50 
JAHA Jay Amin hydroxamic acid 
L Ligand 
LC-ESI Liquid chromatography – electron spray ionization (mass spectrometry) 
MDR Multidrug resistance 
NHC N-heterocyclic carbene 
NMR Nuclear Magnetic Resonance 
NSAID Non-steroidal anti-inflammatory drugs 
PDB Protein database 
Pgp P-glycoprotein 
RAPTA Ruthenium Arene PTA whereby PTA is the abbreviation for the ligand 1,3,4-
triaza-7-phosphatricyclo-[3.3.1.1]decane 
SAHA Suberoylanilide hydroxamic acid 
SAR Structure activity relationship 
Sec selenocysteine 
TrxR thioredoxin reductase 
UV/vis Ultraviolet/visible light 
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2.1 Contributions to the publication 
P.A. designed the experiments, and carried them out together with A.L. The first draft of the 
manuscript was written by P.A. 
 
2.2 Abstract 
The quantum yields for uncaging reactions are in most cases determined relative to other 
uncaging reactions, often of 1-(2-nitrophenyl)ethyl-phosphate (“caged phosphate”). Herein, 
we demonstrate that the quantum yields acquired using this method can be off by an order 
of magnitude at the typical irradiation wavelengths around 350 nm and describe an easy-to-
use alternative procedure using inexpensive azobenzene. 
 
 
 
Keywords: Azo compounds • Caged compounds • Photochemistry • Photouncaging • 
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2.3 Article 
The release of bioactive compounds upon light irradiation has been coined “uncaging”. The 
method has been extensively applied, especially for studies on molecular processes in 
biology.[3] One of the first demonstrations of this technique was the uncaging of adenosine 
triphosphate (ATP) for studying the Na:K pump of human red blood cell ghosts.[4] However, 
although caging substances has since become an established method, the determination of 
uncaging efficiencies is still not trivial. Even today, more than 30 years later, reports on 
convenient methods to determine these quantum yields are being published.[5] Standard 
actinometry protocols which utilize for example ferrioxalate[6] or phenylglyoxylic acid[7] for 
determining the total number of photons reaching the sample can be employed. However, 
they often require several milliliters of concentrated solutions. More conveniently, the 
photolysis rate of the caged compound in question and of a caged compound with a known 
quantum yield can be compared without having to calculate the total photon flux. The 
advantage is that no compromise on the technical setup has to be made regarding volume 
or dilution of sample and reference. Caged compounds are often the result of a tedious 
synthesis and, therefore, are used as sparingly as possible. When using other caged 
compounds for comparison purposes, both reference and sample can be measured in small-
volume cuvettes and in highly dilute solutions. Plots of the percentage of remaining cage 
against the irradiation time/dose can then be used to compute the uncaging quantum yields 
by multiplying the quotient of the slopes with the known quantum yield of the reference 
molecule. To this end, 1-(2-nitrophenyl)ethyl-phosphate (“caged phosphate”)[4] or 1-(2-
nitrophenyl)ethyl-ATP (“caged ATP”)[4,8] have been extensively used (Figure 1 a). The 
quantum yield of caged phosphate has been reported to be 0.54 ± 0.04 as the average of 
two measurements with individual values of 0.50 and 0.58,[4] referencing to ferrioxalate 
actinometry.[9] The illumination setup featured a light source with a peak wavelength of 
342 nm and half-bandwidth of 60 nm. For caged ATP, a quantum yield of 0.63 has been 
reported using a 150 W xenon arc lamp with a Corning 9863 glass band-pass filter (300–
350 nm),[8] referencing to caged phosphate.[4] The choice of the reference compound 
depends therefore on the irradiation wavelength one wishes to apply. Caged ATP is used as 
reference for irradiation at 313 nm.[5] Caged phosphate in phosphate buffered saline (PBS) 
has often been used as a reference for the determination of uncaging quantum yields around 
an irradiation wavelength of 350 nm, for example when using a Rayonet photo-reactor with 
light bulbs emitting at a center wavelength of 350 nm and a half-bandwidth of approximately 
36 nm (see Figure S1 in the Supporting Information, SI, for an emission spectrum).[10,11,12] It 
has been assumed that caged phosphate has the same uncaging quantum yield under these 
irradiation conditions as at 342 nm (vide supra).[4] To the best of our knowledge, no uncaging 
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action spectrum of caged phosphate has been determined. However, the uncaging action 
spectrum of the caged ATP, which relies on the same photocaging group, shows a 
difference of approximately 30% between 342 nm and 355 nm (Figure 2).[13,14] It therefore 
appears questionable if the quantum yield at 350 nm is the same as at 342 nm. Furthermore, 
data presented by Baldwin and coworkers suggest that the photolysis of caged phosphate at 
308 or 355 nm gave a significantly lower quantum yield,[15] i.e. the maximum amount of 
released phosphate upon photolysis, compared to the value by Kaplan and coworkers upon 
irradiation at around 342 nm.[4] Taking these findings into consideration, a proper 
determination of the uncaging quantum yield of caged phosphate upon irradiation at around 
350 nm is missing. 
 
 
Figure 1. a) Caged compounds used in this study. Caged ATP and caged phosphate are often used 
as references for the determination of uncaging quantum yields. Re-PLPG-NLS is a recently reported 
caged compound with cytotoxic activity upon light irradiation;[16] b) trans-cis isomerization of 
azobenzene. The process can be monitored by UV/Vis spectroscopy or analytical HPLC with UV 
detection. 
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Figure 2. Normalized uncaging action spectrum of caged ATP. General conditions: pH=7.4, 200 W 
mercury lamp equipped with a monochromator, amount of free ATP determined by a luciferase assay. 
Adapted from [14], copyright 1998, with permission from Elsevier. 
To evaluate the uncaging quantum yield of caged phosphate upon irradiation around 
350 nm, experiments using ferrioxalate as reference were carried out. To gain the most 
precise and transferable data possible, measurements were performed using a Nd:YAG 
laser frequency-tripled to emit at 355 nm which was part of a laser flash photolysis 
spectrometer. Such setups have been used for the investigation of uncaging 
processes.[8,17,18,19] The monochromatic light has the advantage of being more reproducible 
between setups of different research groups. Using a standard ferrioxalate actinometry 
procedure,[20] the total photon flux per laser shot was hence determined. Based on this, the 
fraction of photons absorbed by the caged compound, and the rate of uncaging of caged 
phosphate, the uncaging quantum yield of the latter was calculated. It was found to be 
merely 0.04, only 8% of the assumed 0.54. 
An additional referencing system based on azobenzene was designed to verify the low 
quantum yield. The cis-trans isomerization of azobenzene is a known actinometer in 
methanol (Figure 1 b) and it has been used before for the determination for uncaging 
quantum yields, but at other wavelengths and without description of the exact protocol.[12,21] 
Depending on the irradiation wavelength used, complicated mathematical procedures are 
required to determine the photon flux.[20,22,23] At wavelengths greater than approximately 
340 nm, there is no total absorption of all photons due to insufficiently low molar absorptivity 
of both azobenzene isomers and hence, the total photon flux cannot be determined directly. 
However, we found that a protocol based on the irradiation of a dilute solution of 
azobenzene can be applied (see SI for details). This protocol can generally be adapted for 
the determination of uncaging quantum yields. Shortly, dilute solutions of trans-azobenzene 
and the caged compound in question were separately irradiated under identical conditions 
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with the laser at 355 nm. Subsequent comparison of the reaction rates leads directly to the 
quantum yield for the uncaging process, similarly to and with the same advantages as using 
another caged compound as reference (vide supra). As an additional benchmark the total 
photon flux was determined based on the isomerization of azobenzene under consideration 
of the fraction of absorbed photons. The procedure leads, within the typical error range of 
10%,[4,5,24,25] to the same total photon flux as ferrioxalate. For the determination of the photo-
uncaging quantum yields the total number of photons is not required, in contrast to the 
ferrioxalate method. The quantum yields of uncaging processes can be easily computed by 
direct comparison of the uncaging rate with the isomerization rate of solutions with the same 
optical densities. The resulting uncaging quantum yield for caged phosphate relative to 
azobenzene is 0.036 and therefore in line with the values obtained using ferrioxalate 
actinometry. 
The current literature does not offer a straight-forward explanation for this drastic difference. 
To shed some light on possible reasons the uncaging quantum yield of caged ATP was 
determined in the same way and found to be 0.02. Based on the uncaging action spectrum 
of caged ATP (Figure 2) and the uncaging quantum yield at 313 nm,[8] again a more than 
tenfold higher quantum yield was expected. As result of these findings, we suspect that 
shorter wavelength light in the originally used broadband light source led to faster uncaging 
and therefore overestimation of the quantum yield of caged phosphate. As caged ATP was 
referenced to it, the inaccuracy was carried on. In order to avoid such problems 
monochromatic light sources, which are nowadays ubiquitous, should be used for the 
determination of quantum yields. 
Recently, our group started investigating the uncaging of inert bioactive metal 
complexes.[16,26] To illustrate the dramatic effect that the above findings have on the 
determination of uncaging quantum yields of new compounds, solutions of the caged 
compound Re-PLPG-NLS (see Figure 1 a) in PBS were tested against caged phosphate, 
ferrioxalate, and the azobenzene protocol (Table 1). Caged phosphate was used for 
irradiation with the laser setup at 355 nm as well as the often used Rayonet UV-reactor 
setup with a center wavelength of 350 nm (vide supra). In both cases, Re-PLPG-NLS was 
uncaging approximately three times as fast as caged phosphate. This would correspond to 
an uncaging quantum yield of 1.62 in the UV-reactor and 1.39 with the laser setup (Table 1, 
Entries A and B), respectively. With today’s understanding of the nitrobenzyl-uncaging 
mechanism, it is physically impossible to achieve uncaging quantum yields greater than 
1.[7,8,11,18,19,21,27] The moderate difference between the two values obtained relative to 
ferrioxalate or azobenzene can be explained by two reasons:1) The presence of shorter 
wavelength light in the emission spectrum of the UV-reactor; these photons are very likely 
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more efficiently inducing uncaging (compare Figure 2); 2) the inherently low accuracy in 
quantum yield determinations; errors of 10-20% are generally accepted.[4,5,24] The 
ferrioxalate and azobenzene methods were only applied upon laser irradiation at 355 nm, as 
the broad emission spectrum of the UV reactor inevitably leads to errors such as 1). Using 
the ferrioxalate method,[20] a quantum yield of merely 0.11 for Re-PLPG-NLS was 
determined (Table 1, Entry C). Similarly, the azobenzene protocol led to an uncaging 
quantum yield of 0.10 (Table 1, Entry D). In summary, the quantum yield obtained with 
caged phosphate as reference deviates more than tenfold from the actual values. 
Table 1. Quantum yield of Re-PLPG-NLS relative to different reference molecules. 
Entry Irradiation Conditiona Reference Molecule Corresponding Quantum Yield
A UV Caged phosphate 1.62 
B Laser Caged phosphate 1.30 
C Laser Ferrioxalate 0.11 
D Laser Azobenzene 0.10 
a For detailed experimental descriptions corresponding to the indicated irradiation conditions, see SI. 
In short, UV reactor: Rayonet RMR-200 photo reactor, light bulbs with peak wavelength of 350 nm; 
laser: Nd:YAG laser frequency-tripled to 355 nm. All experiments were carried out in PBS except for 
the azobenzene experiments, which were carried out in methanol. 
The herein described azobenzene protocol is experimentally very convenient. Its flexibility 
regarding the concentration of the used solutions and the fractions of irradiated solution, for 
example due to different flask geometries, was investigated. To this end, measurements in 
different cuvettes, i.e. with different path lengths and window sizes, were compared (see SI 
for details). It was found that the relative uncaging rates of azobenzene and the caged 
compounds were, as expected, independent from the absolute concentration and fraction of 
irradiated solutions, as long as the conditions were identical for all samples. The 
azobenzene-based protocol for the acquisition of uncaging quantum yields therefore 
combines the experimental ease of relative methods (referencing to other caged 
compounds) with the precision of experimentally inflexible absolute methods (actinometers 
like ferrioxalate). It should be noted however, that the temperature should not exceed typical 
room temperatures to avoid temperature-induced isomerization of azobenzene.[22] 
In summary, we could demonstrate using two independent protocols, that caged phosphate, 
although frequently used by scientists working with caged compounds, is not an appropriate 
reference for the determination of uncaging quantum yields around 350 nm using the 
literature value reported at 342 nm. Comparison of the values obtained for Re-PLPG-NLS 
with caged phosphate and with two other references showed a more than tenfold deviation. 
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Caged ATP showed the same trend as caged phosphate at an irradiation wavelength of 
355 nm. To obtain the correct uncaging quantum yields, a protocol based on the well-
understood photochemical cis-trans isomerization of azobenzene can be applied. This 
protocol allows for convenient, inexpensive, and accurate determination of uncaging 
quantum yields for irradiation wavelengths around 355 nm. Given the great popularity of 
cage compounds in chemical biology and this wavelength range for studying them, the 
presented findings will undoubtedly have an important impact on this research field. 
 
2.4 Acknowledgements 
This work was supported by the Swiss National Science Foundation (Professorship N° 
PP00P2_133568 and Research Grants N° 200021_129910 and N° 200020_146776 to 
G.G.), the University of Zurich (G.G.) and the Stiftung für Wissenschaftliche Forschung of 
the University of Zurich (G.G.). 
  
Part I – Photo-Activatable Compounds
2 Quantum Yields for UV-A Induced Photouncaging
54 
 
2.5 Supporting Information 
 
2.5.1 Materials and Instrumentation 
UV/Vis spectroscopy was performed on PerkinElmer Lambda 25 and Varian Cary 100 
instruments. 1H and 13C NMR spectra were recorded on Bruker Avance (400 and 500) 
spectrometers. 13C NMR measurements were carried out as 13C {H}. NMR spectra were 
referenced to the residual solvent signal. HPLC measurements were performed on a VWR 
Hitachi Chromaster system with 5110 pump, 5210 autosampler, 5310 column oven, and 
5430 diode array detector. The method was run on a Macherey-Nagel EC 250/3 
NUCLEOSIL 100-5 C18 with a flow of 1mL min-1, 0.1% TFA in water : acetonitrile, 0 min: 
90:10, 27 min: 0:100, 31 min: 0:100, 36 min: 99:1, 38 min: 99:1, 40 min: 90:10, 41 min: 
90:10. LC-MS spectra were measured on an Acquity from Waters system equipped with a 
PDA detector and an auto sampler coupled to a Bruker Daltonics HCT 6000 mass 
spectrometer. LC-MS was run using an Agilent Zorbax 300SB-C18 analytical column (3.5 
μm particle size, 300 Å pore size, 150 × 4.6 mm). The LC run (flow rate: 0.5 mL min-1) was 
performed with a linear gradient of A (double distilled water containing 0.1% v/v formic acid) 
and B (acetonitrile containing 0.1% v/v formic acid); t = 0 min, 5% B; t=3 min, 5% B; t=17 
min, 100% B; t=20 min, 100% B; t = 25 min, 5% B. Experiments in the UV-reactor were 
undertaken in a Rayonet RMR-200 photo-reactor, using 6 bulbs emitting around 350 nm 
(see Figure S1 for a detailed emission spectrum). The irradiation power was checked with an 
X11 optometer (Gigahertz-Optik) and determined to be 42 W m-2 at the center of the reactor. 
The temperature inside the reactor was 30 °C. Experiments with laser irradiation were 
undertaken using an Edinburgh Instruments LP920 laser flash photolysis setup with a 
Continuum Surelight Nd:YAG laser, frequency-tripled to generate monochromatic (i.e. 
bandwidth of less than 1 nm) light with a wavelength of 355 nm. The laser was slightly 
misaligned to reach a suitable irradiation power. As every misalignment results in a slightly 
different amount of photons reaching the sample, measurements belonging together were 
performed on the same day. 
All used solvents were HPLC grade, water was doubly distilled. 1-(2-nitrophenyl)ethyl-
phosphate (“caged phosphate”) was prepared as described in the literature.[28] The analytical 
data matched what was reported before.[4,28] Potassium trioxalatoferrate(III) trihydrate 
(“ferrioxalate”) was purchased from Alfa Aesar, 1,10-phenantroline (anhydrous, 99%) from 
ABCR (Germany), sodium acetate (anhydrous, 98.5%) from Fluka (Switzerland), sulfuric 
acid (95-97%) from Merck (Germany), NPE-caged-ATP (10 mM in H2O) from Jena 
Bioscience GmbH (Germany), azobenzene (ANALPEST quality) from Sigma-Aldrich 
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(Switzerland). The purity, especially the absence of the cis isomer was checked by 1H and 
13C NMR spectroscopy and HPLC (see below). All commercial chemicals were used without 
further purification. All experiments were performed in triplicate at room temperature, except 
for the ones in the UV-reactor (see above). 
 
Additional analytical data for trans-azobenzene: ε(λ=236 nm) = 9581 ± 233 M-1cm-1, 
ε(λ=355 nm) = 2992 ± 89.4 M-1cm-1. HPLC: tR = 18.23 min. 
Additional analytical data for cis-azobenzene: HPLC: tR = 13.26 min. 
 
2.5.2 Methods 
Table of Variables and Units 
In all equations consistent units have to be used. The units below only represent a few of the 
possible choices. 
Table S1. Overview over variables, their meaning, and their associated units. 
Variable Representing… Exemplary Units 
A Area of peak %, mAU s 
k “Rate constant” s-1, J-1 cm² 
x Irradiation dose or time s, min, J cm-2, laser shots 
ɸ Quantum yield Dimensionless 
D Absorbed light dose J, J cm-2 
λ Wavelength nm 
Eλ Emission intensity at wavelength λ Dimensionless (relative), J cm-2 
F Fraction of absorbed photons Dimensionless 
Aλ Absorbance at wavelength λ %, mAU 
N Amount of substance Mol 
V Volume L 
l Length (of path through cuvette) cm 
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UV-Reactor Experiments 
The caged compound solutions were prepared by starting from 20 mM DMSO stock 
solutions, and diluting them with “Dulbecco’s PBS modified, without calcium and 
magnesium” (PAA Laboratories GmbH, Pasching/Austria, part of GE Healthcare, pH=7.2) to 
an OD(λ=350 nm)=0.2. The solutions were placed in a fluorescence cuvette (1x1 cm) at the 
center of the reactor and irradiated for certain time intervals. The progress of the uncaging 
reaction was monitored by LC-MS analysis and integration of the corresponding peak of the 
UV chromatogram. The percentage of remaining caged compound was plotted as a function 
of irradiation dose and was fitted by a single exponential (first order kinetics law): 
ܣ ൌ ܣ଴ ൈ ݁ି௞௫ 
with ܣ being the area of the peak after irradiation dose ݔ, ܣ଴ being the area before the 
irradiation, ݇ being the coefficient defining the rate of the process, and ݔ being the irradiation 
dose or time (see Figure S6 and Figure S7). Either the time or dose has to be chosen for all 
calculations. The initial slopes of the fitted curves were determined because there no 
competing chromophores, i.e. the products of the reaction, influence the reaction. The slope 
is used to calculate the quantum yields by the following formula: 
߶௦௔௠௣௟௘ ൌ ߶௥௘௙௘௥௘௡௖௘ ൈ
ݏ݈݋݌݁௦௔௠௣௟௘
ݏ݈݋݌݁௥௘௙௘௥௘௡௖௘ ൈ
ܦ௥௘௙௘௥௘௡௖௘
ܦ௦௔௠௣௟௘  
with ߶ being the corresponding quantum yields, and ܦ being the respective absorbed light 
doses: 
ܦ ൌ නܧఒ ൈ ܨ	݀ߣ 
with ܧఒ being the wavelength dependent emission intensity of the light source (see Figure 
S1) and ܨ being the fraction of absorbed photons as defined by: 
ܨ ൌ 1 െ 10ି஺ഊ 
with ܣఒ being the absorbance at wavelength λ. 
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Figure S1. Normalized emission spectrum of UV lamps. Reprinted with permission from Southern 
New England Ultraviolet Co Inc., Branfort, CT, USA. 
 
Laser Experiments 
500 µL of sample solutions with an OD(λ=355 nm)=0.2 along the 0.2 cm path of a Starna 
28F/Q/10 cuvette (2x10 mm fluorescence cuvette, 700 µL maximum volume) were irradiated 
for certain time intervals, characterized by a certain number of laser shots. The progress of 
the uncaging reaction was monitored as described above for RE-PLPG-NLS, caged 
phosphate, and caged ATP, except for the following. As lower conversion points could be 
monitored by this irradiation method, linear fits of the decomposition of the first 20% were 
sufficient to determine the uncaging rates. Exponential fits were not needed. The monitoring 
of ferrioxalate and azobenzene was done as described below. 
The following procedure can be used to calculate the uncaging quantum yields if 1) the 
same cuvette with 2) the same filling level for all measurements (to ensure the same fraction 
of molecules being irradiated) and 3) the graphs have been brought to the same units (e.g. 
percent of remaining caged compound or amount of converted compound (in moles)): 
߶௦௔௠௣௟௘ ൌ ߶௥௘௙௘௥௘௡௖௘ ൈ ݏ݈݋݌݁௦௔௠௣௟௘ݏ݈݋݌݁௥௘௙௘௥௘௡௖௘ ൈ
ܨ௥௘௙௘௥௘௡௖௘
ܨ௦௔௠௣௟௘  
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with ܨ being the fraction of absorbed photons by the corresponding substance. For 
ferrioxalate actinometry experiments described herein, ܨ௥௘௙௘௥௘௡௖௘ ൌ 1. For dilute samples, 
the fraction of absorbed photons ܨ is defined as described in the UV-reactor section. 
Consequently, the factor ிೝ೐೑೐ೝ೐೙೎೐ிೞೌ೘೛೗೐ ൌ 1 if the absorbances of the reference and the sample 
are identical at λ=355 nm. 
 
Ferrioxalate Actinometry 
Ferrioxalate actinometry was performed as described by Montalti.[20] In short, 3.00 mL of a 
ferrioxalate solution (0.012 M in 0.05 M H2SO4) were irradiated in a fluorescence cuvette 
(10x10 mm, 3.5 mL volume, Starna 23/Q/10) as described above. Less than 10% of the 
ferrioxalate complex should be destroyed during the irradiation. 0.50 mL of a 1,10-
phenanthroline (0.1 weight-% in acetate buffer made from 225 g sodium acetate trihydrate / 
1 L 0.5 M H2SO4) were added and the solution well mixed. Absorbance at 510 nm was 
directly measured. All data points were acquired as triplicates, plotted against the irradiation 
amount, and fitted with a linear function (see Figure S8). 
In the following, the calculation of the total photon flux in general is described and 
exemplified with the data presented in Figure S8. The slope of the fitting function (Δܣହଵ଴	௡௠) 
was used to determine the amount of freed Fe2+ per laser shot: 
݊ሺܨ݁ଶାሻ
݈ܽݏ݁ݎ	ݏ݄݋ݐ ൌ 	
ܸ ൈ Δܣହଵ଴	௡௠
݈ ൈ ߝହଵ଴	௡௠ ൌ
0.00350	ܮ	 ൈ 0.02712
1	ܿ݉	 ൈ 11100 ܮ݉݋݈ ൈ ܿ݉
ൌ 8.55 ൈ 10ିଽ݉݋݈ 
with ܸ being the volume of solution taken for determination of the absorbance, ݈ being the 
path length of the cuvette, and ߝହଵ଴	௡௠ being the molar absorptivity of Fe(phen)32+ at 
λ=510 nm. The number of photons per laser shot is then: 
݊ሺ݄ߥሻ
݈ܽݏ݁ݎ	ݏ݄݋ݐ 	ൌ 		
݊ሺܨ݁ଶାሻ
݈ܽݏ݁ݎ	ݏ݄݋ݐ	 ൈ 	߶ ൌ
8.55 ൈ 10ିଽ݉݋݈
1.25 ൌ 6.84 ൈ 10
ିଽ݉݋݈ 
with ߶ being the quantum yield of the Fe2+ production at 355 nm, which is 1.25. 
 
Azobenzene Actinometry 
trans-Azobenzene was dissolved in methanol to a concentration of 3.36x10-4 M. The 
absorbance of the solution was determined in a Starna 28F/Q/10 cuvette (2x10 mm 
fluorescence cuvette, 700 µL maximum volume) to be OD(λ=355 nm)=0.20. 500 µL 
(݊ሺܽݖ݋ܾ݁݊ݖ݁݊݁ሻ ൌ 1.68 ൈ 10ି଻	݉݋݈) of the solution were irradiated. All data points were 
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acquired as triplicates, plotted against the irradiation amount, and fitted with a linear function 
(Figure S9). 
The slope of the fitting function was determined to be 5.19796 ൈ 10ିସ. Consequently, a 
fraction of 
5.19796 ൈ 10ିସ
0.200 ൌ 0.00260 ൌ 0.260% 
of trans-azobenzene was converted to cis-azobenzene with each laser shot. The backwards 
reaction of cis-azobenzene to trans-azobenzene can be neglected, as less than the first 10% 
of conversion have been taken into account and the absorbance of cis-azobenzene is 
significantly lower at λ=355 nm than the absorbance of trans-azobenzene. This hypothesis is 
generally correct as long as the reaction rate does not change over time, i.e. the plotted 
curve remains linear. The amount of generated cis-azobenzene is given by: 
݊ሺܿ݅ݏ	– ܽݖ݋ܾ݁݊ݖ݁݊݁ሻ 	ൌ 	 ሺ݂ݎܽܿݐ݅݋݊	݋݂	ܽݖ݋ܾ݁݊ݖ݁݊݁	ܿ݋݊ݒ݁ݎݐ݁݀ሻ ൈ ݊ሺܽݖ݋ܾ݁݊ݖ݁݊݁ሻ
ൌ 0.00260 ൈ 1.68 ൈ 10ି଻݉݋݈ ൌ 4.37 ൈ 10ିଵ଴݉݋݈ 
with ݊ሺܽݖ݋ܾ݁݊ݖ݁݊݁ሻ being the total amount of azobenzene. The fraction of absorbed photons 
ܨ is: 
ܨ ൌ 1 െ 10ି஺యఱబ	೙೘ ൌ 	1 െ 10ି଴.ଶ଴଴ ൌ 0.370 
The amount of photons can then simply be expressed as: 
݊ሺ݄ߥሻ
݈ܽݏ݁ݎ	ݏ݄݋ݐ 	ൌ 		
݊ሺܿ݅ݏ െ ܽݖ݋ܾ݁݊ݖ݁݊݁ሻ
	߶	௧௥௔௡௦→௖௜௦ ൈ ܨ ൌ 	
4.37 ൈ 10ିଵ଴݉݋݈
0.15 ൈ 0.370 ൌ 7.89 ൈ 10
ିଽ݉݋݈ 
with 	߶	௧௥௔௡௦→௖௜௦ being the quantum yield for the transcis photoisomerization, which can be 
assumed to be 0.15 between 334 and 365 nm.[20] 
 
Comparison of Ferrioxalate and Azobenzene Actinometry 
The mean value of the azobenzene and ferrioxalate measurements for the determination of 
photon flux is 7.36x10-9 (±10%). 
 
Comparison for Azobenzene Referencing for the Use of Different Cuvettes and Concentrations 
Measurements for azobenzene-isomerization and uncaging of caged phosphate were 
repeated in a 100 µL cuvette (1 cm x 0.2 cm, Hellma 105.202-QS). The absorbance was 
adjusted to OD(λ=355 nm)=0.2 along the 1 cm path and irradiation took place along the 
2 mm path length. The sample concentrations were thus lower by a factor of 5, compared to 
the measurements described above, due to the different path lengths in absorbance 
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measurements. Due to the smaller total sample volume, the fraction of actually irradiated 
azobenzene molecules is greater than in the case of the 700 µL cuvette. Consequently, the 
isomerization rate differed from the previous measurements by a factor of 3. However, the 
ratio between the uncaging rate of caged phosphate and the isomerization of azobenzene 
remained constant, and hence the determined uncaging quantum yield for caged phosphate 
did not change either.  
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2.5.3 UV/Vis Spectroscopy 
 
Figure S2. UV/Vis spectrum of Re-PLPG-NLS in phosphate buffered saline. 
 
 
Figure S3. UV/Vis spectrum of trans-azobenzene in methanol. 
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Figure S4. UV/Vis spectrum of caged phosphate in phosphate buffered saline. 
 
 
Figure S5. UV/Vis spectrum of caged ATP in phosphate buffered saline. 
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2.5.4 Representative Uncaging Graphs 
A representative graph for uncaging of Re-PLPG-NLS relative to azobenzene upon laser 
irradiation has recently been published by our group.[16] 
 
 
Figure S6. Percentage of remaining caged phosphate as a function of light dose. The data was 
acquired by irradiation with the UV reactor. 
 
 
Figure S7. Percentage of remaining Re-PLPG-NLS as function of light dose. The data was acquired 
by irradiation with the UV reactor. 
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Figure S8. Absorbance at 510 nm, attributable to Fe(phen)3, as function of irradiation amount. The 
data was acquired by irradiation with the laser. Values for the fit: ܣହଵ଴	௡௠ ൌ 0.0348 ൅ 0.02712 ൈሺ݅ݎݎܽ݀݅ܽݐ݅݋݊	ܽ݉݋ݑ݊ݐሻ. R²=0.99, error for intercept: 0.00521, error for slope: 0.00107. 
 
 
Figure S9. Absorbance at 355 nm, attributable to trans-azobenzene, as function of irradiation 
amount. The data was acquired by irradiation with the laser. Values for the fit: ܣଷହହ	௡௠ ൌ 0.20083 െ5.19796 ൈ 10ିସ ൈ ሺ݅ݎݎܽ݀݅ܽݐ݅݋݊	ܽ݉݋ݑ݊ݐሻ. R²=0.99. Error for intercept: 2.9205 ൈ 10ିସ, error for slope: 
2.48257 ൈ 10ିହ. 
 
Part I – Photo-Activatable Compounds
2 Quantum Yields for UV-A Induced Photouncaging
65 
 
 
Figure S10. Percentage of remaining caged phosphate as a function of irradiation amount. The data 
was acquired by irradiation with the laser. Note, that this graph has been acquired on a different day 
using a different laser power than the exemplary graphs for azobenzene and ferrioxalate depicted 
above. Values for the fit: ܥ݋݉݌݋ݑ݊݀ሺ%ሻ ൌ 100 െ 0.73693 ൈ ሺ݅ݎݎܽ݀݅ܽݐ݅݋݊	ܽ݉݋ݑ݊ݐሻ. R²=0.99. The 
intercept was fixed to 100, error for slope: 0.04031. 
 
 
Figure S11. Percentage of remaining caged ATP as a function of irradiation amount. The data was 
acquired by irradiation with the laser. Note, that this graph has been acquired on a different day using 
a different laser power than the exemplary graphs for azobenzene and ferrioxalate depicted above. 
Values for the fit: ܥ݋݉݌݋ݑ݊݀ሺ%ሻ ൌ 100 െ 0.03719 ൈ ሺ݅ݎݎܽ݀݅ܽݐ݅݋݊	ܽ݉݋ݑ݊ݐሻ. R²=0.99. The intercept 
was fixed to 100, error for slope: 0.0009947. 
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The following graphs have been acquired pairwise on the same day with the same laser 
power and are thus directly comparable (S12 with S13 and S14 with S15). 
 
Figure S12. Percentage of remaining trans-azobenzene, as determined by monitoring the 
absorbance at 355 nm, and plotted as function of irradiation amount. The data was acquired by 
irradiation with the laser. Values for the fit: ܥ݋݉݌݋ݑ݊݀ሺ%ሻ ൌ 100 െ 0.94571 ൈ ሺ݅ݎݎܽ݀݅ܽݐ݅݋݊	ܽ݉݋ݑ݊ݐሻ. 
R²=0.99. Error for intercept: 8.43882 ൈ 10ିସ, error for slope: 0.02649. 
 
 
Figure S13. Percentage of remaining caged phosphate as a function of irradiation amount. The data 
was acquired by irradiation with the laser. Values for the fit: ܥ݋݉݌݋ݑ݊݀ሺ%ሻ ൌ 99.99983 െ 0.21237 ൈ
ሺ݅ݎݎܽ݀݅ܽݐ݅݋݊	ܽ݉݋ݑ݊ݐሻ. R²=0.99. Error for intercept: 0.00563, error for slope: 0.00878. 
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Figure S14. Percentage of remaining trans-azobenzene, as determined by monitoring the 
absorbance at 355 nm, and plotted as function of irradiation amount. The data was acquired by 
irradiation with the laser. Values for the fit: ܥ݋݉݌݋ݑ݊݀ሺ%ሻ ൌ 99.57124 െ 1.86924 ൈ 
ሺ݅ݎݎܽ݀݅ܽݐ݅݋݊	ܽ݉݋ݑ݊ݐሻ. R²=0.99. Error for intercept: 0.78914, error for slope: 0.12679. 
 
 
Figure S15. Percentage of remaining caged ATP as a function of irradiation amount. The data was 
acquired by irradiation with the laser. Values for the fit: ܥ݋݉݌݋ݑ݊݀ሺ%ሻ ൌ 99.45488 െ 0.28753 ൈ
ሺ݅ݎݎܽ݀݅ܽݐ݅݋݊	ܽ݉݋ݑ݊ݐሻ. R²=0.98. Error for intercept: 0.75399, error for slope: 0.02816.  
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3.2 Abstract: 
Two-photon cages have been synthetically modified to allow for attachment of enzyme 
inhibitors via an alcohol or carboxylic acid function. The cages furthermore can be 
conjugated to a targeting vector using click chemistry. Most importantly, the control of 
enzyme activity is being directly demonstrated with a caged cyclooxygenase-2 inhibitor. 
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3.3 Article 
Enzymes are one of the largest families of proteins and play a vital role in many biological 
signaling pathways and metabolic processes. However, even in cases where the reaction 
catalyzed by the enzyme is known, exploring its full significance within its biological network 
context remains challenging to date.[1,2] In order to gain more insight into the exact functions 
and effects of enzymes within their biological network, temporal and spatial control over their 
activity is needed. The use of light in this context is extremely appealing since it is known to 
not bias biological systems at certain wavelengths and doses.[3,4] Despite the enormous 
impact that such a discovery would have, the examples of specific enzyme inhibitors whose 
activity can be turned on on demand using light are extremely scarce. Photoswitchable 
inhibitors have been recently reported for acetylcholinesterase.[5] However, this concept 
requires the design of completely new compounds with special properties and is likely 
impossible in many instances.[6] Furthermore, the effects of common drugs cannot be 
investigated by this technique as they are not photoswitchable. Nanoscopic carrier systems 
with the ability to release their cargo upon light irradiation have recently been reported.[7] 
However, macromolecular approaches are fundamentally different and less controllable than 
ones relying on small molecules.[8] 
A potential alternative to control the biological activity of a biomolecule using light is through 
(photo-)caging. In this case, a photo-labile protecting group is attached to a crucial functional 
group of a biomolecule thereby deactivating its biological function. Upon irradiation with UV 
light, the original bioactive compound is released and its bioactivity hence restored. This 
technique has been successfully applied in chemical biology to understand or modulate 
biological processes.[4,9] For example, we recently reported the successful single-photon 
caging/uncaging of metal complexes to control their anti-cancer activity.[10] However, the use 
of light in the UV range is problematic since it is absorbed by biomolecules and is known to 
damage them. Over the last few years, new cages have been developed, which can be 
cleaved by two-photon excitation upon irradiation in the near-IR range.[11] This quantum 
mechanical phenomenon allows the excitation of a molecule by near-simultaneous 
absorption of two photons. Each of these two photons only needs half the power, 
respectively twice the wavelength that single photon excitation would require. The light is 
therefore not absorbed by biomolecules, making it less harmful and allowing for deeper 
tissue penetration. An additional advantage of the two-photon process is the better spatial 
resolution stemming from the need of high photon densities for this phenomenon to occur. In 
combination with focused lasers, this leads to a subcellular three-dimensional resolution. 
Consequently, two-photon uncaging facilitates chemical biological investigations with 
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unprecedented precision in temporal (femtosecond scale) and spatial (femtoliter scale)[12] 
dimensions. This has already led to many important discoveries, especially in the field of 
neuroscience, where it has been employed for the release of neurotransmitters.[13] 
Nevertheless, the impact of two-photon uncaging on other fields, such as the 
aforementioned investigations on enzymes, is limited so far. A few caged enzyme inhibitors 
with the potential to be two-photon-uncaged have been reported.[14–17] For those compounds, 
either no biological two-photon experiments were performed,[16] the irradiation times needed 
were very long (several hours),[14,15] the inhibition change upon uncaging was only 
moderate,[14] or the uncageable concentrations were physiologically irrelevant.[17] Herein, we 
report an important step towards applicability of two-photon uncageable for studying enzyme 
function. The design, synthesis and physicochemical properties of a two-photon uncaging 
platform, which can be used for studying enzyme function in a time and space controlled 
manner are described. We caged two drugs which selectively inhibit cyclooxygenase 2 
(COX-2), namely Celecoxib and Lumiracoxib. Celecoxib is FDA-approved for use against the 
localized disease arthritis and has been shown to have anticancer activity. Lumiracoxib had 
been approved for the treatment of arthritis as well, but has no anticancer activity. The 
differences in the physiological effect are so far not understood because of the multitude of 
interdependent effects triggered by COX inhibition,[1] and caged probes could help 
elucidating these differences. The two drugs have to be caged via different functional 
groups. This has been realized by adjusting the respective functional group on the cage, 
namely an alcohol for Lumiracoxib and a carboxylic acid for Celecoxib. Of high interest, the 
cage structures can furthermore be decorated with a targeting moiety. This is demonstrated 
by the attachment of a peptide, which specifically directs the cage towards cancer cells. The 
targeting could be used in chemical biological investigations to study the influence of bio-
distribution on the function of the inhibitor. The potential to control the activity of an enzyme 
by a targeted two-photon caged enzyme inhibitor is being demonstrated in an in vitro assay. 
Enzyme activity assays have been shown to be good benchmarks for caged inhibitors in UV-
uncaging experiments.[18] 
Based on a two-photon cage developed by Goeldner and co-workers,[19] which has already 
been used on HeLa cells,[20] we developed cages 1 and 2 (see Scheme 1). The syntheses 
are described in the Supporting Information. The carboxylic acid of Lumiracoxib and 
sulfonamide function of Celecoxib were caged to the alcohol and carboxylic acid moieties of 
1 and 2, respectively, to give caged Lumiracoxib 3 and caged Celecoxib 4. Other cage 
structures with carboxylic acid attachment groups have been reported before,[21] but to the 
best of our knowledge, 2 is the first biphenyl nitro cage capable of caging via a carboxylic 
acid function. The biphenyl-core of both cages is substituted with a tetraethylene glycol chain  
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Scheme 1. Caging of the COX-2 selective inhibitors Lumiracoxib (top) and Celecoxib (bottom), 
exemplary attachment of a targeting peptide to caged Celecoxib (bottom right), and the previously 
reported caged glutamate (top right).[19] Reaction conditions: a) N,N’-dicyclohexylcarbodiimide, DMAP, 
Lumiracoxib, CH2Cl2, 0 °C to rt, 20 h, 80%; b) 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, DMAP, Celecoxib, CH2Cl2, rt, 2 h, 54%; c) CuSO4, sodium ascorbate, IFLLWQR(Pra)RR, THF/H2O 2:1, rt to 60 °C, 30 h. DMAP: 4-dimethylaminopyri-dine; Pra: (S)-2-amino-4-pentynoic acid. 
to increase solubility in aqueous media, a critical parameter for the hydrophobic two-photon 
cages, as well as membrane permeability.[22] The terminal azide group can be used to 
additionally attach any alkyne-containing targeting biomolecules via click chemistry. This 
gives the opportunity to target the biological effect with two orthogonal methods, i.e. 1) by 
directing the caged compound towards the intended tissue with the targeting vector and 2) 
by light activation. Importantly, the attachment of the targeting moiety to the caged 
compounds is by design the last step in the synthesis and hence conveniently adjustable to 
different cellular or subcellular units. To exemplify this, a peptide which binds to annexin-1 
and has been shown to function as a targeting moiety towards certain cancer cells,[23] has 
been attached to caged Celecoxib 4, producing targeted caged Celecoxib 5 (see Scheme 1). 
The caged compounds 3, 4, and 5 were photo-physically investigated and the results are 
summarized Table 1. Notably, although photo-degradation of azides to reactive nitrene 
groups has been reported[24] we never observed such reactions for 3 or 4, neither upon UV 
nor fs-pulsed near-IR irradiation. The caged glutamate by Goeldner et al. (Scheme 1) has 
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been shown to have a quantum yield of 0.1 at 313 nm, relative to 1-(2-nitrophenyl)ethyl-ATP 
(caged ATP).[19] We determined the single photon uncaging quantum yields upon irradiation 
with a frequency-tripled Nd-YAG laser at 355 nm with azobenzene as reference, as 
discussed in our recent article on the accurate determination of uncaging quantum yields.[25–
27] For 3, which links the bio-active compound also via an ester to the same cage 
chromophore, a similar uncaging quantum yield of 0.094 was determined. 4, which has a 
sulfonamide as linking group, has a significantly lower quantum yield of 0.013. The quantum 
yield of 5 is with 0.0047 in the range of 4, but still smaller. This difference demonstrates a 
moderate effect of the targeting moiety on the single-photon uncaging. Low single-photon 
uncaging rates are in principle desired since unwanted photolysis under ambient conditions 
is suppressed. However, in this case, the differences between the compounds are mostly 
due to the chemical reactions following photo-excitation since the biphenylnitro core is the 
same for all three compounds. Consequently, also lower two-photon uncaging action cross-
sections (δaΦu) can be expected for 4 and 5, compared to 3. These properties were 
determined upon irradiation at 800 nm with a fs-pulsed laser with a 5 kHz repetition rate 
using the known reference 7-hydroxycoumarin-4-ylmethyl acetate.[28,29] As expected, the 
uncaging action cross-sections δaΦu of 4 (0.063 GM) and 5 (0.053 GM) were found to be 
lower than the one of 3 (0.37 GM). Importantly, the attachment of the targeting peptide was 
found to not majorly influence the two-photon uncaging efficiency. As for the single photon 
uncaging, the value for 3 is in the same range as the one for caged glutamate.[19] Notably, 
the two-photon uncaging action cross-section of a dye attached to the same biphenylnitro 
cage core has been shown to be more than an order of magnitude greater at wavelengths 
around 740 nm.[20] However, tissue transparency is better at 800 nm than at 740 nm and 
therefore an even more useful wavelength with respect to future applications.[30] 
Table 1. Photophysical uncaging properties of the caged compounds 3, 4, 5 and of the literature-
known caged glutamate.[19] 
Compound ɸ (λ=355 nm)a δaΦu (λ=800 nm)b 
Caged glutamate 0.1 (313 nm) 0.45 GM 
3 0.094 ±0.02 0.37 ±0.04 GM 
4 0.013 ±0.001 0.063 ±0.008 GM 
5 0.0047 ±0.0004 0.053 ±0.008 GM 
a Acquired with a Nd-YAG laser, relative to the photoisomerizaion of azobenzene;[25–27] b Acquired with 
a fs-pulsed laser with 5 kHz repetition rate relative to 7-hydroxycoumarin-4-ylmethyl acetate; [28,29] for 
details on both methods, see Supporting Information. 
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In a study which investigated two-photon uncaging at 740 nm, it has been stated that two-
photon uncaging action cross-sections of at least 0.1 GM are required for biological 
applications.[28] Accordingly, the two-photon uncaging of 4 and 5 would be insufficient for 
biological studies. However, the minimum value certainly depends on the wavelength, which 
was 740 nm in the previous study, and most likely also on additional laser properties, such 
as the repetition rate of the laser. Most two-photon uncaging studies used lasers with MHz 
repetition rates.[29,31] However, 103 smaller repetition rates (kHz), like in this study, have also 
been used before.[19] With the same average powers and peak lengths, the peak photon 
densities differ therefore by the same factor of 103. Thus, the commonly quoted paradigm 
that two-photon uncaging only occurs in the focal point of a laser beam is not generally true. 
Indeed, we and others[19] found that with the laser beam used for this study it was not 
necessary to focus since the photon density was sufficient with a collimated beam. These 
observations raise the question if biologically relevant uncaging is still possible with two-
photon uncaging cross-sections below 0.1 GM at 800 nm. To this end, the inhibition potential 
of COX-2 by the caged compounds 4 and 5, whose uncaging efficiencies are clearly below 
0.1 GM, was tested with a fluorescent inhibitor screening assay (see Figure 1). The 
irradiation time was chosen to be 15 min since this time frame has been used in biological 
studies before.[22,32] Notably, this time is significantly shorter than what was required in other 
reports on uncaging of drugs.[14,15,33] To test if the high photon densities influence 
biomolecules, the enzyme was irradiated using these experimental conditions and its activity 
tested in comparison to a non-irradiated sample. The activity of the enzyme was found to be 
unaffected by the pulsed laser light. In addition, Celecoxib was irradiated. No decomposition 
could be detected by HPLC analysis and its inhibitory potential towards COX-2 remained 
unchanged at around 60-70 nM. Likewise, solutions of the caged compounds 4 and 5 were 
tested. Before uncaging, no inhibition of COX-2 could be detected within the limits given by 
the solubility of the caged compounds. After 15 min of irradiation, the uncaging progress was 
around 70% for 4 and 40% for 5. The amount of free Celecoxib was determined by HPLC. 
The IC50 values relative to the released Celecoxib are for both 4 and 5 identical to the non-
caged Celecoxib. Relative to the caged starting materials, the IC50 values are slightly higher 
due to the incomplete release in the given timeframe. Nevertheless, at least five- and ten-
fold increases for 4 and 5, respectively, were observed. 
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Figure 1. Inhibition constants of Celecoxib, 4, and 5, without and upon irradiation with a pulsed laser 
at 800 nm for 15 min. The values are relative to the concentrations of caged compound, or released 
Celecoxib, as indicated. For details, see Supporting Information. 
In summary, we could demonstrate that targetable two-photon uncaging can be employed to 
control enzyme activity. The two drugs Celecoxib and Lumiracoxib, which both selectively 
inhibit COX-2, were deactivated by conjugation to a targetable cage. A targeting peptide 
could be attached to the cage without significantly altering the uncaging efficiency. The 
uncaging process was shown to be adequate for controlling the inhibition of an enzyme in an 
in vitro assay. The concept holds great promise for the future, not only for chemical 
biological studies on enzyme function, but potentially also for applications in therapeutic 
targeted drug delivery. Currently, Photodynamic Therapy (PDT) is the most prominent 
method which utilizes light for the treatment of different skin conditions, certain types of 
cancer,[34] and its potential against infective diseases is currently being explored.[35] PDT 
depends on the generation of reactive oxygen species, especially singlet oxygen. However, 
many cancerous tissues are hypoxic and therefore oxygen-independent phototherapies 
could advance therapy tremendously.[36] We believe that therapeutic two-photon uncaging, 
with the ability to activate virtually any drug without depending on additional factors such as 
oxygen, could therefore further promote non-invasive light based therapies. 
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3.5 Supporting Information 
 
3.5.1 Instrumentation and Materials 
1H, 13C and 19F NMR spectra were recorded on Bruker Avance (400 and 500) spectrometers. 
13C and 19F NMR measurements were carried out as 13C {H} and 19F {H}, respectively. 1H 
and 13C NMR spectra were referenced to the residual solvent signal, the 19F spectrum to 
CCl3F. IR spectra were acquired on a Perkin-Elmer Spectrum 2 FT-IR, UV/Vis spectra on a 
Varian Cary 100 instrument. High resolution ESI-MS spectra were measured with a Bruker 
ESQUIRE-LC quadrupole ion trap instrument and MALDI-MS spectra on a Bruker Autoflex I. 
Preparative HPLC purification was carried out with a Varian ProStar with two solvent delivery 
modules, an UV/Vis detector and an Agilent PrepHT 300 SB-C18 column. Analytical HPLC 
traces were acquired on a VWR Hitachi Chromaster with a 5110 pump system, a 5260 auto 
sampler, a 5310 column oven, a 5430 diode array detector, and a Macherey-Nagel EC 250/3 
NUCLEOSIL 100-5 C18 column. Microwave heated reactions were carried out in an Anton 
Paar Monowave 300. Single-Photon uncaging was performed with an Edinburgh Instruments 
LP920 laser flash photolysis setup with a Continuum Surelight Nd:YAG laser, frequency-
tripled to generate light with a wavelength of 355 nm. Two-photon uncaging was carried out 
using using a Ti:sapphire amplifier system (Spitfire Pro, 5 kHz, 90 fs, 800 µJ per pulse; 
Spectra-Physics). Chemicals were acquired from Sigma-Aldrich, Acros, and TCI Europe. 
Celecoxib was acquired from AK Scientific, Inc. (Union City, CA, USA) and Lumiracoxib was 
acquired from Kemprotec Ltd. (Cumbria, UK). Amino acids were acquired from Bachem 
(Bubendorf, Switzerland), and Iris-Biotech (Marktredwitz, Germany). The Tentagel S Ram 
resin for the peptide synthesis was acquired from Rapp Polymers (Tübingen, Germany). 
Enzyme inhibition was tested using the “COX Fluorescent Inhibitor Screening Assay Kit” 
from Cayman Chemical Company (Ann Harbor, MI, USA) according to the manual. The 
fluorescence measurements were carried out with a Molecular Devices SpectraMax m2E 
microplate reader. 
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3.5.2 Methods 
 
Single Photon Uncaging Quantum Yields 
The single photon uncaging quantum yields were determined as described by us earlier.[25–
27] In short, the samples were dissolved in a 1:1 mixture of acetonitrile and phosphate buffer 
saline (pH=7.2, 20 mM) to have an optical density OD(λ=355 nm) = 0.2. The samples were 
irradiated for certain intervals with an Edinburgh Instruments LP920 laser flash photolysis 
setup with a Continuum Surelight Nd:YAG laser, frequency-tripled to generate light with a 
wavelength of 355 nm. The laser was slightly misaligned to reach a suitable irradiation 
power. A fresh aliquot was used for each irradiation. The percentage of remaining caged 
compound was determined by peak integration of analytical HPLC UV-traces and setting the 
value in relation to the value obtained without irradiation. The percentage values were 
plotted against the irradiation, and the slope msample of the curve was determined for the 
linear range (approx. the first 20% of decomposition). As reference, trans-azobenzene was 
dissolved in methanol to the same OD(λ=355 nm) = 0.2. The irradiation was carried out as 
described for the uncaging samples. Subsequently, the absorbance was determined at 
355 nm and the percentage of remaining trans-azobenzene was plotted against the 
irradiation. The slope mreference of the curve was determined for the linear range (approx. the 
first 20% of decomposition). Exemplary uncaging plots including linear fits are shown in the 
section below. Comparison of the slopes of the curves gave the uncaging quantum yields of 
the caged compounds under consideration of the number of molecules with the following 
formula: 
߶௦௔௠௣௟௘ ൌ ߶௥௘௙௘௥௘௡௖௘ ൈ	
݊௦௔௠௣௟௘,଴ ൈ ݉௦௔௠௣௟௘
݊௥௘௙௘௥௘௡௖௘,଴ ൈ ݉௥௘௙௘௥௘௖௘ 
At least three independent sets of measurements were averaged to obtain the single-photon 
uncaging quantum yields. 
 
Exemplary uncaging plots: 
For an azobenzene-isomerization plot, the reader is referred to our recent publication on this 
topic.[25]  
The data sets of the individual compounds plotted below have not been recorded on the 
same day and the slopes therefore cannot be compared to one another. 
Part I – Photo-Activatable Compounds
3 Two-Photon Uncageable Enzyme Inhibitors
80 
 
 
Figure S1. Single-photon uncaging of 3. Values for the fit: y = 96.659 - 3.592 x; R² = 0.91. 
 
 
Figure S2. Single-photon uncaging of 4. Values for the fit: y = 99.732 - 0.5170 x; R² = 0.99. 
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Figure S3. Single-photon uncaging of 5. Values for the fit: y = 100.24 - 0.1863 x; R² = 0.96. 
 
Two-Photon Uncaging Action Cross-Sections 
The two-photon uncaging action cross-sections were determined as previously 
described.[19,29] In short, the samples were dissolved in a 1:1 mixture of acetonitrile and 
phosphate buffer saline (pH=7.2, 20 mM) to have an optical density OD(λ=400 nm)=0.2. As 
reference, 7-hydroxycoumarin-4-ylmethyl acetate[28] was dissolved in a 1:1 mixture of 
acetonitrile and phosphate buffer saline (pH=7.2, 20 mM) to have OD(λ=400 nm)=0.2. The 
respective solutions were separately illuminated for certain time intervals in Hellma 105.202-
QS cuvettes (window size 2.5x2 mm², 50 µL volume, 10 mm light path). A fresh aliquot was 
used for each irradiation. An amplified Ti:sapphire laser system was used to obtain 90 fs 
pulses centered at 800 nm with a 5 kHz repetition rate. The intensity was reduced to 40 to 
100 µJ using a neutral density filter. The beam diameter was reduced to only illuminate the 
cuvette window by the use of a telescope. The disappearance of the caged compounds was 
detected by integration of the peaks in the UV traces of analytical HPLC measurements and 
plotted against the irradiation time. Exemplary plots including linear fits are shown in the 
section below. The slopes of these curves were used to calculate the two-photon uncaging 
action cross-sections, according to the following formula: 
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߶௦௔௠௣௟௘ ൌ ߶௥௘௙௘௥௘௡௖௘ ൈ
ݏ݈݋݌݁௦௔௠௣௟௘
ݏ݈݋݌݁௥௘௙௘௥௘௡௖௘ 
At least three independent sets of measurements were averaged to obtain the two-photon 
uncaging action cross-section. 
 
Exemplary uncaging plots: 
The data sets of the individual compounds plotted below have not been recorded on the 
same day and the slopes therefore cannot be compared to one another. 
 
Figure S4. Two-photon uncaging of CouOAc. Values for the fit: y = 99.71 - 0.04197 x; R² = 0.97. 
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Figure S5. Two-photon uncaging of 3. Values for the fit: y = 100.18 - 0.1034 x; R² = 0.98. 
 
 
Figure S6. Two-photon uncaging of 4. Values for the fit: y = 100.83 - 0.0222 x; R² = 0.90. 
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Figure S7. Two-photon uncaging of 5. Values for the fit: y = 100.02 - 0.0297 x; R² = 0.99. 
 
Enzyme Inhibition Assays 
Enzyme inhibition was tested using the “COX Fluorescent Inhibitor Screening Assay Kit” 
from Cayman Chemical Company (Ann Harbor, MI, USA). All experiments were performed 
at least as duplicates of duplicates. The assay was carried out as described in the 
manufacturer’s manual, with the following adjustments.  
The incubation time for all samples was 20 min, as opposed to the 5 min period 
recommended in the manual. 
For the experiments in which the COX-2 enzyme was irradiated, 10 µL of ready-to-use 
diluted COX-2 solution was further diluted with COX-FIS Assay Buffer 1x diluted to 50 µL 
and subsequently irradiated in a Hellma 105.202-QS cuvette as described above for the 
acquisition of two-photon uncaging cross-sections. The power was adjusted to values of 
180-200 µJ with neutral density filters. The solution was then transferred to the 96-well plate. 
The amount of buffer used for this determination was reduced by 40 µL to compensate for 
the additional volume due to the diluted the enzyme solution. As reference, the same 
procedure was done without irradiating. A decrease in COX-2 activity was observed for both 
the irradiated and non-irradiated samples, which could be due to aggregation effects in the 
cuvette. The effect was identical for both the irradiated and the non-irradiated enzyme 
samples. 
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Below, exemplary enzyme activity plots of irradiated and non-irradiated caged compounds 
are shown. 
 
Figure S8. Enzyme inhibition of caged Celecoxib 4 before and after irradiation at 800 nm with a 
pulsed laser.	
 
Figure S9. Enzyme inhibition of caged Celecoxib 4 before and after irradiation at 800 nm with a 
pulsed laser. 
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3.5.3 Syntheses 
 
Overview over Synthetic Steps not Depicted in the Article 
 
Scheme S1. Synthetic steps not depicted in the main article; procedures: a) 1. Pd(PPh3)4, Na2CO3, toluene, 90 °C, 16 h, 2. Tetrabutylammonium fluoride, THF, rt, 2 h, 98%; b) CH3I, NaH, THF, 0 °C  rt, 64 h, 45%; c) Pd(PPh3)4, Na2CO3, water, toluene, 95 °C, 17 h, 2. Tetrabutylammonium fluoride, THF, rt, 3 h, 84%; d) K2CO3, MeOH, microwave, 100 °C, 10 h, a: 78%, b: 51%; e) Trifluoroacetic acid, CH2Cl2, rt, 20 h, 100%. 
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Compound 6 
 
The title compound was prepared as described by Bühler et al.[37] The analytical data 
matched what was reported there. 
 
Compound 7 
 
The title compound was prepared as described by Jeanjot et al.[38] The analytical data 
matched what was reported there. 
 
Compound 8 
 
Under an atmosphere of N2, 6 (307 mg, 1 mmol), 7 (303 mg, 1.19 mmol), toluene (20 mL), 
saturated Na2CO3 solution (10 mL), and water (3 mL) were mixed and degassed. Pd(PPh3)4 
(116 mg, 0.10 mmol) was added and the mixture was stired at 105 °C for 20 min, and 90 °C 
for 3.5 h. The reaction mixture was allowed to cool down to rt. Water was added and 
extracted with diethyl ether (3x). The combined organic layers were dried (Na2SO4), filtered, 
and concentrated in vacuo. 
Under exclusion of light and moisture, the residue (710 mg) was dissolved in THF (8 mL), 
Tetrabutylammonium fluoride (1 M in THF, 2 mL) was added and the mixture was stirred for 
2 h at rt. Afterwards, saturated NH4Cl solution was added. The organic layer was diluted with 
diethyl ether, separated and washed with water and brine. Drying (Na2SO4), filtration, and 
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concentration afforded the crude product. Column chromatography (silica gel, 
hexanes/EtOAc 7:4) afforded 8 as a yellow solid (98%, relative to 6). 
Rf = 0.09 (Hexanes/EtOAc 7:3). IR (KBr) 3469 (s), 2952 (w), 2925 (w), 1635 (m), 1612 (s), 
1517 (m), 1349 (m), 823 (s) cm-1. 1H NMR (400 MHz, CDCl3) ∂ 7.84 (d, J = 8.5 Hz, 1 H), 7.58 
(d, J = 1.9 Hz, 1 H), 7.53–7.40 (m, 3 H), 6.91 (d, J = 8.6 Hz, 2 H), 5.11 (bs, 1 H), 3.90–3.75 
(m, 2 H), 3.72–3.58 (m, 1 H), 1.36 (d, J = 7.0 Hz, 3 H). 13C NMR (100 MHz, CDCl3): ∂ 156.3, 
149.0, 145.4, 138.9, 131.7, 128.8, 126.3, 125.3, 125.0, 116.0, 68.0, 36.4, 17.6. HRMS m/z 
calcd. for C15H15NNaO4 ([M+Na]+) 296.08933, found 296.08886. 
 
Compound 9 
 
The title compound was synthesized as described by Katayama et al.[39] The analytical data 
matched what was reported there. 
Additional analytical data: 
Rf = 0.13 (hexanes/EtOAc 40:1). 13C NMR (100 MHz, CDCl3): ∂ 168.5, 148.5, 142.1, 137.6, 
132.1, 126.4, 100.8, 82.2, 40.6, 27.9. HRMS m/z calcd. for C12H14INNaO4 ([M+Na]+) 
385.98597, found 385.98598. 
 
Compound 10 
 
Under an atmosphere of N2 9 (1.00 g, 2.75 mmol) was added to a suspension of NaH (60% 
in oil, 110 mg, 2.75 mmol) in dry THF (10 mL). The purple mixture was cooled to 0 °C and 
methyl iodide (343 µL, 782 mg, 5.51 mmol) was added dropwise. The mixture was stirred 
first for 2 h at 0 °C, then for 62 h at rt. The reaction was quenched by adding water and HCl 
(1 M, 5 mL) at 0 °C. The mixture was extracted with EtOAc (3x). The combined organic 
layers were washed with brine, dried (MgSO4), filtered, and concentrated in vacuo. The 
crude residue was purified by column chromatography (hexanes/EtOAc 42:1) to yield 10 as 
a light yellow solid (468 mg, 45%). 
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Rf = 0.19 (hexanes/EtOAc 38:3). IR (neat) 2975 (w), 1721 (s), 1598 (w), 1556 (w), 1514 (m), 
1335 (m), 1243 (s), 1151 (s), 858 (m), 844 (m), 832 (m) cm–1. 1H NMR (400 MHz, CDCl3) ∂ 
7.80 (d, J = 1.9 Hz, 1 H), 7.74 (dd, J = 1.9 Hz, 8.5 Hz, 1 H), 7.62 (d, J = 8.5 Hz, 1 H), 4.15 (q, 
J = 7.2 Hz, 1 H), 1.54 (d, J = 7.2 Hz, 3 H),1.38 (s, 9 H). 13C NMR (100 MHz, CDCl3): ∂ 171.6, 
148.7, 138.4, 137.4, 137.0, 126.1, 100.4, 81.8, 42.1, 27.8, 17.4. ESI-MS m/z 400.00 (100, 
[M+Na]+) 343.94 (10, [M-tBu+Na]+). HRMS m/z calcd. for C13H16INNaO4 ([M+Na]+) 
400.00162, found 400.00153. 
 
Compound 11 
 
10 (250 mg, 663 µmol) and 7 (201 mg, 694 µmol) were mixed in toluene (10 mL), saturated 
Na2CO3 solution (6.4 mL) and water (2 mL). N2 was bubbled through the bi-layered solution 
for 20 min. Pd(PPh3)4 (76.6 mg, 66.3 µmol) was added and the mixture stirred at 95 °C for 
17 h. The solution was allowed to cool to rt. Water and Et2O were added and the two layers 
were separated. The aqueous layer was extracted wit Et2O (3x). The combined organic 
fractions were dried (MgSO4), filtered, and concentrated. 
Tetra-n-butylammonium fluoride (1 M in THF, 1.33 mL, 1.33 mmoL) was added to a solution 
of the crude residue (289 mg) in THF (8 mL). The solution was stirred for 3 h at rt. Saturated 
NH4Cl solution and Et2O were added and the two layers were separated. The aqueous layer 
was extracted wit Et2O (3x). The combined organic fractions were dried (MgSO4), filtered, 
and concentrated. The residue was purified by column chromatography (hexanes/EtOAc 
7:3), yielding pure 11 (191 mg, 84% relative to 10) as a colorless solid. 
Rf = 0.65 (hexanes/EtOAc 3:7). IR (neat) 3317 (w), 2989 (w), 1725 (s), 1604 (m), 1579 (m), 
1514 (s), 1332 (s), 1304 (m), 1220 (m), 1152 (m), 830 (s) cm–1. 1H NMR (400 MHz, CDCl3) ∂ 
8.01 (d, J = 8.6 Hz, 1 H), 7.60 (d, J = 2.0 Hz, 1 H), 7.54 (dd, J = 8.6 Hz, 2.0 Hz, 1 H), 7.48 (d, 
J = 8.6 Hz, 2 H), 6.92 (d, J = 8.6 Hz, 2 H), 5.12 (bs, 1 H), 4.32 (q, J = 7.2 Hz, 1 H), 1.62 (d, 
J = 7.2 Hz, 3 H), 1.41 (s, 9 H). 13C NMR (125 MHz, CDCl3) ∂ 172.7, 156.5, 147.2, 145.8, 
136.3, 131.2, 128.7, 127.6, 125.7, 125.6, 116.0, 81.6, 42.6, 27.9, 17.6. HRMS m/z calcd. for 
C19H21NNaO5 ([M+Na]+) 366.13119, found 366.13131. 
 
Part I – Photo-Activatable Compounds
3 Two-Photon Uncageable Enzyme Inhibitors
90 
 
Compound 12 
 
The title compound was prepared as described in the literature. The analytical data matched 
what was reported before,[40] except for the 13C{1H} NMR spectrum in which 8 instead of 7 
signals were observed (see below). 
Additional/deviating analytical data: 
13C NMR (125 MHz, CDCl3): ∂ 72.0, 70.74, 70.71, 70.3, 70.1, 70.0, 50.7, 2.9. HRMS m/z 
calcd. for C8H16IN3NaO3 ([M+Na]+) 352.01286, found 352.01288. 
 
Compound 13 
 
11 (300 mg, 0.874 mmol), 12 (261 mg, 0.794 mmol) and K2CO3 (121 mg, 0.874 mmol) were 
suspended in MeOH (2 mL). The mixture was stirred and heated with a microwave reactor 
for 12 h at 100 °C. The solvent was removed and the red residue was taken up in saturated 
NH4Cl solution and CH2Cl2. The two layers were separated. The organic layer was washed 
with saturated NH4Cl solution (2x) and water. The combined aqueous layers were extracted 
with CH2Cl2 (3x). The combined organic layers were washed with water, dried (MgSO4), 
filtered, and concentrated. Purification with column chromatography (hexanes/EtOAc 8:1  
1:1) gave pure 13 as yellow oil (245 mg, 51%). 
Rf = 0.43 (hexanes/EtOAc 3:7). IR (neat) 2880 (w), 2103 (s), 1726 (m), 1605 (s), 1516 (s), 
1344 (s), 1248 (s), 1149 (s), 827 (m) cm–1. 1H NMR (400 MHz, CDCl3) ∂ 8.01 (d, J = 8.5 Hz, 
1 H), 7.61 (d, J = 1.9 Hz 1 H), 7.58–7.49 (m, 3 H), 7.04–6.99 (m, 2 H), 4.31 (q, J = 7.2 Hz, 
1 H), 4.23–4.14 (m, 2 H), 3.94–3.82 (m, 2 H), 3.79–3.63 (m, 10 H), 3.44–3.33 (m, 2 H), 1.61 
(d, J = 7.2 Hz, 3 H), 1.40 (s, 9 H). 13C NMR (125 MHz, CDCl3) ∂ 172.4, 159.5, 147.3, 145.7, 
136.5, 131.3, 128.5, 127.6, 125.6, 125.5, 115.2, 81.4, 70.9, 70.73, 70.72, 70.69, 70.0, 69.7, 
67.6, 50.7, 42.5, 27.9, 17.6. HRMS m/z calcd. for C27H36N4NaO8 ([M+Na]+) 567.24254, found 
567.24254. 
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Targeting Peptide IFLLQR(Pra)RR 
 
The peptide synthesis was performed according to previously published procedures.[41] In 
short, solid-phase peptide synthesis was carried out manually in a single-use polypropylene 
syringe with a filter frit. The syringe was filled with 515 mg Tentagel S Ram (0.24 mmol/g). 
The resin was swollen in DMF for 1 h before use. All reactions were performed on a 
mechanical shaker with 600 rpm, soaking approximately 2.5–3.5 mL of freshly prepared 
solutions into the syringe. Fmoc deprotection steps were performed with piperidine in DMF 
(2:8, v/v; two runs of 2 min and 10 min, repsectively).Fmoc/Pbf protected amino acids 
(4 equiv.) were pre-activated in Eppendorf tubes before every coupling step for 5 min with 
TBTU (3.9 equiv.) and DIPEA (10 equiv.) in DMF under sonication. For each coupling step 
the resin beads were treated with the activated acid and subsequently washed with DMF 
(5x) and CH2Cl2(5x). The coupling step was monitored with the Kaiser test. The resin beads 
were then washed again with DMF (5x). The whole procedure (deprotection, coupling, 
monitoring) was repeated for every monomer until the sequence was completed. The resin 
was then shrunk with methanol (30 min) and dried under vacuum. Final cleavage of the 
peptide from the resin and deprotection of the Pbf side chain protecting group were 
simultaneously performed in TFA/triisopropylsilane (TIS)/H2O (38:2:1, v/v/v; 3x 2 h). 
Following the removal of all volatiles under reduced pressure, the crude product was purified 
by preparative HPLC (20 mL/min, H2O+0.1% TFA : acetonitrile = 0 min 95:5, 31 min 0:100, 
33 min 0:100, 36 min 95:5, 37 min 95:5). 
MALDI-MS calcd. for C66H105N22O11 ([M+H]+) 1381.8, found 1381.6. HPLC (1 mL/min, 
acetonitrile: H2O+0.1%TFA = 0 min 0:100, 30 min 100:0, 35 min 100:0, 36.5 min 0:100): 
tR = 12.0 min. 
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Compound 1 
 
8 (583 mg, 2.14 mmol), 12 (787 mg, 1.95 mmol) and K2CO3 (296 mg, 2.14 mmol) were 
suspended in MeOH (4 mL). The mixture was stirred and heated with a microwave reactor 
for 10 h at 100 °C. The solvent was removed and the red residue was taken up in NaOH 
(1 M) and CH2Cl2. The two layers were separated. The organic layer was washed with 
NaOH (1 M). The combined aqueous layers were extracted with CH2Cl2 (3x). The combined 
organic layers were washed with water, dried (MgSO4), filtered, and concentrated. 
Purification with column chromatography gave pure 1 as yellow oil (726 mg, 78%). 
The combined aqueous layers were acidified with conc. HCl and subsequently extracted with 
CH2Cl2 (3x). The combined organic extracts were washed with water, filtered, and 
concentrated. The residue was pure 8 (119 mg, 20% of what had been used). 
Rf = 0.32 (CH2Cl2/MeOH 95:5). IR (KBr) 3446 (w), 2873 (w), 2102 (m), 1604 (m), 1583 (w), 
1515 (s), 1478 (w), 1348 (w), 1292 (m), 1248 (s), 1116 (m), 1059 (m), 827 (m), 632 (m), 536 
(m) cm-1. 1H NMR (500 MHz, CDCl3): ∂ 7.85 (d, J = 8.5 Hz, 1 H), 7.61 (s, 1 H), 7.55–7.45 (m, 
3 H), 7.02 (d, J = 8.8 Hz, 2 H), 4.21–4.16 (m, 2 H), 3.94–3.58 (m, 15 H), 3.37 (t, J = 5.0 Hz, 
2 H), 1.81 (bs, 1 H), 1.38 (d, J = 6.9 Hz, 3 H). 13C NMR (125 MHz, CDCl3): ∂ 159.4, 148.8, 
145.4, 140.0, 131.6, 128.4, 126.2, 125.2, 125.0, 115.2, 70.8, 70.68, 70.67, 70.6, 70.0, 69.6, 
67.9, 67.5, 50.6, 36.4, 17.6. ESI-MS m/z 497.20 (100, [M+Na]+), 513.18 (10, [M+K]+).HRMS 
m/z calcd. for C23H30N4NaO7 ([M+Na]+) 497.20067, found 497.20128.  
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Compound 2 
 
13 (219 mg, 403 µmol) was dissolved in 5% TFA in CH2Cl2 (v/v; 38 mL). The mixture was 
stirred under exclusion of light for 20 h. Water was added and the mixture was extracted with 
CH2Cl2 (3x). The combined organic layers were dried (MgSO4), filtered, and concentrated in 
vacuo to give pure 2 as a highly viscous oil (197 mg, 100%). 
IR (neat) 2921 (w), 2877 (w), 2103 (m), 1731 (m), 1604 (s), 1585 (m), 1516 (s), 1343 (s), 
1249 (s), 1184 (m), 1121 (m), 943 (w), 827 (m) cm–1. 1H NMR (500 MHz, CDCl3) ∂ 8.06 (d, 
J = 8.5 Hz, 1 H), 7.62 (d, J = 1.9 Hz 1 H), 7.60–7.46 (m, 3 H), 7.06–6.99 (m, 2 H), 4.46 (q, 
J = 7.1 Hz, 1 H), 4.18 (m, 2 H), 3.92–3.86 (m, 2 H), 3.78–3.63 (m, 10 H), 3.40–3.34 (m, 2 H), 
1.68 (d, J = 7.1 Hz, 3 H). 13C NMR (125 MHz, CDCl3) ∂ 176.9, 159.7, 146.8, 146.2, 135.5, 
131.1, 128.6, 128.0, 126.1, 126.0, 115.3, 70.9, 70.72, 70.71, 70.68, 70.0, 69.7, 67.6, 50.7, 
41.6, 17.6. HRMS m/z calcd. for C23H28N4NaO8 ([M+Na]+) 511.17993, found 511.18034. 
 
Caged Lumiracoxib 3 
 
Under an atmosphere of N2, 1 (52.4 mg, 110 µmol) was dissolved in dry CH2Cl2 (10 mL). At 
0 °C, N,N’-dicyclohexylcarbodiimide (34.2 mg, 166 µmol), 4-dimethylaminopyridine (1.3 mg, 
11 µmol), and Lumiracoxib (64.9 mg, 0.221 mmol) were added. The resulting suspension 
was stirred at 0 °C for 10 min and subsequently for 20 h at rt. Saturated NaHCO3 solution 
was added and the mixture was extracted with CH2Cl2 (4x). The combined organic layers 
were dried (MgSO4), filtered, and concentrated. The crude residue was purified by column 
chromatography (hexanes/EtOAc 7:3  1:1). The product containing fractions were 
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suspended in acetonitrile and filtered with a Pasteur pipette filled with silica to give pure 3 as 
a slightly yellow solid (66.0 mg, 80%). 
Rf = 0.51 (hexanes/EtOAc 3:7). IR (neat) 2883 (w), 2103 (m), 1730 (s), 1604 (m), 1584 (m), 
1514 (s), 1479 (m), 1348 (m), 1291 (m), 1245 (s), 1137 (m), 1037 (w), 1046 (w), 906 (m), 
827 (m), 764 (m), 715 (m) cm–1. 1H NMR (500 MHz, CDCl3) ∂ 7.83 (d, J = 8.5 Hz, 1 H), 7.52 
(d, J = 1.9 Hz, 1 H), 7.48–7.41 (m, 3 H), 7.18 (dt, J = 8.1 Hz, 1.3 Hz, 1 H), 7.02–6.93 (m, 
3 H), 6.91–6.85 (m, 3 H), 6.63 (bs, 1 H), 6.56 (dd, J = 8.0 Hz, 3.2 Hz, 1 H), 4.41–4.31 (m, 
2 H), 4.20–4.13 (m, 2 H), 3.95–3.85 (m, 3 H), 3.74–3.63 (m, 12 H), 3.38 (t, J = 5.0 Hz, 2 H), 
2.21 (s, 3 H), 1.38 (d, J = 7.0 Hz, 3 H). 13C NMR (125 MHz, CDCl3): ∂ 172.2, 159.4, 155.3 (d, 
J = 248 Hz), 148.5, 145.4, 139.7, 137.8, 131.6, 131.4, 131.2, 129.6 (d, J = 13.1 Hz), 128.42, 
128.39, 127.2 (d, J = 4.36 Hz), 125.9, 125.38 (d, J = 3.43 Hz), 125.35, 125.0, 123.9, 121.9 
(d, J = 8.66 Hz), 118.3 (d, J = 3.05 Hz), 115.2, 114.8 (d, J = 20.2 Hz), 70.9, 70.71, 70.69, 
70.66, 70.0, 69.6, 68.6, 67.6, 50.7, 38.2, 33.2, 20.5, 17.8. 19F NMR (375 MHz, CDCl3): 
∂ -118.9. HRMS m/z calcd. for C38H41ClFN5NaO8 ([M+Na]+) 772.25199, found 772.25115. 
HPLC (1 mL/min, acetonitrile : H2O+0.1%TFA = 0 min 10:90, 27 min 100:0, 31 min 100:0, 
36 min 1:99, 38 min 1:99, 40 min 10:90, 41 min 10:90): tR = 22.6 min. 
 
Caged Celecoxib 4 
 
1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC, 15.5 mg, 81.1 µmol) 
was added to a stirred solution of 2 (19.8 mg, 40.5 µmol), 4-dimethylaminopyridine (DMAP, 
0.5 mg, 4 µmol) and Celecoxib (16.5 mg, 43.3 µmol) in CH2Cl2 (1.5 mL) and the resulting 
reaction mixture was stirred at rt under exclusion of light for 2 h. Saturated NH4Cl solution 
and EtOAc were added. The layers were separated and the aqueous layer was extracted 
with EtOAc (3x). The combined organic layers were washed with brine, dried (MgSO4), 
filtered, and concentrated. The crude residue was adsorbed to silica and purified by column 
chromatography (hexanes/EtOAc 5:1  1:2) to yield pure 4 (18.5 mg, 54%) as a yellowish 
solid. 
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Rf = 0.39 (CH2Cl2/MeOH 95:5). IR (neat) 2923 (w), 2103 (s), 1719 (m), 1603 (m), 1516 (m), 
1451 (m), 1344 (s), 1237 (s), 1185 (m), 1159 (s), 1127 (s), 1094 (s), 1024 (m), 947 (m), 821 
(s) cm–1. 1H NMR (500 MHz, CDCl3) ∂ 8.72 (bs, 1 H), 7.99–7.91 (m, 3 H), 7.59 (dd, 
J = 8.4 Hz, 1.9 Hz, 1 H), 7.49–7.35 (m, 5 H), 7.16 (d, J = 8.0 Hz, 2 H), 7.06 (d, J = 8.0 Hz, 
2 H), 6.96 (d, J = 8.8 Hz, 2 H), 6.73 (s, 1 H), 4.24 (q, J = 6.9 Hz, 1 H), 4.15 (t, J = 4.8 Hz, 
2 H), 3.89 (t, J = 4.8 Hz, 2 H), 3.78–3.62 (m, 10 H), 3.38 (t, J = 5.0 Hz, 2 H), 2.38 (s, 3 H), 
1.51 (d, J = 6.9 Hz, 3 H). 13C NMR (125 MHz, CDCl3): 169.8, 159.9, 147.0, 146.8, 145.3, 
144.3, 144.0, 143.4, 139.9, 137.4, 134.0, 130.3, 129.8, 129.4, 128.7, 128.5, 127.1, 126.7, 
125.9, 125.6, 125.0, 115.3, 106.5, 70.9, 70.8, 70.73, 70.70, 70.1, 69.6, 67.6, 50.7, 41.6, 
21.3, 17.3. HRMS m/z calcd. for C40H40F3N7NaO9S ([M+Na]+) 874.24525, found 874.24481. 
HPLC (1 mL/min, acetonitrile : H2O+0.1%TFA = 0 min 10:90, 27 min 100:0, 31 min 100:0, 
36 min 1:99, 38 min 1:99, 40 min 10:90, 41 min 10:90): tR = 21.0 min. 
 
Caged Targeted Celecoxib 5 
 
CuSO4 (0.1 M in H2O, 23.1 µL, 2.31 µmol) and sodium ascorbate (0.1 M in H2O, 46.3 µL, 
4.63 µmol) were mixed and shaken for 10 min. The red slurry was added to a solution of 4 
(10.9 mg, 12.7 µmol) and targeting peptide IFLLQR(Pra)RR (16 mg, 11.6 µmol) in a mixture 
of THF/H2O (2:1 v/v; 9 mL). The solution was stirred at rt for 23 h. To drive the reaction to 
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completion, CuSO4 (0.1 M in H2O, 23.1 µL, 2.31 µmol) and sodium ascorbate (0.1 M in H2O, 
46.3 µL, 4.63 µmol) were added, the temperature increased to 60 °C, and stirring continued 
for 7 h. The solvents were removed by evaporation. The residue was dissolved in acetonitrile 
in H2O with 0.1% TFA and purified by preparative HPLC (20 mL/min, H2O+0.1% TFA : 
acetonitrile = 0 min 95:5, 31 min 0:100, 33 min 0:100, 36 min 95:5, 37 min 95:5). 
MALDI-MS calcd. for C106H145F3N29O20S ([M+H]+) 2233.1, found 2233.5. HPLC (1 mL/min, 
acetonitrile : H2O+0.1%TFA = 0 min 10:90, 12 min 53:47, 18 min 59:41, 27 min 100:0, 
31 min 100:0, 36 min 1:99, 38 min 1:99, 40 min 10:90, 41 min 10:90): tR = 14.9 min. 
 
3.5.4 Spectra 
In the following all previously unreported 1H, 13C and 19F NMR spectra are shown. For the 
compounds analyzed by HPLC the UV traces at λ=260 nm are shown. 
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Figure S10. 1H-NMR spectrum of 8 in CDCl3. 
 
Figure S11. 13C-NMR spectrum of 8 in CDCl3.  
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Figure S12. 13C--NMR spectrum of 9 in CDCl3. 
 
Figure S13. 13C-NMR spectrum of 12 in CDCl3.  
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Figure S14. 1H-NMR spectrum of 10 in CDCl3. 
 
Figure S15. 13C-NMR spectrum of 10 in CDCl3. 	
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Figure S16. 1H-NMR spectrum of 11 in CDCl3. 
 
Figure S17. 13C-NMR spectrum of 11 in CDCl3. 	
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Figure S18. 1H-NMR spectrum of 13 in CDCl3. 
 
Figure S19. 13C-NMR spectrum of 13 in CDCl3. 	
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Figure S20. Analytical HPLC trace of the Targeting Peptide IFLLQR(Pra)RR. 
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Figure S21. 1H-NMR spectrum of compound 1in CDCl3. 
 
Figure S22. 13C-NMR spectrum of compound 1 in CDCl3. 	
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Figure S23. 1H-NMR spectrum of compound 2 in CDCl3. 
 
Figure S24. 13C-NMR spectrum of compound 2 in CDCl3. 	
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Figure S25. 1H-NMR spectrum of compound 3 in CDCl3. 
 
Figure S26. 13C-NMR spectrum of compound 3 in CDCl3. 
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Figure S27. 19F-NMR spectrum of compound 3 in CDCl3 with CCl3F as standard. 
 
Figure S28. Analytical HPLC trace of compound 3.  
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Figure S29. 1H-NMR spectrum of compound 4 in CDCl3. 
 
Figure S30. 13C-NMR spectrum of compound 4 in CDCl3. 
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Figure S31. Analytical HPLC trace of compound 4. 
 
Figure S32. Analytical HPLC trace of compound 5.  
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4.1 Contributions to the publication 
P.A. synthesized and characterized the compounds leading to and derived from PLPG2. 
P.A. acquired the photophysical characterization and iron release assay of Fc-PLPG2-MLS 
and partially of Fc-NH2 and Fc-PLPG1-MLS. Contributions to the writing of the manuscript 
were made. 
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4.2 Abstract 
Reactive oxygen species (ROS)-activated aminoferrocene-based prodrug candidates 
successfully take advantage of intrinsically high amounts of ROS in tumor tissues. 
Interestingly, the ROS-initiated activation of these prodrug candidates leads to formation of 
unstable aminoferrocene (Fc-NH2) derivatives, which decay to iron ions. The latter 
catalytically increase ROS concentration to a lethal level. In this work, we prepared light-
controlled aminoferrocene prodrug candidates (Fc-PLPG1-MLS and Fc-PLPG2-MLS) by 
derivatizing Fc-NH2 with an o-nitrophenyl (PLPG1) and an o-nitrobiphenyl (PLPG2) photo-
labile protecting group (PLPG), respectively, and by further conjugation to a mitochondria 
localization signal (MLS) peptide (Cys-D-Arg-Phe-Lys-NH2). The resulting bioconjugates Fc-
PLPG1-MLS and Fc-PLPG2-MLS were found to be more stable and less cytotoxic, in the 
dark, towards human promyelocytic leukemia cells (HL-60) compared to Fc-NH2. Upon light 
irradiation at 355 nm, both Fc-PLPG1-MLS and Fc-PLPG2-MLS released Fc-NH2, albeit 
with very different photolysis quantum yields. The PLPG2 photo-cage was in fact several 
orders of magnitude more efficient than PLPG1 in releasing Fc-NH2. This difference was 
reflected by the light irradiation experiments on HL-60 cell line, in which Fc-PLPG2-MLS 
displayed the highest phototoxicity index (2.5 ± 0.4) of all the compounds tested. The iron 
release assays confirmed the rise in iron ions concentrations upon light irradiation of Fc-
PLPG1-MLS and Fc-PLPG2-MLS. Together with the absence of phototoxicity on the non-
malignant hTERT-immortalized retinal pigment epithelial (hTERT RPE-1) cell line, these 
results indicate catalytic generation of ROS as possible mode of action. 
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4.3 Introduction 
Aminoferrocene-based prodrug candidates recently developed by the Mokhir group have 
shown considerable selectivity towards cancer cells with IC50 values in the lower micromolar 
range (see Scheme 1 for an example of such a prodrug candidate).[1,2] These prodrug 
candidates are activated by reactive oxygen species (ROS) such as 1O2, O2-, HO• and H2O2, 
which cleave the B-C bond in an arylboronic acid pinacol ester linked to an aminoferrocene 
derivative via a carbamate function (see Scheme 1 for mode of action). In water, the 
resulting phenol is in equilibrium with its phenolate form, which spontaneously fragments into 
p-quinone methide and a carbamated aminoferrocene derivative via 1,6-elimination. The 
quinone methide is a known toxic compound that readily reacts with nucleophiles and 
attacks antioxidative defenses cells by alkylating in particular glutathione (Scheme 1, 
Mechanism 1).[3] Indeed, also hydroxyferrocifen – a very efficient anti-cancer drug candidate 
developed by the Jaouen group – is being oxidized to quinone methide metabolites.[4] 
Mokhir’s aminoferrocene-based prodrug candidates possess, however, an additional mode 
of action (Scheme 1, Mechanism 2). The latter is mediated by the carbamated 
aminoferrocene fragment, which decarboxylates under physiological conditions.[1,2] Most 
aminoferrocene derivatives are rather unstable since they are easily oxidized to their 
ferrocenium forms (Fc+),[5] which in turn can decompose into iron ions and cyclopentadiene 
ligands.[1] Both Fc+ and iron ions can catalyze ROS generation elevating cellular levels of 
ROS to a toxic level.[1,6] Tumors generally function at a higher basal concentration of ROS 
than normal tissues[7] and are already harmed by relatively small increases in ROS amount. 
As Mokhir’s aminoferrocene-based prodrug candidates are activated by ROS-induced 
fragmentation, these prodrug candidates are predominantly harming cancer cells.[1,2] As a 
matter of fact, the most toxic prodrug candidate of the series has shown more than a 10-fold 
selectivity for human promyelocytic leukemia cell line (HL-60) over normal fibroblasts.[1] 
Interestingly, the cytotoxicity of the aminoferrocene-based prodrug candidates correlates 
with their efficiency of ROS production in cells, showing that the aminoferrocene moiety 
contributes heavily to the observed cytotoxicity.[1,2] A similar concept has also been 
implemented by the Jacob group using ROS-activated organochalcogen compounds 
catalyzing ROS generation.[8] 
Besides internal triggers such as high ROS levels, external triggers, e.g. light-activation, can 
be used to control the activity of a compound. Photosensitizers – molecules able to generate 
toxic singlet oxygen upon light irradiation – are already being applied in the clinic in 
photodynamic therapy (PDT).[9] A great number of organic photo-active compounds that are 
activated via cleavage of a light-sensitive bond have been reported.[10,11] When it comes to  
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Scheme 1. A) Activation of a previously reported aminoferrocene-based prodrug candidate by ROS. 
B) Mechanisms of cytotoxicity.[1] 
metal complexes, some of them are inherently photo-reactive by themselves via light-
induced redox and/or ligand exchange reactions. These changes can be exploited to 
increase the cytotoxicity of metal compounds[12] or to construct metal-based photo-cages 
(e.g. for neurotransmitters).[13] Encouraged by the recent use of organic photo-cages in the 
design of light-activated metal-containing prodrug candidates,[14,15] we envisaged photo-
caging a simple cytotoxic ferrocenyl derivative, namely aminoferrocene (Fc-NH2) with o-
nitrophenyl-based and o-nitrobiphenyl-based photo-labile protecting groups (PLPG) via a 
carbamate bond (Scheme 2). The resulting derivatives were expected to be more stable in 
physiological conditions compared to aminoferrocene itself due to the electron-withdrawing 
effect of the carbamate. The aminoferrocene would then be liberated upon UV-A light 
irradiation and oxidized to its ferrocenium form and irons ions, which could act as ROS-
generation catalysts in cancer cells. Furthermore, a mitochondrial localization signal (MLS) 
peptide (Cys-D-Arg-Phe-Lys-NH2) was added to the photo-caged aminoferrocene 
Part I – Photo-Activatable Compounds
4 Photo-Release of Aminoferrocene
117 
 
 
bioconjugate to target mitochondria – organelles where the redox balance plays an 
especially important role.[16] 
 
4.4 Results and discussion 
 
4.4.1 Synthesis and Characterization 
Aminoferrocene (Fc-NH2) was caged with an o-nitrophenyl-based photo-linker also known 
as the Dmochowski photo-labile protecting group (PLPG1). Interestingly, this PLPG allows 
for coupling to a further moiety such as a targeting biomolecule. Our group has previously 
reported the preparation of PLPG-containing bioconjugates of a rhenium(I) complex[17] and 
the coupling procedure could be successfully applied to the photo-caging and bioconjugation 
of Fc-NH2. Following this synthetic protocol, the primary amino group of Fc-NH2 was blocked 
with PLPG1 via N-hydroxysuccinimide ester coupling to give Fc-PLPG1 (Scheme 2 A). The  
 
Scheme 2. A) Synthesis of Fc-PLPG1-MLS: a) Fc-NH2, DIPEA, CHCl3, 62%; b) Cys-D-Arg-Phe-Lys-NH2, acetonitrile/water 1:1. B) Synthesis of Fc-PLPG2-MLS: a) i. N,N'-disuccinimidyl carbonate, triethylamine, acetonitrile; ii. Fc-NH2, DIPEA, CH2Cl2, 50% over both steps; b) Cys-D-Arg-Phe-Lys-NH2, acetonitrile/PBS (pH=7.4) 2:1. DIPEA: diisopropylethylamine. 
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product was fully characterized by 1H- and 13C-NMR, ESI-MS, LC-MS and X-ray 
crystallography (see X-ray crystallography section). The MS spectrum (Figure S1) showed 
the expected mass at m/z = 503.3 [M+] as well as the isotopic pattern characteristic for iron. 
In the 1H-NMR of Fc-PLPG1, the most notable change in shifts compared to the starting 
materials Fc-NH2 and PLPG1 was observed for the aminoferrocene moiety (Figures S3 and 
S5). Indeed, both the amino group proton – now part of the carbamate bond – and the 
substituted cyclopentadienyl (Cp) ring protons shifted significantly downfield of about 3.5 and 
0.8 ppm, respectively. The PLPG1 moiety protons were comparatively less affected (Figures 
S3 and S6). The protons near the newly formed carbamate bond shifted slightly (0.05-
1 ppm) upfield. Interestingly, a slight doubling of peaks of the substituted Cp ring was 
observed in both 1H- and 13C-NMR spectra. 
Likewise, Fc-NH2 was caged with an o-nitrobiphenyl based photo-linker (PLPG2) which was 
previously developed by Goeldner and coworkers (Scheme 2 B).[18] We recently reported a 
derivative of this cage to which a targeting peptide can be attached via click chemistry.[19] 
Here, we introduced a maleimide function to allow for coupling of thiol-containing 
biomolecules. Activation with disuccinimdyl carbonate and subsequent coupling of Fc-NH2 
gave the second caged derivative Fc-PLPG2. The product was fully characterized by 1H and 
13C NMR, IR spectroscopy, and high resolution mass spectrometry. In the 1H NMR 
spectrum, possible shifts of the proton signals belonging to the substituted Cp ring are not 
trackable as in the same region the protons of the tetraethylene glycol linker are observed. 
However, in analogy with Fc-PLPG1 and in contrast to PLPG2, the multiplet in that region 
expands down to 4.7 ppm. This indicates that attachment of Fc-NH2 to PLPG2 resulted in 
the same electronic changes due to the carbamate bond formation. 
The photo-caged aminoferrocenes Fc-PLPG1 and Fc-PLPG2 were then conjugated to a 
mitochondria localization signal peptide (MLS) via Michael addition of the cysteine thiol of 
the peptide to the maleimides of the PLPGs (Scheme 2). After preparative HPLC purification 
and lyophilisation, Fc-PLPG1-MLS and Fc-PLPG2-MLS were obtained as light-yellow 
solids. For Fc-PLPG1-MLS, the presence of the desired product was confirmed by ESI-MS 
where peaks at m/z = 352 [M+3H]3+, 528.1 [M+2H]2+ and 1055.4 [M+H]+ (Figure S10) were 
observed. As for the photo-caged bioconjugate of rhenium (I) complex, small m/z peaks 
corresponding to products of photo-uncaging (PLPG-MLS and Fc-NH-COOH) were 
observed in the LC-MS spectra. This uncaging process happened due to the harsh 
ionization conditions used for LC-MS as uncaged complex and byproducts eluted at different 
times (Figures S11 and 27). Successful synthesis of Fc-PLPG2-MLS was confirmed by ESI-
MS where m/z = 436 [M+3H]3+, 654 [M+2H]2+ and 1307 [M+H]+ (Figure S21) were detected. 
The purities were checked by analytical HPLC (Figure S20).  
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4.4.2 X-Ray Crystallography 
Single crystals of Fc-PLPG1 suitable for X-ray analysis were obtained by vapor diffusion 
recrystallization (see X-ray crystallographic part in the experimental section). Only a few X-
ray structures of compounds consisting of 1-(2’-nitrophenyl)ethyl ester unit are known,[20,21,22] 
but only two of them were actually synthesized as precursors for photolabile 
substances.[20,21] Fc-PLPG1 crystallized in the centrosymmetric triclinic space group P-1 and 
is in an overall bent conformation, essentially like a horseshoe, where the two ends, 
ferrocene and maleimide, almost touch each other (Figure 1). Additionally, Fc-PLPG1 forms 
in the solid state a dimer via two hydrogen bridges: The amide nitrogen N1 is in close 
contact with one of the maleimide oxygen atoms O6_$1 (-x+2, -y+2, -z) at a distance of 
2.9003(15) Å and the amide of that molecule back binds to the original molecule to build the 
cyclic dimer (Figure S8). 
 
Figure 1. ORTEP representation of the crystal structure of Fc-PLPG1. Ellipsoids were drawn at 50% 
probability. 
 
4.4.3 Photolysis Quantum Yields 
With the bioconjugates in hand, the next step in this study was to evaluate the photo-
uncaging of Fc-PLPG1-MLS and Fc-PLPG2-MLS by measuring their laser photolysis 
quantum yield in PBS (pH=7.4) at 355 nm. The decomposition of Fc-PLPG1-MLS and Fc-
PLPG2-MLS was monitored by LC-MS until 20% of the initial compound was photolysed 
(Figures S22-24). Calculated relative to the trans-to-cis photoisomerization quantum yield of 
azobenzene at this wavelength (15%),[23–25] a yield of 0.07 ± 0.02% for Fc-PLPG1-MLS 
indicates a rather inefficient photo-release process, that runs much slower than the 
photolysis of the similar Re(I) bioconjugate.[15] The carbamate-based photo-cages for amines 
first release the amine as a carbamate salt, which then in turn decarboxylates.[11] The rate of 
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decarboxylation depends on the pKa of the amine group and a more acidic aromatic amine 
of aminoferrocene is expected to decarboxylate slower than an aliphatic amine of the 
reported Re(I) complex. However, we monitored the disappearance of Fc-PLPG1-MLS 
rather than the appearance of the released aminoferrocene. Hence, the observed slower 
decomposition cannot be ascribed to the decarboxylation step. Rapid photo-uncaging of the 
Re analogue could be ascribed to the high absorptivity of the Re(I) chromophore at the 
irradiation wavelength, which could enable it to act as an “light-antenna”. Nevertheless, the 
photolysis quantum yield of Fc-PLPG1-MLS at 355 nm is also considerably lower than that 
of phosphate photo-caged with o-nitrophenyl group.[23,25] The exact reasons behind a 
particularly inefficient photo-release of Fc-NH2 from Fc-PLPG1-MLS remain for the moment 
unclear. The uncaging quantum yield of Fc-PLPG2-MLS was determined in a similar 
fashion. The quantum yield is with 1.8 ± 0.48% higher than for Fc-PLPG1-MLS, and is 
accompanied by a seven-fold higher absorptivity at 355 nm compared to Fc-PLPG1-MLS 
(Figures S30-31). The propyl-o-nitrobiphenyl cage core has previously, to the best of our 
knowledge, not been used to cage amines via carbamates. A direct comparison regarding 
the uncaging quantum yield therefore cannot be made in this case. 
 
4.4.4 UV-A Irradiation and Iron Release 
Although a monochromatic laser setup allows accurate determination of uncaging quantum 
yields, it is impractical for cell culture irradiation experiments. To this end, a UV-A reactor 
(Rayonet) equipped with lamps emitting in the 300-400 nm range (emission centered at 
350 nm) was used. To find a suitable UV-A light dose for the cell irradiation experiments, the 
more slowly uncaging Fc-PLPG1-MLS was photolysed under the same experimental setup 
as for cytotoxicity assays (100 μM in PBS buffer solution (pH=7.4) in a covered 96-well 
plate, 30 °C). As expected from the quantum yield measurements, the photolysis of Fc-
PLPG1-MLS proceeded very slowly and required a relatively high light dose to complete 
(18 J/cm2) (Figure S25). Such elevated dose of UV-A light would on its own affect cell 
proliferation, so a maximal UV-A light dose safe for cells (3.3 J/cm2) was used in cytotoxicity 
experiments.[15] Using this light dose, neither the light irradiation nor secondary effects, e.g. 
temperature changes, affected the cells significantly. During irradiation experiments, the 
formation of aminoferrocene and photo-cage byproducts was detected by LC-MS for Fc-
PLPG1-MLS only (Figure S27). This is due to the fact that the sample solutions were 
adjusted to have the same absorbance at the irradiation wavelength. However, Fc-PLPG1-
MLS has a significantly lower molar absorptivity at 355 nm compared to Fc-PLPG2-MLS 
(Figures S30-31). As a result, Fc-PLPG1-MLS was used in a considerably higher 
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concentration and the products of its photolysis were easier to detect. The observation of 
products corresponding to the typical uncaging reaction are indicative of aminoferrocene 
being released via this mechanism, as opposed to direct degradation of Fc-NH2. Of note, to 
observe the appearance of aminoferrocene, the samples had to be analyzed immediately 
after irradiation or kept frozen in liquid nitrogen prior to analysis due to the instability of 
aminoferrocene. The aminoferrocene peak initially increased with the light dose, but was not 
observed at higher doses (Figure S26). The irradiation of aminoferrocene alone 
demonstrated that the compound decomposed faster than the caged Fc-PLPG1-MLS 
released it (Figure S27). The photo-decomposition of aminoferrocene was also followed by 
UV/Vis spectroscopy (Figure S29). At a lower irradiation dose, the UV absorbance of the 
sample actually increases in the 250-350 nm range indicating formation of Fc+, which 
absorbs stronger than ferrocene in this range.[26] Yet, at higher light doses, the characteristic 
Fc transitions in the 275-500 nm range decrease and then disappear completely. 
Studies on aminoferrocene-based prodrug candidates decomposition have shown that such 
molecules could decay into iron ions and cyclopentadienyl ligands.[1,2] The release of iron 
ions played in fact an important role in the cytotoxicity mechanism of Mokhir’s complexes as 
catalysts for ROS generation.[1,2] To verify if the photo-decomposition of Fc-PLPG1-MLS, 
Fc-PLPG2-MLS and Fc-NH2 resulted in the same products, the iron release upon light 
irradiation was monitored. More specifically, the compounds were irradiated by UV-A (as 
described above for UV-A dose determination) and the amount of free iron ions was 
quantified by formation of iron(II) tris(2,2’-bipyridine) complex and monitoring its strong 
absorption at 509 nm.[1] The assay showed that both Fc-PLPG1-MLS and Fc-PLPG2-MLS 
generated iron ions upon light irradiation, but long irradiation times were required to free up 
all iron (Figures S32-33). The iron release in the dark was also followed for 4 h, but no 
significant increase in iron ions was detected (Figures S35-36). Aminoferrocene, on the 
other hand, decomposed rapidly into iron ions even in the dark. Light irradiation only slightly 
increased the rate of iron release (Figure S34). These results demonstrate that the photo-
caging of aminoferrocene succeeds in enhancing its stability at physiological conditions. This 
effect is most likely due to decreased electron donation from the primary amino group, which 
is converted to a carbamate in Fc-PLPG1-MLS and Fc-PLPG2-MLS. The decay into iron 
ions is clearly a complex multi-step process and the observed rate of Fc-PLPG1-MLS, Fc-
PLPG2-MLS and Fc-NH2 photolysis is consequently not always proportional to the 
appearance of iron ions. Indeed, although Fc-PLPG1-MLS decomposes considerably slower 
than Fc-PLPG2-MLS (see the quantum yields and absorptivities above), its iron release rate 
is only about 2-fold slower. 
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4.4.5 Cytotoxicity 
The anti-proliferative effect of Fc-PLPG1-MLS, Fc-PLPG2-MLS and Fc-NH2 was 
investigated on human promyelocytic leukemia (HL-60) and non-cancerous hTERT-
immortalized retinal pigment epithelial (hTERT RPE-1) cell lines. To assess the light 
cytotoxicity, cells were incubated with the compounds for 4 h prior to irradiation and left to 
recover for 44 h afterwards. Cell viability was quantified using the resazurin assay (6 h 
incubation). As shown in Table 1, the dark cytotoxicity of Fc-NH2 towards HL-60 was 
significantly decreased by photo-caging and peptide conjugation. Only a slight increase in 
cytotoxicity (1.3-1.5 fold) was observed for Fc-NH2 and Fc-PLPG1-MLS upon light 
irradiation on HL-60 cells. In the case of Fc-NH2, these results can be rationalized in terms 
of its instability. In fact, most of Fc-NH2 decomposed before the cells were irradiated 
(compare Figure S34). The low cytotoxic impact of Fc-PLPG1-MLS can be explained by an 
extremely low uncaging efficiency of this compound. Fc-PLPG2-MLS is not as benign in the 
dark as Fc-PLPG1-MLS, but possess an improved phototoxic index of about 2.5. Upon light 
irradiation, the IC50 value of Fc-PLPG2-MLS reaches the level of aminoferrocene. All tested 
compounds are less toxic towards non-cancerous hTERT RPE-1 cells and show no effect of 
light-irradiation on this cell line. The difference is likely due to the elevated levels of ROS 
characteristic for tumors. This enhanced ROS generation pushes the ROS scavenging 
system of cancer cells to the limit and a further increase in ROS can tip the scale towards 
cellular death. Our data indicate that the cytotoxicity mechanism of Fc-PLPG1-MLS, Fc-
PLPG2-MLS and Fc-NH2 is likely to involve catalytic ROS generation by the liberated iron 
ions, as suggested by the Mokhir group for their aminoferrocene-based prodrug 
candidates.[1,2] Indeed, the IC50 values of Fc-PLPG1-MLS, Fc-PLPG2-MLS and Fc-NH2 on 
HL-60 cells are in the same range as those reported by the Mokhir group on the same cell  
Table 1. Cytotoxicity (IC50) of PLPG1-MLS, Fc-PLPG2-MLS and Fc-NH2 towards human cell lines. 
 HL-60 hTERT RPE-1 
 darka  
[µM] 
UV-Ab 
[µM] 
Phototoxic 
Index 
darka  
[µM] 
UV-Ab 
[µM] 
Phototoxic 
Index 
Fc-NH2 18.4 ± 0.1 12.1 ± 0.7 1.5 ± 0.1 42.4 ± 9.2 38.2 ± 3.1 1.1 ± 0.3 
Fc-PLPG1-
MLS 
72.6 ± 0.8 55.4 ± 3.9 1.3 ± 0.1 >100 >100 - 
Fc-PLPG2-
MLS 
40.0 ± 0.6 15.7 ± 2.8 2.5 ± 0.4 39.0 ± 1.1 37.1 ± 2.9 1.1 ± 0.1 
a incubated with the compounds for 56 h (including 6 h resazurin assay); b incubated with the 
compounds for 4 h prior to irradiation (10 min, UV-A reactor at 350 nm), then incubated for another 
52 h (including 6 h resazurin assay).  
Part I – Photo-Activatable Compounds
4 Photo-Release of Aminoferrocene
123 
 
 
line. Fc-PLPG2-MLS has in fact the IC50 value very close to that of the most toxic compound 
tested on HL-60 by Mokhir’s group (15.7 ± 2.8 vs 9 ± 2).[1] All in all, the data demonstrate 
that the activity of cytotoxic aminoferrocene compounds can be efficiently controlled by a 
photo-caging strategy. 
 
4.5 Conclusion 
In this work, we have successfully prepared and characterized two light-activatable 
aminoferrocene-based prodrug candidates (Fc-PLPG1-MLS and Fc-PLPG2-MLS) using two 
different photo-cages. Upon UV-A light-irradiation, both bioconjugates released 
aminoferrocene, which rapidly decayed into iron ions under physiological conditions. Despite 
this decomposition – or most likely due to it – aminoferrocene considerably reduced the 
proliferation of cancer cells (HL-60) both in dark and upon light irradiation. While both cages 
improved the stability of aminoferrocene and therefore attenuated its dark cytotoxicity, Fc-
PLPG2-MLS displayed a higher uncaging efficiency, higher phototoxic index and lower light 
IC50 value compared to Fc-PLPG1-MLS. The absence of light effect on healthy cells 
suggests that Fc-PLPG1-MLS and Fc-PLPG2-MLS exploit the elevated ROS levels typical 
of cancer cells. Their mode of action is then likely to be based on the catalysis of ROS 
generation by released iron ions. In addition to the selectivity derived from this inherent 
property of the tumors, our photo-caged aminoferrocene prodrug candidates also offer 
spatial and temporal control of their activity via light irradiation as well as, potentially, 
selective delivery through a targeting vector. We believe that this potential triple selectivity 
concept holds great potential, especially when considering the severe side-effects frequently 
encountered by patients undergoing chemotherapy. 
 
4.6 Experimental Section 
 
4.6.1 Materials and Instruments 
Chemicals and solvents were purchased reagent grade or better from commercial suppliers 
and used without further purification unless otherwise specified. 1H and 13C NMR spectra 
were recorded with Bruker 400 and 500 spectrometers. UV/Vis spectra were recorded on 
Varian Cary 50 Scan and Cary 100 spectrophotometers. ESI-MS and LC-MS were obtained 
with a Bruker Daltonics HCT 6000 mass spectrometer. LC-MS spectra were measured on 
an AcquityTM from Waters system equipped with a PDA detector and an auto sampler using 
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an Agilent Zorbax 300SB-C18 analytical column (3.5 μm particle size, 300 Å pore size, 
150 × 4.6 mm). The LC run (flow rate: 0.3 mL min–1) was performed with a linear gradient of 
A (distilled water containing 0.1% v/v formic acid) and B (acetonitrile, containing 0.1% v/v 
formic acid); t = 0 min, 5% B; t = 3 min, 5% B; t = 17 min, 100% B; t = 20 min, 100% B; 
t = 25 min, 5% B. Analytical HPLC was carried out using a Macherey-Nagel EC 250/3 
NUCLEOSIL 100-5 C18 column on a VWR Chromaster system with 5110 pump, 5210 
autosampler, 5310 column oven and 5430 diode array detector. Analytical HPLC run (flow 
rate1 mL/min) were performed with a linear gradient of A (distilled water containing 0.1% v/v 
TFA) and B (acetonitrile): t = 0 min, B = 5%; t = 18 min, B = 39%; t = 27 min, B = 100%; t = 
31 min, B = 100%; t = 36 min, B = 1%; t = 38 min, B = 1%, t = 40 min, B = 5%; t = 41 min, B 
= 5), unless noted otherwise. HPLC purification was performed on a Merck HITACHI system 
and a Zorbax XB-300 semi-preparative column (5 μm particle size, 300 Å pore size, 
250 mm x 9.4 mm, flow rate: 4 mL min-1), as well as on a Varian ProStar system and an 
Agilent PrepHT 300SB-C18 preparative column (5 μm particle size, 300 Å pore size, 
150 × 21.1 mm. Flow rate: 20 mL min–1). The runs were performed with a linear gradient of A 
(distilled water containing 0.1% v/v TFA) and B (acetonitrile (Sigma–Aldrich HPLC-grade), 
containing 0.1% v/v TFA), unless noted otherwise. Semi-preparative runs: t = 0 min, 5% B; 
t = 12 min, 15% B; t = 32 min, 40% B; t = 50 min, 80% B; t = 51 min, 100% B; t = 56 min, 
100% B; t = 61 min, 5% B. Preparative runs: t = 0 min, 5% B; t = 25 min, 100% B; t = 30 min, 
100% B; t = 32 min, 5% B. Photolysis quantum yields were measured using an Edinburgh 
LP-920 setup equipped with a Continuum Surelite laser (355 nm). Cell culture photo-
irradiation and iron release assays were conducted using a Rayonet RPR-200 
photochemical reactor using 6 bulbs (14 W each) emitting in 300–400 nm range with 
maximum intensity output at 350 nm. The temperature inside the reactor was 30 °C. The 
light intensity was 55 W/m2, as determined with a X11 optometer (Gigahertz-Optik). 
 
4.6.2 Synthesis and Characterization 
Fc-NH2 
Aminoferrocene was prepared using a procedure previously published.[27] The analytical 
data matched what that previously reported.[27] 
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PLPG1 
The photolinker was synthesized following a procedure previously published.[28] The 
analytical data matched what that previously reported.[28] 
 
Fc-PLPG1 
PLPG1 (30 mg, 0.072 mmol) and aminoferrocene (15 mg, 0.072 mmol) were dissolved in 
dry chloroform (1 mL). Diisopropylethylamine (24 mg, 31 μL, 0.18 mmol) was then added to 
the mixture, which was stirred for 4 h at 35 °C. The solvent was then removed under vacuum 
to give a sticky brown solid, which was purified by column chromatography (silica gel, 
CH2Cl2/EtOAc 9:1) to afford Fc-PLPG1 as an orange-red solid (22 mg, 62%). 
Rf = 0.86 (CH2Cl2/EtOAc 9:1). 1H NMR (500 MHz, CDCl3) δ 7.92 (d, 3J = 8.5 Hz, 1H), 7.64 
(s, 1H), 7.39 (d, 3J = 8.5 Hz, 1H), 6.67 (s, 2H), 6.29 (q, 3J = 6.5 Hz, 1H), 6.02 (s, 1H), 4.71 (s, 
2H), 4.49 (m, 1H), 4.46 (m, 1H), 4.15 (s, 5H), 3.98 (m, 1H), 1.63 (d, 3J = 6.5, 3H). 13C NMR 
(500 MHz, CDCl3) δ 170.2, 152.6, 147.0, 142.1, 139.4, 134.5, 128.6, 127.5, 125.5, 69.5, 
69.0, 64.7, 64.6, 60.9, 60.8, 40.9, 22.3, one signal coincidental or not observed. ESI-MS 
calcd. for C24H21FeN3O6 [M]+ 503.3, found 503.1. ESI-HRMS m/z calcd. for C24H21FeN3O6 
([M]+) 503.0780, found 503.0778; calcd. for C24H21FeN3O6Na ([M+Na]+) 526.0677, found 
526.0673; calcd. for C24H21FeN3O6K ([M+K]+) 542.0417, found 542.0411; calcd. for 
C19H16FeN3O6 ([M-Cp]+) 438.0389, found 438.0871; calcd. for C11H11FeNO2 ([FcNHCOOH]+) 
245.0139, found 245.0130. 
 
MLS peptide 
The peptide was prepared following a previously published general peptide synthesis 
procedure.[29] 
ESI-MS m/z calcd. for C24H41N9O4S ([M+H]+) 552.3, found 552.3; calcd. for C24H42N9O4S 
([M+2H]2+) 276.7, found 276.6. 
 
Fc-PLPG1-MLS 
Fc-PLPG1 (20 mg, 40 μmol) and MLS peptide (35 mg, 40 μmol) were first pre-dissolved in 
DMSO (30 μL) and then in acetonitrile/water mixture 1:1 (1 mL). The reaction mixture was 
stirred overnight at room temperature. The solvents were removed by lyophilization and the 
compound was purified by preparative HPLC to obtain light-yellow solid.  
Part I – Photo-Activatable Compounds
4 Photo-Release of Aminoferrocene
126 
 
 
ESI-MS m/z calcd for C48H62FeN12O10S ([M+H]+) 1055.4, found 1055.4; calcd for 
C48H63FeN12O10S ([M+2H]2+) 528.2, found 528.1; calcd for C48H64FeN12O10S ([M+3H]3+) 
352.3, found 352.2. UV absorption (PBS buffer, pH=7.4): ε264 = 13037 ± 173 M-1cm-1. 
 
Fc-PLPG2 
Under an atmosphere of N2, N,N'-disuccinimidyl carbonate (70.3 mg, 0.275 mmol) was 
added to a solution of PLPG2 (82.9 mg, 0.157 mmol) in acetonitrile (2 mL). Triethylamine 
(76.6 µL, 55.6 mg, 0.549 mmol) was added to the stirred suspension, and stirring was 
continued for 6.5 h. All volatiles were removed on a rotary evaporator. The remaining 
residue was taken up in EtOAc and washed with 0.1 M NaHCO3. The layers were separated 
and the aqueous layer was twice extracted with EtOAc. The combined organic layers were 
washed with brine, dried (Na2SO4), filtered and concentrated. Column chromatography 
(silica gel, CH2Cl2/EtOAc 8:2) yielded the intermediate active ester of PLPG2 as a yellow oil 
(55 mg, would correspond to 52%), which was directly used in the next reaction step. 
The active ester of PLPG2 (21 mg, would correspond to 31 µmol), aminoferrocene (8.2 mg, 
41 µmol) and diisopropylethylamine (6.5 mg, 8.5 µL, 50 µmol) were dissolved in dry CH2Cl2 
(4 mL) and stirred under exclusion of light for 15 h at rt. Saturated NH4Cl solution was added 
and the mixture extracted with CH2Cl2 (3x). The combined organic layers were dried 
(MgSO4), filtered and concentrated. Purification by column chromatography (silica gel, 
CH2Cl2/MeOH 200:198:2) gave pure Fc-PLPG2 as brown viscous oil (23 mg, 96% for 2nd 
step, 50% over both steps). 
Rf = 0.46 (CH2Cl2/MeOH 95:5). IR (neat) 3095(w), 2874 (w), 1702 (s), 1604 (m), 1515 (s), 
1346 (m), 1232 (m), 1103 (m), 1074 (m), 932 (w), 824 (s), 695 (m) cm–1. 1H NMR (500 MHz, 
CDCl3) ∂ 7.85 (d, J = 7.9 Hz, 1 H), 7.69–7.42 (m, 4 H), 7.02 (d, J = 7.9 Hz, 2 H),6.67 (s, 2 H), 
5.72 (bs, 1 H), 4.73–3.30 (m, 28 H), 1.41 (d, J = 6.5 Hz, 3 H). 13C NMR (125 MHz, CDCl3): ∂ 
170.6, 159.5, 153.2, 149.0, 145.4, 138.0, 134.1, 131.5, 128.5, 125.9, 125.4, 125.0, 115.2, 
70.9, 70.7, 70.6, 70.1, 69.6, 69.5, 68.8, 67.8, 67.6, 64.7, 60.6, 37.1, 33.3, 17.4, one signal 
coincidental or not observed. ESI-MS m/z 778.2 (100, [M+Na]+), 755.2 (49, [M]+), 389.1 (88, 
[M+Na]2+). HRMS m/z calcd. for C38H41N3O10 ([M]+) 755.21358, found 755.20277. 
 
Fc-PLPG2-MLS 
Fc-PLPG2 (20 mg, 26 µmol) and MLS peptide (15 mg, 26 µmol) were dissolved in a mixture 
of acetonitrile (2 mL) and PBS buffer (1 mL). The solution was stirred for 7 h at rt. The 
solvents were removed by lyophilization. Purification by preparative HPLC (20 mL/min, H2O 
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+ 0.1% TFA : acetonitrile = 0 min: 95:5, 27 min: 35:65, 31 min: 0:100, 33 min: 0:100, 36 min: 
95:5, 37 min: 95:5, tR = 13 min) gave pure Fc-PLPG2-MLS as a brown solid. 
ESI-MS m/z 654 (100, [M+2 H]2+), 436 (40, [M+3 H]3+), 1307 (8, [M+H]+). tR = 22.6 min 
(HPLC analytical gradient). 
 
4.6.3 X-Ray Crystallography 
Crystals were grown by vapour diffusion of cyclohexane into a solution of Fc-PLPG1 in 
methylene chloride.[30] Crystallographic data were collected at 183(2) K with Mo Kα radiation 
(λ = 0.7107 Å) that was graphite-monochromated on an Oxford Diffraction CCD Xcalibur 
system with a Ruby detector. Suitable crystals were covered with oil (Infineum V8512, 
formerly known as Paratone N), placed on a nylon loop that is mounted in a CrystalCap 
Magnetic™ (Hampton Research) and immediately transferred to the diffractometer. The 
program suite CrysAlisPro was used for data collection, multi-scan absorption correction and 
data reduction.[31] The structure was solved with direct methods using SIR97[32] and was 
refined by full-matrix least-squares methods on F2 with SHELXL-97.[33]  
 
4.6.4 Photophysical Characterization 
Photolysis quantum yield 
20 mM DMSO stock solutions of Fc-PLPG1-MLS and Fc-PLPG2-MLS were diluted in 
phosphate buffer (pH=7.4) to obtain optical density at 355 nm (OD(λ = 355 nm)) of 0.2. 
Fluorescence cuvette (1 cm x 0.2 cm, Hellma 105.250-QS with 100 μL of solution was 
irradiated at 355 nm using an Edinburgh LP-920 laser flash photolysis setup equipped with a 
Continuum Surelite Nd:YAG laser, frequency tripled to generate light with a wavelength of 
355 nm. The laser beam was slightly misaligned to obtain a suitable irradiation power. A 
fresh aliquot of solution was used for each irradiation. After a certain number of laser shots 
the solutions were transferred to amber HPLC vials with a 200 μL inlet. The vials were then 
kept frozen in liquid nitrogen and unfrozen 2 min prior to analysis by LC-MS due to the 
instability of released aminoferrocene. The peak corresponding to Fc-PLPG1-MLS or Fc-
PLPG2-MLS was integrated and the percentage of remaining compound (calculated from 
the peak area) was plotted against the number of laser shots. The experiment was 
continued until the number of laser shots that decomposed 20% of Fc-PLPG1-MLS or Fc-
PLPG2-MLS was reached. At less than 20% conversion, the photolysis curve could be fitted 
by a simple linear regression. The slope of the linear fit ݉௦௔௠௣௟௘ was then used to calculate 
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the photolysis quantum yield by comparing it to the quantum yield of azobenzene 
photoisomerization. For that, trans-azobenzene was dissolved in methanol to obtain OD(λ = 
355 nm) = 0.2 and irradiated in the same conditions as Fc-PLPG1-MLS and Fc-PLPG2-
MLS. The conversion of azobenzene was monitored by following the UV/Vis absorbance at 
355 nm. The irradiation was continued until 20% of azobenzene had isomerized. The 
percentage of remaining amount of trans-azobenzene was then plotted versus the irradiation 
dose (measured in number of laser shots) and fitted by a linear curve as for Fc-PLPG1-MLS 
and Fc-PLPG2-MLS (see above). The slope of azobenzene curve ݉௥௘௙௘௥௘௡௖௘ was used to 
calculate the photolysis quantum yield of Fc-PLPG1-MLS or Fc-PLPG2-MLS (߶௦௔௠௣௟௘) 
using the following equation: 
߶௦௔௠௣௟௘ ൌ ߶௥௘௙௘௥௘௡௖௘ ൈ
݊௦௔௠௣௟௘,଴ ൈ ݉௦௔௠௣௟௘
݊௥௘௙௘௥௘௡௖௘,଴ ൈ ݉௥௘௙௘௥௘௡௖௘ 
where ߶௥௘௙௘௥௘௡௖௘ is the quantum yield of azobenzene trans-cis isomerization at 355 nm 
(15%), and ݊଴ are the amounts (in mol) of the respective compounds before irradiation. At 
least three independent sets of experiments were averaged to obtain the single-photon 
uncaging quantum yields. 
 
Photolysis in UV reactor 
To estimate the UV-A dose needed for Fc-PLPG1-MLS uncaging in cells, 20 mM DMSO 
stock solution of it was diluted with PBS buffer (pH=7.4) to obtain a final concentration of 
100 μM (highest concentration used in cytotoxicity experiments). The solution was pipetted 
in 100 μL portions on a 96-well plate (used for cytotoxicity experiments) and irradiated in the 
UV reactor with different light doses. The solution composition was analyzed by LC-MS. The 
relative concentration of the photolysed compound was calculated from the area of the 
corresponding LC-MS peak. Percentage of remaining compound vs. the irradiation dose 
could be fitted by a single exponential (first order kinetics law): 
ܥሺݔሻ ൌ ܥ଴ ൈ ݁ି௞௫ 
where ܥ଴ is the initial concentration, ݇ is the rate constant and ݔ is the irradiation dose. The 
same procedure was applied for aminoferrocene to monitor its decomposition during UV-A 
irradiation. 
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Iron release 
Release of iron ions from aminoferrocene, Fc-PLPG1-MLS and Fc-PLPG2-MLS was 
monitored using a procedure adapted from Mokhir’s work.[1] More specifically, the compound 
of interest (5 μL, 4 mM DMSO stock solution) was diluted in PBS (pH=7.4, 175 μL). The 
concentration of iron ions was then detected by addition of Na2S2O4 (10 μL, 0.8 M in water) 
and 2,2’-bipyridine (10 μL, 12 mM in DMF:water 1:1), which forms iron(II) tris(2,2’-bipyridine) 
complex. The amount of formed complex was quantified by observing its strong absorbance 
at 509 nm. The experiments were conducted in a 96-well plate using a Spectramax M2e 
microplate reader (Molecular Devices). 
 
4.6.5 Cell Culture 
The human promyelocytic leukemia cells (HL-60) were cultured in RPMI (Gibco) 
supplemented with 20% heat inactivated fetal calf serum (Gibco), 100 U/mL penicillin, 
100 μg/mL streptomycin at 37 °C and 5% CO2. The hTERT-immortalized retinal pigment 
epithelial cell line (hTERT RPE-1) was maintained in DMEM (Gibco) supplemented with 10% 
FCS (Gibco), 100 U/mL penicillin, 100 μg/mL streptomycin at 37 °C and 5% CO2. 
 
Photo-toxicity studies 
Photo-toxicity studies were performed on two different cell lines, namely, HL-60 and hTERT 
RPE-1, by a fluorometric cell viability assay using resazurin (Promocell GmbH). Briefly, one 
day before treatment, cells were plated in triplicates in 96-well plates at a density of 
4 × 103 cells/well in 100 μL. Cells were then treated with increasing concentrations of the 
complexes for either 48 h in the dark or 4 h in the dark followed by 10 min irradiation at 
350 nm (3.3 J/cm2) and then placed back in the incubator in the dark for the remaining 44 h. 
After treatment, resazurin (0.2 mg/mL final concentration) was added to the 200 μL. After 6 h 
of incubation at 37 °C, the fluorescence of the highly red fluorescent resorufin product was 
quantified at 590 nm emission with 540 nm excitation wavelength in a SpectraMax M5 
microplate reader. 
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4.8 Supporting Information 
 
4.8.1 Synthesis of PLPG2 precursors 
 
Scheme S1. Synthesis of 6. a) K2CO3, acetone, rt, 28 h, 93%; b) K2CO3, butanone, reflux for 14 h, then rt for 4 d, 50%; c) anisole, 155 °C, 1.5 h, 100%. 
 
Compound 1 
The title compound was prepared as described by Bordi et al.[34] The analytical data 
matched what was reported there. 
 
Compound 2 
The title compound[35] was prepared as described by Tang et al.[28] The analytical data 
matched what was reported there. 
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Compound 3 
The synthesis of the title compound was recently reported by us.[19] The analytical data 
matched what was reported there. 
 
Compound 4 
2 (500 mg, 3.03 mmol) was added to a stirred solution of 1 (2.91 g, 9.08 mmol) in acetone 
(20 mL). The solution was treated with K2CO3 (2.09 g, 15.1 mmol) and the resulting 
suspension was stirred for 28 h at rt. The solvent was removed and the residue was taken 
up in diethyl ether and water. The layers were separated and the aqueous layer was 
extracted with CH2Cl2 (2x). The combined organic layers were dried (Na2SO4), filtered, and 
concentrated in vacuo. The crude brown oil (3.22 g) was subjected to column 
chromatography (silica gel, CH2Cl2/MeOH 99:1  CH2Cl2/MeOH 33:1) to give 4 as colorless 
oil (1.14 g, 93%). 1 could partially be recovered (1.14 g, 3.56 mmol). 
Rf = 0.28 (DCM/MeOH 98:2). IR (neat) 2866 (w), 1775 (w), 1693 (s), 1396 (m), 1096 (m), 
1022 (m), 879 (m) cm–1. 1H NMR (400 MHz, CDCl3) ∂ 6.51 (t, J = 0.89 Hz 2 H), 5.24 (t, 
J = 0.89 Hz, 2 H), 3.82–3.44 (m, 16 H), 2.84 (s, 2 H). 13C NMR (100 MHz, CDCl3): ∂ 176.1, 
136.6, 80.9, 72.5, 70.7, 70.5, 70.4, 70.1, 67.1, 61.8, 47.5, 38.2. ESI-MS m/z 428.1 (100, 
[M+Na]+), 279.0 (16, [M-C8H5NO2+Na]+), 358.0 (8, [M-C4H4O+Na]+). HRMS m/z calcd. for 
C16H22BrNNaO6 ([M+Na]+) 426.05227, found 426.05194. 
 
Compound 5 
3 (128 mg, 0.468 mmol) was added to a stirred suspension of 4 (192 mg, 0.475 mmol) and 
K2CO3 (323 mg, 2.34 mmol) in butanone (15 mL). The mixture was stirred at 65 °C for 22 h. 
Silica (5 g) was added and all volatiles were removed. Purification by column 
chromatography (silica gel, CH2Cl2/MeOH 99:1  98:2) afforded 5 as a yellow oil (184 mg, 
66%). 
Rf = 0.34 (CH2Cl2/MeOH 97:3). IR (neat) 3459 (w), 2873 (m), 1772 (w) 1695 (s), 1604 (m), 
1514 (s), 1347 (m), 1248 (m), 825 (m), 878 (w), 825 (m). 1H NMR (400 MHz, CDCl3) ∂ 7.86 
(d, J = 8.5 Hz, 1 H), 7.62 (d, J = 1.9 Hz, 1 H), 7.55–7.47 (m, 3 H), 7.06–6.98 (m, 2 H), 6.48 
(t, J = 0.9 Hz, 2 H), 5.25 (t, J = 0.9 Hz, 2 H), 4.20–4.16 (m, 2 H), 3.91–3.57 (m, 16 H), 2.83 
(s, 2 H), 1.64 (t, J = 5.8 Hz, 1 H), 1.39 (d, J = 6.9 Hz, 3 H). 13C NMR (100 MHz, CDCl3): ∂ 
176.1, 159.5, 148.9, 145.2, 139.0, 136.6, 131.6, 128.5, 126.3, 125.2, 125.1, 115.3, 80.9, 
70.8, 70.7, 70.62, 70.55, 70.1, 69.7, 67.9, 67.6, 67.1, 47.5, 38.2, 17.6. HRMS m/z calcd. for 
C31H36N2NaO10 ([M+Na]+) 619.22622, found 619.22544. 
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PLPG2 
5 (98.8 mg, 0.166 mmol) were dissolved in anisole (1.9 mL). The solution was stirred for 
1.5 h under an atmosphere of nitrogen at 155 °C, followed by removal of anisole by 
distillation. Clean PLPG2 (87.7 mg, 100%) remained as a brownish oil. 
Rf = 0.25 (CH2Cl2/MeOH 95:5). IR (neat) 3463 (w), 2874 (m), 1702 (s), 1604 (m), 1516 (s), 
1405 (m), 1350 (m), 1248 (m), 825 (s), 695 (s) cm–1. 1H NMR (500 MHz, CDCl3) ∂ 7.85 (d, 
J = 8.5 Hz, 1 H), 7.62 (d, J = 1.7 Hz, 1 H), 7.57–7.47 (m, 3 H), 7.02 (d, J = 8.7 Hz, 2 H), 
6.71–6.66 (m, 2 H), 4.22–4.14 (m, 2 H), 3.91–3.81 (m, 4 H), 3.74–3.53 (m, 14 H) 1.38 (d, 
J = 6.9 Hz, 3 H). 13C NMR (125 MHz, CDCl3): ∂ 170.6, 159.4, 148.9, 145.4, 139.0, 134.1, 
131.6, 128.5, 126.2, 125.2, 125.0, 115.2, 70.9, 70.7, 70.6, 70.1, 69.7, 67.9, 67.8, 67.6, 37.1, 
36.4, 17.6. HRMS m/z calcd. for C27H32N2NaO9 ([M+Na]+) 551.20000, found 551.19946. 
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4.8.2 Spectra 
In the following, analytical spectra of the newly synthesized and previously not characterized 
compounds are shown. 
 
 
Figure S1. ESI-MS spectrum of Fc-PLPG1, showing the full scan range (top) and a magnification of 
the most relevant range (bottom). 
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Figure S2. HR ESI-MS spectrum of Fc-PLPG1. 
 
 
Figure S3. 1H-NMR spectrum of Fc-PLPG1 in CDCl3. 
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Figure S4. LC-MS spectrum of Fc-PLPG1. 
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Figure S5. 1H-NMR spectrum of Fc-NH2 in CDCl3. 
 
 
Figure S6. 1H-NMR spectrum of PLPG1 in CDCl3. 
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Figure S7. 13C-NMR spectrum of Fc-PLPG1 in CDCl3. 
 
 
Figure S8. X-ray structure of Fc-PLPG1. 
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Figure S9. ESI-MS spectrum of MLS peptide. 
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Figure S10. ESI-MS spectrum of Fc-PLPG1-MLS. 
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Figure S11. LC-MS spectrum of Fc-PLPG-MLS1. 
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Figure S12. 1H-NMR spectrum of compound 4 in CDCl3. 
 
Figure S13. 13C-NMR spectrum of compound 4 in CDCl3.  
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Figure S14. 1H-NMR spectrum of compound 5 in CDCl3. 
 
Figure S15. 13C-NMR spectrum of compound 5 in CDCl3.  
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Figure S16. 1H-NMR spectrum of compound PLPG2 in CDCl3. 
 
Figure S17. 13C-NMR spectrum of compound PLPG2 in CDCl3.  
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Figure S18. 1H-NMR spectrum of Fc-PLPG2 in CDCl3. 
 
Figure S19. 13C-NMR spectrum of Fc-PLPG2 in CDCl3.  
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Figure S20. Analytical HPLC trace of Fc-PLPG2-MLS. 
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Figure S21. ESI-MS of Fc-PLPG2-MLS. 
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4.8.3 Laser Photolysis Quantum Yield Determination 
 
Figure S22. Determination of photolysis quantum yield: conversion of trans-azobenzene upon laser 
irradiation at 355 nm in MeOH, quantified by UV/Vis spectroscopy. 
 
 
Figure S23. Determination of photolysis quantum yield: decomposition of Fc-PLPG1-MLS in PBS 
(pH=7.4) upon laser irradiation at 355 nm, quantified by UPLC. 
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Figure S24. Determination of photolysis quantum yield: decomposition of Fc-PLPG2-MLS in PBS 
(pH=7.4) upon laser irradiation at 355 nm, quantified by UPLC. 
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4.8.4 UV-A Photoreactor Photolysis 
 
Figure S25. Decomposition of Fc-PLPG1-MLS and Fc-NH2 in PBS (pH=7.4) upon UV-A irradiation (Rayonet reactor) quantified by LC-MS. 
 
 
Figure S26. LC spectra of the decomposition of Fc-PLPG1-MLS in PBS (pH=7.4) upon UV-A 
irradiation (Rayonet reactor). 
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Figure S27. LC-MS spectra of the decomposition of Fc-PLPG1-MLS after UV-A irradiation (3 J/cm2 
dose, Rayonet reactor) in PBS (pH=7.4) quantified by LC-MS (top) and the possible byproducts of 
PLPG1 (below). 
Fc-NH2
MLS-PLPG1-cyclized
MLS-PLPG1-NO2
MLS-PLPG1-NO
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Figure S28. Variation of the UV/Vis spectrum of Fc-PLPG1-MLS during UV-A irradiation (Rayonet 
reactor) in PBS (pH=7.4). 
 
 
Figure S29. Variation of the UV/Vis spectrum of Fc-NH2 during UV-A irradiation (Rayonet reactor) in PBS (pH=7.4).  
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4.8.5 UV/Vis Spectra 
 
Figure S30. UV/Vis spectrum of Fc-PLPG1-MLS in PBS (pH=7.4). 
 
 
Figure S31. UV/Vis spectrum of Fc-PLPG2-MLS in PBS (pH=7.4). 
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4.8.6 Iron Release upon UV-A Irradiation 
 
Figure S32. Iron release from Fc-PLPG1-MLS in PBS (pH=7.4) during light irradiation (Rayonet 
reactor). 
 
Figure S33. Iron release from Fc-PLPG2-MLS in PBS (pH=7.4) during light irradiation (Rayonet 
reactor). 
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Figure S34. Iron release from Fc-NH2 in PBS (pH=7.4) in the dark and during light irradiation (Rayonet reactor). 
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4.8.7 Iron Release in the Dark 
 
Figure S35. Iron release from Fc-PLPG1-MLS in PBS (pH=7.4) in the dark at room temperature. 
 
 
Figure S36. Iron release from Fc-PLPG2-MLS in PBS (pH 7.4) in the dark at room temperature.
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5 Outlook 
 
The photo-caging of bio-active compounds has two main fields of application, namely 
chemical biology and medicinal therapy. In chemical biology, as discussed in chapter 3, 
especially the two-photon technique is of interest since it offers subcellular resolution.[1] This 
is already being exploited, but almost exclusively for studying brain function upon release of 
neurotransmitters such as γ-aminobutyric acid (GABA) or glutamate.[2] However, other 
research areas could profit from a more locally controlled release. A look at the COX 
inhibitors in chapter 3 gives a good example for this. Although Celecoxib and Lumiracoxib 
were both thought to selectively act as COX-2 inhibitors, they have rather different effects on 
cancer cells. Celecoxib is cytotoxic, while Lumiracoxib is not. Recent research results 
suggest that these effects could be due to COX-2 independent interactions, which greatly 
differ between the non-steroidal anti-inflammatory drugs.[3] Notably, aspirin does not only  
inhibit COX, but also alters gene expression.[4] Finding and evaluating such off-target effects 
could be greatly facilitated by subcellular targeting and uncaging. 
The second application of the photo-caging of bioactive molecules is undoubtedly in the field 
of therapy. Currently, Photodynamic therapy (PDT) is the most important therapy which is 
based on the modulation of the activity of molecules with light.[5,6] It is in use for the 
treatment of cancer,[6] and its potential against infective diseases is currently being 
explored.[7] PDT relies on the photo-physical excitation of a drug dye to its excited singlet 
state and subsequent formation of reactive species, mainly 1O2. Classical PDT suffers from 
several shortcomings, including the nature of the therapeutically used light as well as the 
phototoxic side-effects of the photosensitizers. Solutions for many of these problems are 
currently under investigation.[5,8] However, despite the clinical success and on-going 
research in the field of PDT, a fundamental limitation of this technique is not solvable: The 
mechanism of action is based upon the production of 1O2, while most tumors are hypoxic. 
This constitutes an important selectivity problem. Furthermore, PDT is restricted to diseases 
where cells need to be killed. Other localized diseases, such as arthritis, cannot benefit from 
the advantages of light-triggered curing with PDT. As discussed in the previous chapters, the 
potential of photochemistry goes well beyond the production of 1O2. A much more universal 
and selective approach would be to use the concept of caging. 
Although (two-photon) uncaging has mostly been applied to answer questions in chemical 
biology (vide supra), therapeutic agents have also been caged.[10] Nevertheless, to date,  
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Figure 1. Two-photon cages and their uncaging action cross-sections at 800 nm; a) caged 
Lumiracoxib, as described in chapter 3 of this thesis; b) a recently developed new generation cage by 
Goeldner, Specht and coworkers;[9] c) proposed new cage structures. 
caging has remained a tool for research only. The implementation of the concept for 
therapeutic use is very intriguing, because it provides the opportunity to utilize known 
chemical entities with already known biological properties. It even might allow to “recover” 
compounds, which previously failed clinical trials[11] or have been withdrawn from the market 
due to adverse drug effects,[12] as side effects could be circumvented by activating the 
compounds only where and when they are needed. This could potentially lower the immense 
costs of developing completely new drug candidates. Given the imminent increased 
appearance of cancer, especially in developing countries,[13] approaches which decrease the 
therapeutic costs are of great importance. The most foreseeable (chemical) problems on the 
way will be the solubility of the caged compounds in aqueous media, and the effectiveness 
of uncaging. Scattering in discrete biological tissues might become a significant problem.[14] 
Both difficulties could be tackled by modifying the cage core (see Figure 1). Although it is not 
possible to date to predict the two-photon uncaging cross-section for a given compound, it 
seems that push-pull systems are favorable.[15] Consequently, the introduction of electron-
donating groups at the donor system could improve the effectiveness of the uncaging 
process. Goeldner, Specht and coworkers have recently reported a cage with improved two-
photon uncaging cross-section following this principle (Figure 1 b).[9] Additional substituents 
at the lower phenyl ring could therefore further increase the uncaging efficiency, while at the 
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same time improving the solubility in aqueous systems (Figure 1 c). Alternative approaches, 
which try to separate the two-photon absorption from uncaging process are currently under 
investigation by other groups.[16] Greatly increased two-photon absorbances can be 
expected, but with the trade-off of needing even bigger molecular systems with even lower 
solubility in water. 
In conclusion, the further development of two-photon uncaging as mean to deliver photo-
activatable bio-active components is of high interest. Moving towards more complex 
biological methodologies based on the research presented in this thesis, will show if further 
improvements on the chemical, or maybe even physical/instrumental side, are needed. On 
both levels further improvements are possible, casting the chances for further successful 
advances in a positive light. 
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6.2 Abstract 
DNA is a major player in the field of bio-nanotechnology and many interesting applications 
have been realized using this oligonucleotide. In contrast, the use of peptide nucleic acid 
(PNA), which is a non-natural, neutral analogue of DNA with superior hybridization strengths 
compared to DNA, is still in its infancy in bio-nanotechnology. However, as demonstrated in 
this short review using selected studies, promising examples demonstrating the tremendous 
opportunities that PNA can offer for bio-nanotechnology were recently described. 
 
Keywords: Biotechnology • Nanoparticle • Nanotechnology • Peptide nucleic acid (PNA) • 
Sensing. 
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6.3 Article 
DNA bio-nanotechnology has over the last decade become an important and quite diverse 
field of research, including studies about the assembly of DNA strands by themselves (DNA 
origami),[1] DNA modified nanoparticles,[2] and the combination of all sorts of other 
nanomaterials with DNA, e.g. nanotubes.[3] For applications of DNA, peptide nucleic acid 
(PNA), which is a non-natural analogue of DNA, has become an interesting alternative (see 
Figure 1 for the comparison of the structures of PNA and DNA).[4,5] To understand if and how 
PNA can impact bio-nanotechnology, the differences and consequential potential 
advantages of PNA over its naturally occurring analogues DNA and RNA have to be 
considered (see Figure 1). The nucleobases as well as their spatial arrangement are 
identical and complementary to each other in PNA, DNA and RNA. Complementary strands 
of the different nucleic acid oligomers can therefore bind to one another. Consequently, 
combinations of existing DNA bio-nanotechnology with PNA are possible. What 
distinguishes the different oligonucleotides is the backbone. While DNA and RNA possess a 
backbone consisting of (desoxy-)ribose sugars connected by phosphodiesters, PNA relies 
on a N-(2-aminoethyl)glycine based framework, which links the subunits like in a peptide 
with amide bonds. This change results in a number of important differences between PNA 
and its natural analogues, and has sparked great interest in various fields of research.[5] 
Although N-(2-aminoethyl)glycine has recently been found to be produced by 
cyanobacteria,[6] the PNA backbone is still regarded as unnatural and as such cannot be 
degraded enzymatically. Most importantly, the backbone is uncharged, making PNA highly 
interesting for use in electronic devices. Moreover, it eliminates the intrinsic electrostatic 
repulsion between individual nucleotide strands contributing to greater hybridization 
strengths. Partially due to this and for entropic reasons the binding strength of PNA 
oligomers to both complementary PNA and DNA strands is higher than of DNA strands. 
Finally, the single base mismatch sensitivity is usually greater for PNA than for DNA. 
In the past, our group has mainly been engaged in combining PNA with metal complexes,[7] 
and we were wondering why PNA has only scarcely been applied in bio-nanotechnology. In 
this short review we highlight, on basis of selected literature examples, how the above 
mentioned properties of PNA can indeed be exploited to advance bio-nanotechnology. 
Relatively much work has been done with PNA-functionalized silicon nanowires (SiNWs).[8–
11] The main reason for this is probably due to the uncharged nature of PNA, which is a 
significant advantage for SiNW based semiconductors, as they rely on charge differences on 
the SiNW surface for sensing (vide infra). Additionally, procedures for modification of SiNWs 
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Figure 1. Chemical structures of PNA and DNA. 
with PNA are straight-forward and known for more than ten years.[12] For example, PNA-
functionalized SiNWs were used for label-free detection of a specific DNA sequence (Figure 
2).[12] The SiNWs were modified with PNA as “receptors” with the well-established biotin-
avidin immobilization methodology. The SiNWs were used as semiconducting element 
between two electrodes and were, at the same time, inside a microfluidic channel. Upon 
addition of the complementary DNA sequence binding between the DNA and the PNA 
occurred, leading to a fast increase of conductance due to the electrostatic gating effect. 
Addition of non-complementary DNA did not substantially alter the conductance. A detection 
limit of 10 fM for a deletion of three bases in the gene encoding for cystic fibrosis 
transmembrane receptor, which leads to the corresponding disease, could be achieved due 
to the superior binding properties of the PNA. The sensor design and manufacturing process 
has since been improved, allowing for preparation of highly uniform SiNW arrays.[9] The 
potential advantages of using PNA compared to DNA for SiNW sensors have been pointed 
out by Gao and coworkers:[9] 1) increased hybridization efficiency due to stronger binding of 
DNA/PNA hybrids than of DNA/DNA hybrids; 2) lower basal conductance due to the 
uncharged nature of PNA allowing for the use of a regime of low ionic strength, which 
minimizes the appearance of strong electric fields and thereby background signal; 3) the 
greater mismatch sensitivity of PNA compared to DNA.[13] Indeed, PNA improved the 
performance of the sensor, showing greater conductance differences upon binding of the 
complementary DNA strand than the corresponding DNA-based SiNW sensors (see Figure 3 
for comparison between DNA- and PNA-based SiNW sensors).[9] In another direct 
comparison, a SiNW sensor with PNA capture probe was four times more sensitive than the 
equivalent sensor with DNA-functionalization.[8] 
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Figure 2. (A) Schematic representation of the PNA and SiNW based sensor for DNA detection. The 
SiNW (yellow) connects two electrodes (black) and spans a microfluidic channel (green). The arrows 
indicate the direction of the flow. (B) PNA-modified SiNW before addition of complementary DNA. (C) 
PNA-modified SiNW after addition of complementary DNA which leads to PNA-DNA hybridization. 
Reprinted with permission from [12]. Copyright 2004 American Chemical Society. 
 
Figure 3. “Resistance of the SiNW after different treatments. (1) A blank SiNW, (2) (1)+DNA capture 
probes, (3) (2) after hybridized with 1.0 nM complementary PNA, (4) (2) after hybridized with 1.0 nM 
complementary DNA, (5) a blank SiNW, (6) (5)+PNA capture probes, and (7) (6) after hybridized with 
1.0 nM complementary DNA. Same capture probe and sample sequences were used, respectively.”[9] 
Reprinted with permission from [9]. Copyright 2007 American Chemical Society. 
Apart from the sensing of DNA, PNA functionalized SiNWs have been employed for 
investigating an important physical property of SiNW sensors, namely the distance 
dependence of their field effect.[10] The response depends on the distance between the 
SiNW and the charge layer, i.e. the charged DNA. A neutral linker between the DNA and the 
SiNW had therefore to be employed, and PNA fulfilled this task. The report has general 
implications for the future design of SiNW sensors, e.g. for the detection of DNA and RNA. 
Also single-walled carbon nanotubes (SWNTs) have been functionalized with PNA. The 
attachment can be achieved covalently via NHS active ester chemistry[14] or non-covalently 
via π-π-stacking between the PNA bases and the SWNT and electrostatic interactions 
between the amino groups of the PNA and the SWNT.[15] These conjugates were capable of 
binding complementary DNA or RNA strands, respectively, presumably with greater strength 
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than it would have been possible with DNA functionalized SWNTs. The absence of charges 
in PNA reduces non-specific electrostatic interactions with electrodes and surfaces, making 
them especially interesting for self-assembled nano-electronics applications.[14] First studies 
into this direction have been undertaken.[16] Interestingly, non-covalently bound DNA and 
PNA wrap very differently around SWNTs.[17] This observation has, to the best of our 
knowledge, not been put to any use yet. 
 
In analogy to the non-covalent binding to SWNTs, single stranded oligonucleotides can also 
bind to graphene oxide, a water-soluble derivative of graphene. This interaction relies again 
on π-π-stacking. Because of its great π-π-stacking ability, graphene oxide is known to 
quench the fluorescence of dyes in close proximity.[18] Small fluorophore-labeled PNA 
oligomers can be used to detect complementary DNA and RNA, as the formation of 
oligonucleotide duplexes can lead to their detachment from the graphene oxide. This has 
been applied for monitoring the function of RNA polymerase. As soon as complementary 
RNA has been synthesized, the labeled PNA strands quantitatively bind the RNA, leading to 
desorption of the PNA from the graphene oxide and lighting up of the fluorophore. The 
advantage of PNA probes for this system lies in the stronger binding to even low 
concentrations of RNA, rendering the assay independent from buffer concentrations and 
external influences such as temperature.[19] 
Recently, the same concept for sensing RNA with a fluorophore-labeled PNA and, in this 
case, nano graphene oxide (NGO) has even been applied for monitoring microRNA (miRNA) 
expression levels in living cells (Figure 4).[20] Notably, previous methods were not able to 
achieve this goal.[21] NGO is negatively charged at physiological pH, and therefore 
uncharged PNA was expected to lead to less unspecific desorption than negatively charged 
DNA. Indeed, it was shown that PNA-NGO adducts are stable when treated with cell lysate, 
while DNA-NGO adducts disassembled leading to non-specific fluorescence. Moreover, the 
PNA based system has a very low detection limit (~1 pM) due to the superior binding 
strength of PNA to miRNAs. The system could even be used to detect multiple miRNAs 
simultaneously by employing multiple complementary PNA strands with different dye labels. 
Another area of interest for PNA application is surface-enhanced Raman spectroscopy 
(SERS). This technique relies on the strong amplification of Raman signals by metallic 
nanostructures.[22] PNAs have already been used in this context.[23,24,25] For example, Bazan 
and coworkers have developed a SERS sensor for single stranded DNA (Scheme 1). 
Interestingly, this sensor  would not work with DNA instead of PNA.[24] More specifically, in  
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Figure 4. Schematic representation of the working principle of intracellular miRNA sensing using 
NGO and PNA. Extracelullarly, fluorophore labeled PNA binds to NGO, leading to quenching of the 
fluorophore. After crossing of the cellular membrane, the PNA-NGO complex stays intact until a 
complementary miRNA strand is in proximity. A PNA-RNA duplex is then formed leading to desorption 
of the construct from NGO. Thereby, the fluorophore is not quenched anymore and can be detected. 
Adapted with permission from [20]. Copyright 2013 American Chemical Society. 
 
Scheme 1. PNA is deposited on a glass slide. Addition of non-complementary DNA with AgNPs and a 
SERS reporter (Rhodamine 6 G, R6G) leads to no assemblies. Complementary DNA strands bind to 
the PNA, thereby immobilizing negative charges. Positively charged AgNPs are electrostatically 
bound to the hybrids, R6G can bind to the AgNPs, and finally SERS can be observed. Reprinted with 
permission from [24]. Copyright 2007 American Chemical Society. 
this study, PNA was immobilized on a glass slide. Subsequently, complementary DNA was 
hybridized to the PNA, while non-complementary DNA was washed away. The negative 
charges on the backbone of the complementary DNA then lead to electrostatic attraction of 
positively charged silver nanoparticles (AgNPs). After addition of a SERS reporter dye, 
which binds to AgNPs, strongly enhanced Raman signals could be observed. If, in contrast, 
only non-complementary DNA was added, no enhancement was observed, as no AgNPs 
were deposited. The use of DNA instead of PNA would have led to non-specific deposition of 
the AgNPs due to the inherent negative charge of DNA. 
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As can be seen with the previous example, the interplay of nanoparticles with PNA is very 
intriguing due to the unique physico-chemical properties of nanoparticles and PNA. Indeed, 
PNA has also been used to functionalize nanoparticles such as silica-coated magnetic 
nanoparticles (γ-Fe2O3), which were immobilized on a silver substrate,[23] gelatin 
nanoparticles,[26] and others.[27] Gold nanoparticles (AuNPs) still represent the arguably most 
prominent class of nanoparticles. Recently, DNA modified AuNPs were shown to be quickly 
and efficiently hybridized with PNAs carrying different functionalities, ranging from small 
molecules like fluorophores and drugs, to differently sized biomolecules like siRNA, 
aptamers and antibodies.[28] Their in vitro use as imaging agent has been demonstrated. 
 
However, there are, generally, only very few reports about PNA modified AuNPs, especially 
about directly PNA-modified AuNPs, i.e. with attachment of the PNA to the gold surface of 
the NP.[29,30,31] There is a straight-forward explanation: Addition of PNAs to unmodified 
AuNPs lead to their agglomeration and subsequent precipitation from solution (Figure 5). 
This effect is thought to be mainly due to the adsorption of PNA bases to gold surfaces, 
which is stronger than for negatively charged DNA.[32] Thus, the initial stabilization of the 
AuNPs is lost and the general tendency of the NPs to aggregate induces the destabilization. 
The precipitation is permanent, and the non-specific binding of PNA to AuNPs is therefore 
not reversible, in contrast to its binding to graphene oxide (vide supra). It has been shown 
that this aggregation tendency is even strong enough to be used for sequence-selective 
quantification of DNA[33] and RNA.[34] 
 
Figure 5. Evolution of aggregation and precipitation of AuNPs upon addition of PNA. Time frame from 
first to last picture: less than one minute. 
The problem can be circumvented by immobilizing the AuNPs e.g. on an Au(1,1,1) surface 
via thiol/amine linkers before modification with thiol-linked PNA.[35] The pre-disposition of the 
AuNPs obviously prevents aggregation upon addition of PNA. It was found that the single-
mismatch sensitivity of PNA/DNA hybrids is already improved on unmodified Au(1,1,1) 
surfaces, compared to PNA/DNA hybrids in solution.[31] Immobilization of AuNPs on the 
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Au(1,1,1) surfaces further increased the mismatch discrimination, mainly due to the greater 
melting temperatures (Tm) of the fully complementary hybrids.[35] This effect was greater for 
PNA than for DNA probes. The study therefore shows the potential of combining AuNPs with 
PNA. Notably, the Tm of the PNA/DNA hybrid was depending on the size of the AuNPs, 
leading to higher Tm with smaller NP diameter. This was attributed to the greater PNA probe 
density on smaller particles. This last point shows that the “nanoscopic” environment has a 
noticeable impact on the molecular level. Consequently, it can be expected that particles 
which are not immobilized on a surface have distinct properties. Apart from that, having the 
particles in solution allows for additional applications, e.g. they can be added to setups with 
differently functionalized surfaces. 
Recently, in collaboration with the Bach group at Monash University (Australia), we have 
reported a new method for generating such directly PNA modified AuNPs in solution.[29] To 
overcome the abovementioned stability issues, we proposed a two-step process for the 
synthesis (Scheme 2). First, the AuNPs were modified with a thiolated surfactant which 
provides steric and electrostatic stabilization. In a second step, the particles can be treated 
with thiol-linked PNA without inducing agglomeration of the AuNPs. The PNA-modified 
AuNPs were tested in comparison to analogous DNA-modified AuNPs by assaying the self-
assembly properties towards PNA modified gold surfaces. The test was carried out in the 
absence of ions, where DNA-DNA assembly would not be possible due to electrostatic 
repulsion between the charged oligonucleotide backbones. The PNA modified AuNPs 
showed superior binding affinity towards the complementary PNA strands on the surface. 
Notably, the nature of the thiol linker (short, long, monothiol, trithiol) did not have an 
influence on the outcome of the self-assembly experiment. The methodology therefore 
seems to be flexible and the linker of the PNA can, in future studies, be chosen to best fit the 
application, without running into problems with nanoparticle stability again. These new PNA 
modified AuNPs will likely entail new innovations, as many of the great applications of DNA-
modified AuNPs can potentially be improved by using PNA-modified AuNPs instead. 
 
Scheme 2. Overview of the two-step process for functionalization of AuNPs with a stabilizing 
surfactant and thiol-linked PNA. Adapted with permission from [29]. Copyright 2013 WILEY-VCH 
Verlag GmbH & Co. KGaA, Weinheim. 
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In summary, DNA-based bio-nanotechnology can be greatly advanced by the use of PNA. 
Worthy of note, there are many more examples than the ones described above, e.g. miRNA 
sensing with PNA in nanogaps[36] or self-assembled PNA/DNA nanostructures.[37] 
Nevertheless, it has to be pointed out that the field is still in its infancy, and studying PNA for 
bio-nanotechnology will still hold many obstacles. There are, for example, also reports where 
the use of PNA instead of DNA brings basically no advantages.[38] Incompatibility issues like 
the ones of “naked” AuNPs towards PNA could be encountered for other systems as well. 
Nevertheless, the promises this technology holds are great and further investigations are 
likely to lead to innovative discoveries. 
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7.2 Abstract 
PNA does it better: Peptide nucleic acid (PNA) oligomers were attached to gold 
nanoparticles (AuNPs) through a variety of mono- and trithiol linkers. These functionalized 
particles had sufficient stability for sequence-specific self-assembly onto gold surfaces (see 
figure) in the absence of ions or surfactants. The nanoparticle surface densities obtained 
were superior to comparable DNA-modified AuNPs. 
 
 
 
Keywords: Gold nanoparticles • Nanoparticles • Peptide nucleic acids • Self-Assembly • 
Solid-phase synthesis. 
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7.3 Article 
DNA-based gold-nanoparticle (AuNP) systems are currently employed in a growing range of 
applications,[1] which include gene regulation,[2] nanofabrication,[3] sensing,[4–6] and plasmonic 
rulers.[7,8] However, a disadvantage of the assembly of DNA-modified NPs is the need for 
salt to keep their assemblies stable. Halogens are known to damage silver nanoparticles 
(AgNPs),[9] while the addition of salt in general destabilizes colloidal particles. Additionally, 
the presence of substantial amounts of ions is problematic for the study and use of physical 
phenomena that rely on electrostatics.[10,11] Thus, the functionalization of nanoparticles with 
the non-natural DNA analogue peptide nucleic acid (PNA), instead of DNA, is extremely 
attractive. PNA has many advantages over DNA including a higher stability against 
biodegradation, greater mismatch sensitivity, and higher binding efficiency to PNA, DNA, 
and RNA.[12] Hence, shorter oligonucleotide strands could potentially be used for the 
assembly of PNA-functionalized AuNPs compared to those required for stable DNA-based 
assembly. An increase in the resolution control of close-packed gold nanoparticles could 
therefore be observed. Additionally, the stability of PNA-DNA and PNA-PNA hybrids is 
independent of the ionic strength of the medium.[13] In comparison, DNA alone is not able to 
form assemblies under ion-free conditions as the electrostatic repulsion between the 
negatively charged strands is too high. Therefore, AuNP assemblies relying on PNA 
hybridization could be formed without the addition of salt, unlike DNA-AuNP hybrids. Despite 
the huge potential of PNA-based AuNPs, there are only a few articles reporting the direct 
attachment of PNA onto AuNPs.[14,15] Part of the reason for this is the strength of the 
interaction between gold and the neutral PNA, which is much stronger than with the 
negatively charged DNA.[16] The stronger tendency of PNA to adsorb flat onto the gold 
particle through direct interaction of the bases with the gold surface, rather than the 
preferred covalent linkage through a thiol–gold bond, results in a significantly thinner PNA 
layer and a strongly reduced PNA loading, leading to poor colloidal stabilization. This, 
combined with the lack of surface charge, results in inherently poor colloidal stability of PNA-
modified metal nanoparticles.[17] This problem has not been sufficiently overcome with the 
PNA-functionalized AuNPs reported so far (see below). Herein, we use a conjugation 
technique that allows, for the first time, the synthesis of highly stable PNA-functionalized 
metal nanoparticles. We first functionalized the AuNPs with a stabilizing surfactant 
commonly used for DNA functionalization[18,19] and, in a second step, covalently attached the 
PNA to the AuNP surface. A variety of linkers were used, showing the wide applicability of 
the described method. Furthermore, we demonstrated the binding specificity of the PNA-
functionalized nanoparticles to complementary oligomers, and the accessibility of the PNA 
strands, by directed assembly of PNA-AuNP conjugates to PNA-functionalized gold 
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substrates. Scanning electron microscopy (SEM) imaging was used to show the sequence-
specific binding to unstructured and micropatterned surfaces. 
Functionalization of gold nanoparticles or surfaces with PNAs requires the modification of 
the oligomers with a terminal thiol group. Usually, either a cysteine or a similar monothiol-
containing linker is inserted at the amino end of a PNA strand (Table 1, entry 1). Trithiol-
capped DNA oligomers have been shown to bind more efficiently to AuNP surfaces and are 
displaced more slowly by other thiols compared to mono- and cyclic dithiol-capped 
derivatives.[20] As this stability towards subsequent ligand-exchange manipulation is of 
interest, for example, for sensing applications, we wanted to link the PNA strand in an 
analogous manner. However, to the best of our knowledge, trithiol ligands have not 
previously been used with solid-phase peptide/PNA synthesis (SPPS).[21] To fill this gap, we 
designed a novel and easy-to-prepare trithiol linker (1, Scheme 1). More specifically, the 
tribromide 2[22] was converted into the trithioether 1 by reaction with triphenylmethanethiol in 
the presence of NaH. 1 could then be attached directly to different PNA sequences using 
standard SPPS procedures (Table 1, entry 2).[23] To assess the impact of the distance 
between the PNA and the AuNPs, PNA sequences containing ethylene glycol spacers 
between the PNA and the tripodal ligand were also synthesized (Table 1, entry 4). 
Importantly, the final step of SPPS, which necessitates trifluoroacetic acid (TFA) to cleave 
the PNA sequence from the solid support, also removes the trityl protecting groups of the 
thiols. An excess of a reducing agent such as tris(2-carboxyethyl)phosphine (TCEP) is 
required in this step to prevent formation of a disulfide bridge network. 
 
Scheme 1. a) Synthesis of SPPS-compatible trithiol linker; b) Synthesis of a trithiol-linker-containing 
PNA oligomer. Conditions: 1) Ph3CSH, NaH, THF, 50  °C, 62 h, 63 %; 2) Fmoc-SPPS: i) 20 % piperidine in DMF; ii) Fmoc-protected PNA-monomer (5 equiv), HATU (4.5 equiv), DIPEA (10 equiv), 
2,6-lutidine (10 equiv), DMF; 3) 1 (3 equiv), HATU (2.75 equiv), DIPEA (13 equiv), 2,6-lutidine 
(13 equiv), procedure repeated again; 4) TFA:phenol:triisopropylsilane 38:2:1 (v/v/v), TCEP 
(1000 equiv). Fmoc=fluorenylmethoxycarbonyl; Bhoc=benzhydryloxycarbonyl; HATU=O-(7-azobenzo-
triazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; DIPEA=N,N-diisopropylethylamine. 
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Table 1. Overview over the PNA and DNA conjugates (see “Type” for differentiation) with thiol linkers. 
Entry Linker Structure 
Sequencea
Type Corresponding NPb a a' 
1 
 
4 9 PNA AuNP-4 
2 
OSH
SH
HS
 
5 10 PNA AuNP-5 
3 
 
6 11 PNA AuNP-6 
4 7 12 PNA AuNP-7 
5 HS T15  8 13 DNA AuNP-8 
a The sequences, denoted NC terminus (PNA), or 5′3′ (DNA), respectively, are as follows: a: 
TCTCAGTATT; a′: AATACTGAGA; b 40 nm AuNPs, functionalized with 3 and the respective 
oligonucleotide. 
With the thiol-containing PNA sequences made, we then investigated their ability to form 
stable PNA-functionalized AuNPs. Duy et al. reported the synthesis of PNA-modified 
particles in highly concentrated Tween 20 solutions.[15] However, we found that the particles 
prepared using this method were not sufficiently stable for self-assembly purposes and 
therefore, did not provide the anticipated advantages of PNA on AuNPs. In the presence of 
Tween 20, we observed only non-selective aggregation. If the Tween 20 concentration was 
lowered, the PNA-functionalized NPs aggregated, even in the absence of ions. For DNA-
modified particles, it was demonstrated that the additional attachment of 1-mercapto-6-hexyl-
tri(ethylene glycol) improves salt stability through steric shielding without decreasing the 
hybridization efficiency.[24] Because PNA, in contrast to DNA, lacks negative charges, 32-
mercapto-3,6,9,12,15,18,21-heptaoxadotriacontan-1-oic acid 3 was chosen for pre-
functionalization of the AuNPs, because 3 incorporates steric shielding as well as additional 
electrostatic stabilization (Scheme 2).[18] The final particles were, therefore, envisioned to 
remain stable in the presence of ions as well as under a wide range of pH values.[25] 
Additionally, 3 was used as a linker molecule for PNA (Table 1, entry 3). After in situ trityl 
protection of the thiol group of 3, the carboxylate was coupled to the PNAs on the solid  
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Scheme 2. a) Illustrations of 3 and 6 and chemical formula of 3; b) Overview of the two 
functionalization steps in the synthesis of PNA-modified AuNPs with stabilizing 3 and a representative 
PNA. 
support (see Supporting Information for more details). This reaction did not proceed in the 
commonly used solvent for such coupling reactions, namely dimethylformamide (DMF). By 
switching to tetrahydrofuran (THF), which has a significantly lower dielectric constant, the 
desired product could be obtained.[26] We believe that the critical micelle concentration 
(CMC) of the PEG-derivative 3 and/or its activated ester is too low in DMF, rendering the 
carboxylate and/or active ester site of the respective molecules inaccessible. For 
comparison, DNA-modified AuNPs were prepared using a linker with a 15-mer thymine 
spacer. Such linkers are often used for DNA-modified AuNPs because thymine has a very 
low affinity towards gold.[27] 
The thermal stability of the PNA-PNA, PNA-DNA, and DNA-DNA hybrids in the absence of 
AuNPs was measured using UV/Vis spectroscopy (see Supporting Information). Consistent 
with previous reports,[28] the melting temperatures of the PNA-PNA duplexes were 
significantly higher than for the corresponding DNA-PNA or DNA-DNA duplexes, indicative 
of their greater stability. This highlights a major advantage of using PNA (as compared to 
DNA), because the PNA-modified particles have the potential to create assemblies with 
either shorter inter-particle distances or stronger hybridization than DNA-based systems, as 
fewer bases are required to achieve sufficient binding. Moreover, the PNA is not responsible 
for the stabilization of the particles and therefore the colloidal stability is largely independent 
of the oligomer length, unlike in the case of the common DNA-functionalized particles. 
The preparation of PNA-modified AuNPs is described in detail in the Supporting Information. 
In brief, Tween 20,[29] phosphate buffer (pH 7.4), and 3 were successively added to a 
solution of AuNPs (40 nm diameter). After incubation for 12 hours, a sufficiently dense layer 
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of 3 formed, protecting the AuNPs. The thiolated PNA was then added, and the incubation 
continued for another eight hours. Using this procedure, similar surface charges were 
predicted for all AuNPs, including the DNA modified AuNP-8. 
The stability of particles functionalized with the different PNAs was investigated using UV/Vis 
spectroscopy. Partial aggregation results in a decrease of the extinction coefficient and/or 
red shifting/broadening of the localized surface plasmon resonance and can therefore easily 
be detected. In 1 mM phosphate buffer solutions, no changes in the UV/Vis spectra could be 
observed after 20 hours for any of the AuNPs (see Supporting Information for spectra). 
Similarly, in 10 mM buffer solutions, only minor decreases of λmax were observed. At a 
phosphate buffer concentration of 0.1  M, aggregation and precipitation were visible within 
seconds for AuNP-6 while the λmax decreased less than 20 % over the course of 15 hours for 
all other PNA-functionalized AuNPs. 
Self-assembly experiments were carried out in the absence of additional ions or surfactants. 
Gold-coated substrates were modified with complementary PNA 7 or with non-
complementary PNA 12, as a negative control. After incubating 5 μL of NP solution on the 
PNA-modified substrates for four hours in a humidification chamber, the substrates were 
washed four times with water. After drying, SEM measurements were performed to 
determine the coverage densities of AuNPs on the substrate surface (see Figure 1 and 
Table 2). To the best of our knowledge, these are the first images proving the sequence-
specific self-assembly of PNA modified nanoparticles. 
All PNA- and DNA-functionalized nanoparticles selectively bound to the surfaces modified 
with complementary 7. The PNA-modified AuNPs showed almost identical particle densities 
of about 40 μm−2 (i.e. 40 particles per μm2). These observations along with the even 
distribution of particles on the surface suggest that the average distance between NPs 
adsorbed to the surface is dictated by the electrostatic repulsion forces between the 
negatively charged NPs. Also the trithiol-substituted AuNPs AuNP-5 and AuNP-7 reached  
 
 
Figure 1. SEM images of surfaces modified with a) complementary PNA 7 and b) non-complementary 
PNA 12 after incubation with AuNP-6. Scale bars=500 nm. 
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Table 2. Number of bound nanoparticles per μm2.a 
Nanoparticle Complementary 7 [µm-2] Non-Complementary 12 [µm-2] 
AuNP-4 38 3.6 
AuNP-5 39 5.1 
AuNP-6 39 2.8 
AuNP-7 43 5.5 
AuNP-8 26 1.1 
a As determined by particle counting in the SEM images. 
this threshold and are expected to withstand oxidation or replacement by analytes if used, 
for example, for sensing applications in future studies.[20] Moreover, the similar surface 
coverage density of AuNP-5 with AuNP-6 demonstrates effective PNA hybridization, despite 
the use of a linker that is significantly shorter than the stabilizing surfactant 3. Notably, the 
coverage density of the DNA-modified AuNP-8 is lower compared to the PNA-modified 
AuNPs. This is in line with the results of the thermal denaturation experiments; different 
charge densities of the particles could also be a reason for this result, but this is unlikely 
because of the identical preparation conditions. Some non-complementary binding occurs in 
all cases, although slightly less in case of AuNP-8. 
 
Figure 2. SEM images of micropatterned surfaces with a) complementary PNA 7 and PEG-modified 
silica, b) non-complementary PNA 12 and PEG-modified silica, c) complementary PNA 7 and 
fluoroalkyl-modified silica, d) non-complementary PNA 12 and fluoroalkyl-modified silica, after 
incubation with AuNP-6. Scale bars=1 μm. The magnification of the insets is double that of the parent 
image. 
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DNA-based systems have been shown to be usable for specific deposition of AuNPs onto 
patterned substrates, a feature especially of interest in the context of nanoelectronics.[30] To 
test if our PNA-modified AuNPs were capable of fulfilling this task as well, we incubated 
AuNP-6 on micropatterned substrates with lines of Au and silica. The substrates were first 
modified with hydrophilic PEGylated silanes or hydrophobic fluoroalkyl silanes and then with 
PNAs 7 or 12, as described above for gold-coated substrates. AuNP-6 assembles 
exclusively onto the areas with complementary PNA (Figure 2). Hence, the nanoparticles 
stick to neither hydrophilic nor hydrophobic surfaces but rather only to complementary 
oligonucleotide sequences. This further demonstrates the rigidity and practicality of our PNA-
based system. 
In summary, we have demonstrated the preparation of stable PNA-modified particles 
through a novel approach involving the use of a thiolated alkyl PEG carboxylate surfactant. 
Standard, as well as novel, mono- and trithiol linkers were found to be compatible with this 
approach. The potential of these PNA-nanoparticles as new building blocks for self-
assembling systems was confirmed by synthesizing particles that were able to self-assemble 
under additive-free conditions, an endeavor which has, to the best of our knowledge, not 
been directly shown with any other DNA/PNA-based systems. The superior properties of 
PNA compared to DNA make these particles highly interesting for future studies. Ion-free 
conditions are needed for investigation of electrostatic phenomena[10,11] and are not 
compatible with DNA hybridization. Sensing applications[4–6] could also benefit from the 
increased binding strength of PNA hybrids. This strength also allows for the investigation of 
optical phenomena at unprecedentedly small inter-particle distances.[7,8] 
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7.5 Supporting Information 
 
7.5.1 Instrumentation and Materials 
PNA monomers and [2-(2-(Fmoc-amino)ethoxy)ethoxy]acetic acid (Fmoc-AEEA-OH spacer) 
were purchased from Link Technologies Ltd. (Lanarkshire, Scotland), TentaGel S RAM resin 
beads from Rapp Polymers GmbH (Germany), citrate stabilized AuNP solutions from Ted 
Pella, Inc. (USA), triphenylmethanethiol from Sigma-Aldrich (USA), thiol-modified DNA 
oligomers from Fidelity Systems (USA), TCEP from TCI Europe and Apollo Scientific (UK), 
32-mercapto-3,6,9,12,15,18,21-heptaoxadotriacontan-1-oic acid 3 was obtained from 
ProChimia Surfaces (Poland). Water used for AuNP modification and self-assembly was 
deionized with a Millipore Milli-Q Advantage (conductivity: 18.2 MΩ/cm at rt). 1H and13C 
NMR spectra were recorded on Bruker Avance (400 and 500) spectrometers. 13C NMR 
measurements were carried out as 13C {H}. NMR spectra were referenced to the residual 
solvent signal. IR spectra were acquired on a Perkin-Elmer Spectrum 2 FT-IR instrument. 
High resolution ESI-MS spectra were measured with a Bruker ESQUIRE-LC quadrupole ion 
trap instrument and MALDI-MS spectra on a Bruker Autoflex I. UV-ozone cleaning was 
performed with a Sumaco Inc. UV-1. AuNP stability measurements were performed on an 
Agilent Cary 60 UV/Vis. Temperature dependent UV/Vis experiments were performed on 
Varian UV Cary 100 Bio and Varian UV Cary 500 Scan instruments. SEM images were 
acquired with a FEI Nova NanoSEM 430. 
 
7.5.2 Synthetic Procedures 
General Procedure for solid phase peptide synthesis (SPPS) 
SPPS was performed manually in 5 mL polypropylene one-way syringes as reaction vessels, 
which were equipped with a frit at the bottom. They were filled with 98 mg of polystyrene 
resin beads TentaGel S RAM (0.24 mmol/g). The resin was swollen in DMF before use for 
1 h. All reactions were performed on a mechanical shaker with 600 rpm, soaking 
approximately 2.5–3.5 mL of freshly prepared solutions into the syringe. Fmoc/Bhoc 
protected PNA monomers (5 equiv.) were pre-activated in Eppendorf tubes before every 
coupling step for 5 min with HATU (4.5 equiv.) in DMF, adding DIPEA and 2,6-lutidine 
(10 equiv. each) under sonication. For each coupling step the resin beads were treated with 
the activated acid and subsequently washed with DMF. The coupling step was monitored 
with the Kaiser test. Substances other than the usual PNA monomers were coupled in the 
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same way, unless noted otherwise. Double Fmoc deprotection was performed with 
piperidine in DMF (2:8, v/v; 2 min, 10 min). The resin beads were then washed successively 
with DMF, DCM and DMF. The whole procedure (deprotection, coupling, monitoring) was 
repeated for every monomer until the sequence was completed. The resin was then shrunk 
with methanol (30 min) and dried under vacuum. Final cleavage of the PNA oligomer from 
the resin and the deprotection of all Bhoc and Boc side chain protecting groups were 
simultaneously performed in TFA/triisopropylsilane (TIS)/H2O (38:2:1, v/v/v; 3x 2 h). 
Following the removal of TFA under reduced pressure, the crude product was purified by 
HPLC with a gradient of 0.1% TFA in water and acetonitrile (Agilent Zorbax SB300-C18, 4 
mL/min, 0 min 95:5, 8 min 85:15, 28 min 60:40, 50 min 20:80, 51 min 0:100, 56 min 0:100, 
61 min 95:5). MALDI-MS spectra, LC/MS, and analytical HPLC traces (Macherey-Nagel EC 
250/3 NUCLEOSIL 100-5 C18, 1 mL/min, 0.1% TFA in water : acetonitrile 95:5  0:100 over 
30 min) were recorded. The purities were determined from the HPLC UV traces at 260 nm. 
 
3-(tritylthio)-2,2-bis((tritylthio)methyl)propanoic acid 1 
 
Triphenylmethanethiol (1.63 g, 5.89 mmol) was slowly added to a cooled (0 °C) suspension 
of NaH (177 mg, 7.36 mmol) in dry THF (20 mL). After 15 min, 2 (499 mg, 1.47 mmol) was 
added. The mixture was heated to 50 °C and stirred at that temperature for 62 h. The 
reaction was quenched with H2O. CH2Cl2 and HCl (1 M, 8 mL) were added. The layers were 
separated and the aqueous layer was extracted with CH2Cl2 (3x). The combined organic 
layers were washed with brine, dried (MgSO4), filtered, and concentrated. The crude product 
was purified by column chromatography (hexanes/EtOAc 170:1  8:2) giving pure 1 
(860 mg, 63%) as a colorless solid. 
Rf = 0.10 (hexanes/EtOAc 8:2). IR (KBr) 3056 (m), 3030 (m), 2923 (w), 1706 (m), 1594 (w), 
1489 (m), 1443 (m), 741 (s), 699 (s). 1H NMR (400 MHz, CDCl3) ∂ 7.40–7.30 (m, 18 H), 
7.20–7.07 (m, 27 H), 2.29 (s, 6 H). 13C NMR (100 MHz, CDCl3): ∂ 177.0, 144.6, 129.8, 128.0, 
126.8, 66.5, 49.6, 36.8. HRMS m/z calcd. for C62H51O2S3 ([M-H]-) 923.30567, found 
923.30487. 
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Precursor sequence a’ PAN087 
 
SPPS was performed according to the general procedure (vide supra), until the last coupling 
was completed. 
 
Precursor sequence a PAN088 
 
SPPS was performed according to the general procedure (vide supra), until the last coupling 
was completed. 
 
Compound 4 
 
4 was synthesized according to the general procedure for SPPS (vide supra). In the last 
coupling step 3-(tritylthio)propionic acid (5 equiv) was used instead of a PNA monomer. 
MALDI-MS calcd. for C111H142N52NaO34S ([M+Na]+) 2802.1, found 2802.2. ESI-MS m/z 927.5 
(65, [M+3 H]3+), 696.0 (100, [M+4 H]4+), 557.0 (15, [M+5 H]5+). HPLC: tR = 7.13 min, 92% 
purity 
 
Compound 5 
 
5 was synthesized according to the general procedure for SPPS (vide supra), with the 
following modifications: 1 (3 equiv.) was pre-activated in a Eppendorf tube before each 
coupling step for 15 min with HATU (2.75 equiv.) in DMF, adding DIPEA and 2,6-lutidine 
(13 equiv. each). The activated acid was then coupled for 4 h to ¼ of PAN088. The coupling 
was repeated to ensure completion. Before adding TFA to cleave the PNA from the resin, 
approximately 3 mg of TCEP were added. 
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MALDI-MS calcd. for C113H147N52O34S3 ([M+H]+) 2872.1, found 2872.0. ESI-MS m/z 1436.4 
(2, [M+2 H]2+), 958.2 (100, [M+3 H]3+), 719.0 (47, [M+4 H]4+), 575.5 (4, [M+5 H]5+). HPLC: 
tR = 8.34 min, 99% purity. 
 
Precursor PAN100 
Carboxylic acid 3 (45 mg, 86 µmol) was dissolved in dry THF (400 µL). 
Triphenylchloromethane (27 mg, 96 µmol) and DIPEA (16 µL, 12 mg, 96 µmol) were added 
and the resulting solution was stirred at rt for 40 h. Appropriate aliquots were taken and 
treated with N,N'-diisopropylcarbodiimide (1 equiv.), hydroxybenzotriazole (1 equiv.), and 
DIPEA (2 equiv.). The solution was shaken for 30 min before employing it as activated acid 
in SPPS (see 11, 6). 
 
Compound 6 
 
6 was synthesized according to the general procedure for SPPS (vide supra), with the 
following modifications: ½ of PAN088 was deprotected and washed with THF (2x). The resin 
was then soaked with the solution PAN100 (24 µmol acid, 2 equiv.). The coupling procedure 
was repeated to increase the amount of coupled linker. Before adding TFA to cleave the 
PNA from the resin, approximately 3 mg of TCEP were added. 
MALDI-MS calcd. for C133H187N52O41S ([M+H]+) 3200.4, found 3200.4. ESI-MS m/z 1067.6 
(7, [M+3 H]3+), 801.1 (100, [M+4 H]4+), 641.1 (24, [M+5 H]5+). HPLC: tR = 15.1 min, 95% 
purity. 
 
Compound 7 
O
O O
HN
O
O O
HN
O
O O NH
O HS
SH
SH
NH
ttatgactct
O
H2N  
Fmoc-AEEA-OH spacer (5 equiv.) was coupled to ¼ of PAN088 according to the general 
SPPS procedure. The procedure was repeated twice to attach a total of three spacers. 1 
(3 equiv.) was pre-activated in a Eppendorf tube before each coupling step for 15 min with 
HATU (2.75 equiv.) in DMF, adding DIPEA and 2,6-lutidine (13 equiv. each). The coupling 
was repeated to ensure completion.  
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MALDI-MS calcd. for C131H179N55NaO43S3 ([M+Na]+) 3329.3, found 3329.4. ESI-MS m/z 
1103.3 (13, [M+3 H]3+), 827.9 (100, [M+4 H]4+), 662.5 (16, [M+5 H]5+). HPLC: tR = 9.15 min, 
92% purity. 
 
Compound 9 
 
9 was synthesized according to the general procedure for SPPS (vide supra). In the last 
coupling step 3-(tritylthio)propionic acid (5 equiv) was used instead of a PNA monomer. 
MALDI-MS calcd. for C112H140N63O28S ([M+H]+) 2847.1, found 2847.0. ESI-MS m/z 949.8 
(56, [M+3 H]3+), 712.7 (100, [M+4 H]4+), 570.4 (78, [M+5 H]5+), 475.6 (13, [M+6H]6+). HPLC: 
tR = 6.71 min, 92% purity. 
 
Compound 10 
 
10 was synthesized according to the general procedure for SPPS (vide supra), with the 
following modifications: 1 (3 equiv.) was pre-activated in an Eppendorf tube before each 
coupling step for 15 min with HATU (2.75 equiv.) in DMF, adding DIPEA and 2,6-lutidine 
(13 equiv. each). The activated acid was then coupled for 4 h to ¼ of PAN087. The coupling 
was repeated to ensure completion (without intermediate deprotection). Before adding TFA 
to cleave the PNA from the resin, approximately 3 mg of TCEP were added. 
MALDI-MS calcd. for C114H144N63O28S3 ([M+H]+) 2939.1, found 2938.8. ESI-MS m/z 980.5 (8, 
[M+3 H]3+), 735.7 (46, [M+4 H]4+), 588.8 (100, [M+5 H]5+), 490.9 (13, [M+6 H]6+). HPLC: 
tR = 7.80 min, 98% purity. 
 
Compound 11 
 
11 was synthesized according to the general procedure for SPPS (vide supra), with the 
following modifications: ½ of PAN087 was deprotected and washed with THF (2x). The resin 
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was then soaked with the solution PAN100 (24 µmol acid, 2 equiv.). The coupling procedure 
was repeated to increase the amount of coupled linker. Before adding TFA to cleave the 
PNA from the resin, approximately 3 mg of TCEP were added. 
MALDI-MS calcd. for C134H184N63O35S ([M+H]+) 3267.4, found 3267.3. ESI-MS m/z 817.8 
(28, [M+3 H]3+), 654.5 (100, [M+4 H]4+), 546.6 (20, [M+5 H]5+). HPLC: tR = 14.5 min, 99% 
purity. 
 
Compound 12 
 
Fmoc-AEEA-OH spacer (5 equiv.) was coupled to ¼ of PAN087 according to general SPPS 
procedure. The procedure was repeated twice to attach a total of three spacers. 1 (3 equiv.) 
was pre-activated in a Eppendorf tube before each coupling step for 15 min with HATU 
(2.75 equiv.) in DMF, adding DIPEA and 2,6-lutidine (13 equiv. each). The coupling was 
repeated to ensure completion.  
MALDI-MS calcd. for C132H176N66NaO37S3 ([M+H]+) 3396.4, found 3396.3. ESI-MS m/z 
1125.5 (9, [M+3 H]3+), 844.6 (100, [M+4 H]4+), 675.9 (71, [M+5 H]5+), 563.5 (11, [M+6 H]6+). 
HPLC: tR = 8.70 min, 94% purity. 
 
General Procedure for Preparation of PNA modified AuNP  
A citrate stabilized AuNP (40 nm diameter) solution with an OD=1 was concentrated from 
0.5 mL to 50 µL by centrifugation (3800 rpm, 45 min). Tween20 (2.5% v/v in water, 2 µL), 
phosphate buffer (0.1 M, pH=7.4, 30 µL), thiol 3 (1.66 mM in water, 3 µL), and bis(p-
sulfonatophenyl)phenylphosphine dihydrate dipotassium salt (BSPP, 0.1 M, 2.5 µL) were 
subsequently added. The solution was incubated on a shaker overnight (12 h). PNA 
(100 µM, 4 µL) was added, and incubation continued for 8 h. The nanoparticles were 
washed by adding 0.5 mL water, centrifuging (3800 rpm, 45 min), and removing the 
supernatant. The washing procedure was repeated another three times. The particles were 
dispersed in water (25µL). 
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General Procedure for Preparation of DNA modified AuNP  
A citrate stabilized AuNP (40 nm diameter) solution with an OD=1 was concentrated from 
0.5 mL to 50 µL by centrifugation (3800 rpm, 45 min). Tween20 (2.5% v/v in water, 2 µL), 
phosphate buffer (0.1 M, pH=7.4, 30 µL), thiol 3 (1.66 mM in water, 3 µL), DNA (100 µM, 
4 µL), and BSPP (0.1 M, 2.5 µL) were subsequently added. The solution was incubated on a 
shaker for 20 h. The nanoparticles were washed by adding 0.5 mL water, centrifuging 
(3800 rpm, 45 min), and removing the supernatant. The washing procedure was repeated 
another three times. The particles were dispersed in water (25µL). 
 
General Procedure for Gold-coated Silicon Substrates 
Au coated substrates were fabricated on a 4-inch silica-coated silicon wafer 
(Universitywafers.com). The wafer was cleaned by immersing it in an acetone bath at 70 °C 
for 3 min followed by rinsing with iso-propanol and was dried under a stream of N2. 3 nm of 
Ti and 30 nm of Au were deposited with an electron-beam evaporator. The substrate was 
treated with an UV-ozone cleaner (0.5 L/min, 3 min). The substrate was then immersed into 
a solution of PNA (100 µM, 35 µL) and BSPP (0.1 M, 5.25 µL) in EtOH (138 µL) for 24 h. 
After this surface treatment, the substrate was washed by rinsing it with ethanol, 
acetonitrile:water 1:1, water, ethanol, and dried under N2. 
 
Micropatterned Substrates 
Micropatterned substrates were fabricated on a 4-inch silica-coated silicon wafer 
(Universitywafers.com). The wafer is patterned with 2 μm lines on a 4 μm period covering 
12 mm2. The wafer was cleaned by immersing it in an acetone bath at 70 °C for 3 min 
followed by rinsing with iso-propanol and finally dried under a stream of N2. A positive 
photoresist (AZ 1512HS: AZ Electronics Materials) was spin-coated at 3,000 rpm for 30 
seconds on the wafer, which was softbaked at 90 °C for 1 min, exposed to UV light 
(45 mJ/cm2) through a chromium mask (MiniFAB Pty. Ltd., Scoresby, VIC, Australia) and 
finally developed for 50 s in a 3:2 mixture of AZ 726 MIF developer (AZ Electronics 
Materials) and ultrapure water. The exposed areas of the wafer were then etched 65 nm with 
reactive ion etching with a mixture of SF6 (7 sccm) and CHF3 (50 sccm), a gas pressure of 
7 mT, an ICP power of 2500 W, a RIE power of 50 W and a He back pressure of 10 mT. 
3 nm of Ti and 12 nm of Au were deposited with an electron-beam evaporator. The 
photoresist was removed by sonicating the substrate in acetone for 10 min followed by 
10 min of UV-ozone cleaning (0.5 L/min, 3 min). The substrate was then immersed into a 
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mixture of 2.5 μl of 2-[methoxy(polyethyleneoxy)propyl]trimethoxy-silane (PEG-silane, 
Gelest), 1.25 mL of toluene and 1 μL of concentrated HCl (Sigma Aldrich) for 50 min. After 
this surface treatment, the substrate was washed by rinsing it with toluene, ethanol, ultrapure 
water and dried under N2. The substrate was then immersed into a solution of PNA (100 µM, 
35 µL) and BSPP (0.1 M, 5.25 µL) in EtOH (138 µL) for 24 h. After this surface treatment, 
the substrate was washed by rinsing it with ethanol, acetonitrile:water 1:1, water, ethanol, 
and dried under N2. 
 
General Procedure for Self-Assembly of AuNPs onto Substrates 
PNA modified (micropatterened) substrates were placed in a humidity chamber with droplets 
of phosphate buffer (0.1 mM, pH=7.4) in the humidification wells. PNA or DNA modified 
AuNPs (5 µL) were put on top of the substrates. After 4 h incubation in the closed chamber, 
the substrates were washed with water (4x) and partially dried with a tissue (Kimwipe), by 
putting it on the edge of the substrate and making use of the capillary force. The substrate 
was allowed to completely dry under ambient conditions. 
 
7.5.3 Spectra 
In the following analytical spectra of the newly synthesized and previously not characterized 
compounds are shown.  
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Figure S1. 1H spectrum of compound 1 in CDCl3. 
 
 
Figure S2. 13C spectrum of compound 1 in CDCl3.  
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Figure S3. Analytical HPLC trace of compound 4. 
 
 
Figure S4. MALDI-MS spectrum of compound 4. 
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Figure S5. Analytical HPLC trace of compound 5. 
 
 
Figure S6. MALDI-MS spectrum of compound 5.  
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Figure S7. Analytical HPLC trace of compound 6. 
 
 
Figure S8. MALDI-MS spectrum of compound 6.  
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Figure S9. Analytical HPLC trace of compound 7. 
 
 
Figure S10. MALDI-MS spectrum of compound 7.  
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Figure S11. Analytical HPLC trace of compound 9. 
 
 
Figure S12. MALDI-MS spectrum of compound 9.  
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Figure S13. Analytical HPLC trace of compound 10. 
 
 
Figure S14. MALDI-MS spectrum of compound 10.  
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Figure S15. Analytical HPLC trace of compound 11. 
 
 
Figure S16. MALDI-MS spectrum of compound 11.  
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Figure S17. Analytical HPLC trace of compound 12. 
 
 
Figure S18. MALDI-MS spectrum of compound 12.  
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7.5.4 UV/Vis Melting Curve Experiments 
The melting experiments were carried out as described by Metzler-Nolte and coworkers.[1] 
The oligonucleotide, buffer, and TCEP concentrations are described in Table S1. 
 
Figure S19. Temperature dependent UV/Vis Absorbance at λ=260 nm of a solution of 4 and 9 under 
conditions I (see Table S1). The individual lines represent different heating or cooling runs. 
 
 
Figure S20. Temperature dependent UV/Vis Absorbance at λ=260 nm of a solution of 8 and 9 under 
conditions I (see Table S1). The individual lines represent different heating or cooling runs. 
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Figure S21. Temperature dependent UV/Vis Absorbance at λ=260 nm of a solution of 8 and 13 under 
conditions I (see Table S1). The individual lines represent different heating or cooling runs. 
 
 
Figure S22. Temperature dependent UV/Vis Absorbance at λ=260 nm of a solution of 4 and 9 under 
conditions II (see Table S1). The individual lines represent different heating or cooling runs. 
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Figure S23. Temperature dependent UV/Vis Absorbance at λ=260 nm of a solution of 8 and 9 under 
conditions II (see Table S1). The individual lines represent different heating or cooling runs. 
 
 
Figure S24. Temperature dependent UV/Vis Absorbance at λ=260 nm of a solution of 8 and 13 under 
conditions II (see Table S1). The individual lines represent different heating or cooling runs. 
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Table S1. Melting temperatures (Tm) of oligonucleotide hybrids as obtained by UV/Vis experiments 
between 5 °C and 90 °C. At least 5 runs were averaged. 
Sequence a Sequence a’ Conditionsa Tm [° C] 
4 9 I 60 
4 13 I 45 
8 13 I 31 
4 9 II 66 
4 13 II 42 
8 13 II Not observed 
a I: 0.1 M PBS buffer, 1 mM TCEP, 1 µM of each oligonucleotide; II: 1 µM of each oligonucleotide. 
 
7.5.5 UV/Vis Stability Experiments 
 
 
Figure S25. AuNP-4 in 100 mM phosphate buffer (pH=7.4). 
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Figure S26. AuNP-5 in 100 mM phosphate buffer (pH=7.4). 
 
 
Figure S27. AuNP-6 in 100 mM phosphate buffer (pH=7.4). 
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Figure S28. AuNP-7 in 100 mM phosphate buffer (pH=7.4). 
 
 
Figure S29. AuNP-8 in 100 mM phosphate buffer (pH=7.4). 
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Figure S30. AuNPs synthesized following the general procedure, but without addition of 
oligonucleotide, in 100 mM phosphate buffer (pH=7.4). 
 
 
Figure S31. AuNP-4 in 10 mM phosphate buffer (pH=7.4). 
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Figure S32. AuNP-5 in 10 mM phosphate buffer (pH=7.4). 
 
 
Figure S33. AuNP-6 in 10 mM phosphate buffer (pH=7.4). 
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Figure S34. AuNP-7 in 10 mM phosphate buffer (pH=7.4). 
 
 
Figure S35. AuNP-8 in 10 mM phosphate buffer (pH=7.4). 
  
Part II – Peptide Nucleic Acid for Nanotechnology
7 Peptide Nucleic Acid-Modified Gold Nanoparticles
216 
 
 
 
 
Figure S36. AuNPs synthesized following the general procedure, but without addition of 
oligonucleotide, in 10 mM phosphate buffer (pH=7.4). 
 
 
Figure S37. AuNP-4 in 1 mM phosphate buffer (pH=7.4). 
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Figure S38. AuNP-5 in 1 mM phosphate buffer (pH=7.4). 
 
 
Figure S39. AuNP-6 in 1 mM phosphate buffer (pH=7.4). 
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Figure S40. AuNP-7 in 1 mM phosphate buffer (pH=7.4). 
 
 
Figure S41. AuNP-8 in 1 mM phosphate buffer (pH=7.4). 
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Figure S42. AuNPs synthesized following the general procedure, but without addition of 
oligonucleotide, in 1 mM phosphate buffer (pH=7.4). 
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7.5.6 Scanning Electron Microscopy (SEM) Imaging 
 
 
Figure S43. SEM image of surface modified with complementary PNA 7 after incubation with AuNPs 
AuNP-4. 
 
 
Figure S44. SEM image of surface modified with non-complementary PNA12 after incubation with 
AuNPs AuNP-4. 
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Figure S45. SEM image of surface modified with complementary PNA 7 after incubation with AuNPs 
AuNP-5. 
 
 
Figure S46. SEM image of surface modified with non-complementary PNA12 after incubation with 
AuNPs AuNP-5. 
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Figure S47. SEM image of surface modified with complementary PNA 7 after incubation with AuNPs 
AuNP-6. 
 
 
Figure S48. SEM image of surface modified with non-complementary PNA12 after incubation with 
AuNPs AuNP-6. 
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Figure S49. SEM image of surface modified with complementary PNA 7 after incubation with AuNPs 
AuNP-7. 
 
 
Figure S50. SEM image of surface modified with non-complementary PNA12 after incubation with 
AuNPs AuNP-7. 
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Figure S51. SEM image of surface modified with complementary PNA 7 after incubation with AuNPs 
AuNP-8. 
 
 
Figure S52. SEM image of surface modified with non-complementary PNA12 after incubation with 
AuNPs AuNP-8. 
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Figure S53. SEM image of micropatterned surface with complementary PNA 7 and fluoroalkyl-
modified silica after incubation with AuNPs AuNP-6. 
 
 
Figure S54. SEM image of micropatterned surface with non-complementary PNA 12 and fluoroalkyl-
modified silica after incubation with AuNPs AuNP-6. 
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Figure S55. SEM image of micropatterned surface with complementary PNA 7 and PEG-modified 
silica after incubation with AuNPs AuNP-6. 
 
 
Figure S56. SEM image of micropatterned surface with non-complementary PNA 12 and PEG-
modified silica after incubation with AuNPs AuNP-6. 
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8 Outlook 
 
The possibilities which PNA modified AuNPs open up in nanotechnology are exciting. For 
example, PNA-modified gold nanoparticles could be coupled to other PNA-modified 
nanoscopic objects, allowing for especially short inter-particle distances or higher binding 
affinities, compared to DNA-modified gold nanoparticles. To this end, we have prepared 
PNAs with diamine linkers for attachment to quantum dots (Figure 1). Our collaborative 
partners, Dr. Alison Funston and co-workers at Monash University (Australia) are currently 
investigating the potential of these new PNA derivatives. 
 
Figure 1. PNA with diamine linker. Only the base adjacent to the linker (thymine) is shown, the 
remaining sequence is abbreviated as R. 
Additionally, further improvements of the of the PNA-modified gold nanoparticles would 
certainly be of interest: Due to the negative charges of the stabilizing layer which we 
reported (see chapter 7),[1] one of the advantages which PNA has on its own, the charge 
neutrality, has been lost. Consequently, there is electrostatic repulsion between the particles. 
Indeed, binding between gold nanoparticles functionalized with complementary PNA-
sequences could not be achieved in solution. Such short-distance particle-assemblies would 
be appealing for the study of plasmonic phenomena.[2] Several approaches to overcome this 
difficulty can be envisaged (Figure 2). If trithiol linked PNAs are employed, the previously 
described stable PNA-functionalized nanoparticles could be subjected to an excess of a thiol 
reagent such as dithiothreitol (DTT; Figure 2 a). It has been shown that DTT can effectively 
replace monothiol substituents on gold nanoparticles, while replacing dithiol substituents 
only slowly, and trithiol almost not at all.[3] Consequently, the stabilizing surfactant would be 
desorbed from the gold surface, while the PNA would stay on the particles. Potentially, the 
presence of additional trithiol-linked PNAs in the solution could fill the so formed “holes” in 
the layer around the particles. Under the right experimental conditions, it seems possible that 
the PNAs stay bound to the particle only over the thiol linkage and do not adsorb via the 
bases onto the particle surface, which would lead to aggregation of the nanoparticles. 
Alternatively, mixing of charged and uncharged reagents could take place during the initial 
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functionalization of the gold nanoparticles (Figure 2 b). Two surfactants, one with charges 
and one without, could be mixed, instead of only using a charged surfactant. The next step 
would again be the addition of PNAs. Also particles with a mixture of neutral PNA and 
charged DNA are imaginable, in which case DNA would serve as a stabilizing agent and 
contribute to the sequence specific binding strength. 
 
Figure 2. Possible pathways leading to stable PNA-substituted gold nanoparticles; a) starting from 
particles as described in chapter 7 with trithiol linked PNA, addition of a replacing agent such as DTT 
in large excess and PNA could replace part of the stabilizing surfactant with additional PNA strands; 
b) in the synthesis as described in chapter 7, the surfactant is substituted by a surfactant mixture, 
made up of charged and neutral molecules; the second step would be identical to the original 
procedure, adding again PNA. 
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